


&5'73/9HUVLRQ 

&/,1,&$/678'<[ZIP_CODE]&2/

$QRSHQODEHOUDQGRPL ]HGVWXG\WRHYDOXDWHW KHORQJWHUPFOLQL FDOVDIHW\DQGHIILFDF\
RIVXEFXWDQHRXVDGPLQLVWUDWLRQRI KXPDQSODVPDGHULYHG&HVWHU DVHLQKLELWRULQWKH
SURSK\ODFWLFWUHDWPHQWR IKHUHGLWDU\DQJLRHGHPD
&RXQWU\6SHFLILF3URWRFRO$ PHQGPHQW1R8QLWHG6WDWHV 
6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/
'HYHORSPHQW3KDVH E
6SRQVRU &6/%HKULQJ*PE+&6/
(PLOYRQ%HKULQJ6WUDVVH
0DUEXUJ
*HUPDQ\
3URWRFRO9HUVLRQ &RXQWU\6SHFLILF$PHQGP HQW1R8QLWHG6WDWHV
(XGUD&71XPEHU  
,1'1XPEHU 
3URWRFRO'DWH -XO\
&RPSOLDQFH 7KLVVWXG\ZLOOEHFRQGXFWHGLQD FFRUGDQFHZLWKVWDQGDUGVRI
*RRG&OLQLFDO3UDFWLFHDVGH ILQHGE\WKH,QWHUQDWLRQDO
&RQIHUHQFHRQ+DUPRQLVDWLRQDQGD OODSSOLFDEOHQDWLRQDODQG
ORFDOUHJXODWLRQV
7KLVSURWRFROLQFOXGHVLQIRUPDWLR QDQGGDWDWKDWFRQWDLQWUDGH VHFUHWVDQGSULYLOHJHGRUF RQILGHQWLDOLQIRUPDWLRQ
WKDWLVWKHSURSHUW\RIWKHVSRQVRU¬≥&6/¬¥7KLVLQIRUPDWLRQP XVWQRWEHPDGHSXEOLFZLWKRXWZULWWHQ
SHUPLVVLRQIURP&6/7KHVHUHVWULFWLRQVRQGLVFORVXUHZLOODSSO \HTXDOO\WRDOOIXWXUHLQIRUPDWLRQVXSSOLHGWR
\RX7KLVPDWHULDOPD\EHGLVFORVHGWRDQGXVHGE\\RXUVWDIID QGDVVRFLDWHVDVPD\EHQHFHVVDU\WRFRQGXFWWKH
FOLQLFDOVWXG\ CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 2 of 130 
([LOCATION_002])  Confidential  List of Personnel and Organizations Responsible for Conduct of the Study  
 
A list of personnel and organizations responsible for the conduct of the study will be supplied 
to study sites as part of the Investigator‚Äôs Study File. This list will be updated by [CONTACT_254815] (or 
delegate) and provided to the study sites as needed.  
  
[COMPANY_003]
[COMPANY_003][COMPANY_003]
[COMPANY_003]
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 4 of 130 
([LOCATION_002])  Confidential  Signature [CONTACT_301650]:  An open-label, randomized study to evaluate the long- term clinical safety and 
efficacy of subcutaneous administration of human plasma-derived C1- esterase inhibitor in the 
prophylactic treatment of hereditary angioedema. Protocol Number:   CSL830_3002 
I have read the protocol titled ‚Äú An open- label, randomized  study to evaluate the long- term 
clinical safety and efficacy of subcutaneous administration of human plasma-derived 
C1-esterase inhibitor in the prophylactic treatment of hereditary angioedema.‚Äù 
By [CONTACT_12570], I agree to conduct the clinical study, after approval by [CONTACT_254816] (as appropriate), in accordance with the protocol, the standards of Good Clinical Practice (as defined by [CONTACT_121026]), and applicable regulatory requirements.  
Changes to the protocol will only be implemented after written approval is received from 
CSL Behring GmbH ( CSL) and the Institutional Review Board or Independent Ethics 
Committee (as appropriate), with the exception of medical emergencies.   
I will ensure that study staff fully understand and follow the protocol. 
 
 
  
Name [CONTACT_4007] i nvestigator 
Affiliation of investigator  
  Date  
(DD MMM YYYY)  
  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 5 of 130 
([LOCATION_002])  Confidential  Protocol Synopsis  
Title An open -label, randomized  study to evaluate the long -term clinical 
safety and efficacy of subcutaneous administration of human 
plasma -derived C1 -esterase inhibitor in the prophylactic treatment 
of hereditary angioedema  
Study Number CSL830_3002  
Sponsor CSL Behring GmbH  (CSL) 
Development Phase  3b 
Study Product CSL830  
Indication  Hereditary Angioedema  (Type I and II ) 
Study Summary  This is a multicenter, randomized, open -label, parallel -arm, phase 
3b study designed to investigate the clinical safety and efficacy of 
subcutaneously administered CSL830 in the prophylactic treatment of hereditary angioedema  (HAE) . The study will consist of 2 
treatment periods. Treatment Period 1 (24 weeks) will be a fixed-dose period. Treatment Period 2 (28 weeks) will be a dose-adjustment period to allow for individual optimization of prophylaxis. S ubjects from the [LOCATION_002] who complete 
Treatment Period 2 will be allowed to participate in an  Extension 
Period to  conti nue to receive treatment with open -label CSL830.  
Subjects belonging to the following categories will undergo 
assessment at a Screening Visit in order to confirm their eligibility:  
‚Ä¢ ‚ÄúCSL830-N a√Øve‚Äù Subjects (subjects who did not participate in 
study CSL830_3001; subjects who participated in study CSL830_3001 but did not receive blinded investigational product). 
‚Ä¢ ‚ÄúCSL830-Interrupted‚Äù Subjects (subjects who completed 
participation in study CSL830_3001, but who delayed entry 
into the current study [ie, > [ADDRESS_1177716] visit of CSL830_3002 Treatment Period 1 ]).  
Subjects belonging to the following category will not have a Screening Visit: 
‚Ä¢ ‚ÄúCSL830-Continuation‚Äù Subjects (subjects who complete 
participation in study CSL830_3001 and who continue directly 
on to participate in the current study [ ie, ‚â§ [ADDRESS_1177717] visit of CSL830_3002 Treatment Period 1] ).  
The eligibility  of ‚ÄúCSL83 0-Continuation ‚Äù Subjects  will include 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 6 of 130 
([LOCATION_002])  Confidential  evaluation based upon  assessments performed in CSL830_3001 
(see additional details in the protocol body).  
Treatment Period 1 will begin with the Day 1 Visit and will end 
with the Week 25 Visit. Treatment Period 2 will begin either  during 
the Week 25 Visit (if CSL830 is administered at the study visit) or 
immediately following the Week [ADDRESS_1177718] visit in Treatment Period 1 : 
‚Ä¢ 40 IU/kg CSL830 treatment group , OR   
‚Ä¢ 60 IU/kg CSL830 treatment group .  
CSL830 will be administered as a single subcutaneous injection 
twice weekly either independently (ie, self -administered by [CONTACT_1560]) or with assistance (ie, with the help of a caretaker such as a parent or guardian) at home during Treatment Period 1 and 
Treatment Period 2. Treatment will be administered in an open -
label manner.  
During the fixed -dose Treatment Period 1, subjects who experience 
very frequent HAE attacks  (ie, ‚â• 12 attacks, as defined  per 
protocol, within a 4 -week evaluation period) are eligible for 
CSL830 dose increases in increments of 20 IU/kg  (up to a 
maximum dose of 80 IU/kg). All CSL830 dose increases are 
optional, and will be made only in subjects who are eligible, at the 
sole discretion of investigator. D ose increases during Treatment 
Period [ADDRESS_1177719] very frequent HAE attack s to 
continue in the study during this  otherwise fixed -dose t reatment 
period .  
Beginning with the Week 25 Visit and throughout Treatment Period 
2, subjects who experience ‚â• 3 HAE attacks (as determined per protocol) within an 8-week evaluation period are eligible for 
CSL830 dose increases in increments of 20 IU/kg  (up to a 
maximum dose of 80 IU/kg). All CSL830 dose increases are 
optional, and will be made only in subjects who are eligible, at the 
sole discretion of investigator. D ose increases during Treat ment 
Period [ADDRESS_1177720]/optimize the dose for subjects who may need a higher dose for prophylaxis .  
An evaluation period for any dose increase in either Treatment Period 1 or Treatment Period 2 is defined as beginning af ter a dose -
stable period (ie,  2 weeks after the initiation or dose increase of 
CSL830). 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 7 of 130 
([LOCATION_002])  Confidential  Subjects will attend a Follow -up Visit occurring 14 days (¬±  3 days) 
after the final visit in Treatment Period 2 or any visit resulting in 
study discontinuation, unless informed consent/assent has been withdrawn  or if the Extension Period starts prior to the scheduled 
Follow- up Visit . During the Follow-up Period, subjects will be 
followed for HAE attacks , the emergence of new adverse events  
(AEs), and the use of concomitant medication . 
Primary Objective(s)  The primary objective is to assess the clinical safety of subcutaneously administered CSL830 in the long- term 
prophylactic treatment of HAE.  
Primary Endpoint(s)  The primary endpoints are the person- time incidence rates of each 
of the following: 
‚Ä¢ Adverse events leading to premature study discontinuation. 
‚Ä¢ Thromboembolic events (TEEs). 
‚Ä¢ Anaphylaxis.  
‚Ä¢ HAE attacks resulting in in -patient hospi[INVESTIGATOR_059]  (where 
hospi[INVESTIGATOR_847041]) . 
‚Ä¢ Solicited AEs (injection site reactions  at the CSL830 injection 
site) graded as severe by [CONTACT_093].  
‚Ä¢ Related serious adverse events (SAEs) , other than events 
specified above. 
‚Ä¢ Anti-C1-INH (anti-C1-esterase inhibitor) antibodies (inhibitory 
or non-inhibitory). 
The person- time incidence rate s are the number of subjects 
experiencing each primary endpoint safety event during treatment  
with CSL830, divided by [CONTACT_847048]‚Äôs time at risk. 
The primary endpoints will be assess ed for Treatment Period  1, 
Treatment Period 2 and Treat ment Periods 1 and 2 together. The 
primary endpoints will also be assessed for the Extension Period 
(only) and for the treatment periods overall  for subjects who are 
included in the Extension Period. 
Secondary 
Objective(s)  The secondary objectives are the following:  
1. To further characterize the clinical safety of subcutaneously 
administered CSL830 in the long- term prophylactic treatment 
of HAE.  
2. To characterize the clinical efficacy of subcutaneously administered CSL830 in the long- term prophylactic treatment 
of HAE.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 8 of 130 
([LOCATION_002])  Confidential  Secondary 
Endpoint(s)  1. The secondary safety endpoints are the following:  
a) The percentage of subjects experiencing the following events: SAEs, temporally -related AEs , increased risk scores 
for deep vein thrombosis (DVT) or pulmonary embolism 
(PE), TEEs , inhibitory anti-C1-INH antibodies, or clinically 
significant abnormalities in laboratory assessments  (ie, lab 
abnormalities reported as AEs) . 
b) The percentage of administrations of CSL830 resulting in 
solicited local AEs (discomfort [eg, pain, burning], swelling, bruising, or itching at the CSL830 injection site).  
c) The percentage of subjects who have at least 1 solicited local AE  (discomfort [eg, pain, burning], swelling, bruising, 
or itchin g at the CSL830 injection site).  
d) The percentage of subjects who become seropositive for human immunodeficiency virus types 1 or 2 (HIV -1/-2), 
hepatitis B virus (HBV), or hepatitis C virus (HCV).  
The secondary safety endpoints will be assessed for Treatment 
Period 1, Treatment Period 2, and Treatment Periods 1 and 2 (together). The secondary safety endpoints will also be assessed for the Extension Period (only) and for the treatment periods overall  
for subjects who are included in the Extension Period .  
2. Efficacy endpoints considered as secondary include the following:  
a) The percentage of subjects who experience a time -
normalized HAE attack frequency of < 1 HAE attack per 
4-week period.  
b) The percentage of subjects who are responders. ‚ÄúR esponse‚Äù 
is defined as a ‚â• 50% relative reduction in the time-
normalized number of HAE attacks during treatment with CSL830, compared with the time -normalized number of 
attacks that is used to qualify the subject for participation in 
the study.
 
The secondary efficacy e ndpoints will be assessed for Treatment 
Period 1, and Treatment Period s 1 and 2 (together). The seconda ry 
efficacy  endpoints will also be assessed for the Extension Period 
(only) and for the treatment periods overall for subjects who are included in the Extension Period. 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO([SORUDWRU\
2EMHFWLYHV









([SORUDWRU\
(QGSRLQWV

 
 
 
 
 

 
 
 
 
 

 
 
 
 


 


CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO
















6WXG\'HVLJQ 0XOWLFHQWHUUDQGRPL]HGRSHQ ODEHOSDUDOOHO DUPSKDVHEVWX G\
1XPEHURI6XEMHFWV 7KHVWXG\SODQVWRHQUROOVXEM HFWVZKRFRPSOHWHSDUWLFLSDWLRQL Q
&6/B$GGLWLRQDOVXEMHFWV ZKRKDYHQRWSDUWLFLSDWHGLQ
VWXG\&6/BZLOOEHHQUROOHGV RWKDWWKHWRWDOQXPEHURI
VXEMHFWVUDQGRPL]HGLV DSSUR[LPDWHO\
$VVXPLQJWKDWXSWRRIVXEMHFWVZLWKGUDZEHIRUHWKH
FRPSOHWLRQRIWKHVWXG\VXEMHFW VDUHSODQQHGWRFRPSOHWHW KH
VWXG\
6XEMHFWVIURPWKH8QLWHG6WDWHV ZKRKDYHFRPSOHWHG7UHDWPHQW
3HULRGDQG7UHDWPHQW3HULRGDUHH OLJLEOHWRHQUROOLQWKH
([WHQVLRQ3HULRG$SSUR[LPD WHO\RIWKHVHVXEMHFWVDUH
DQWLFLSDWHGWRHQUROOL QWKH([WHQVLRQ3HULRG
6WXG\'XUDWLRQ 7UHDWPHQW3HUL RGDQG7UHDWPHQW3HULRG
7KHGXUDWLRQRIWKHVWXG\IRUD QLQGLYLGXDOVXEM HFWLVH[SHFWHG WREH
XSWRZHHNV7KLVHVWLPDWLRQLVEDVHGRQCCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 11 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ A Screening Period  lasting up to 4  weeks  (‚â§ 28 days) , as 
needed . 
‚Ä¢ Two treatment periods totaling  52 weeks  (367 days ¬± 2 days) . 
‚Ä¢ A Follow-up Period lasting 2 weeks  (14 days ¬± 3 days). 
Extension Period  (Optional)  
The Extension Period (88 weeks) followed by [CONTACT_847049]- up (2 weeks) will begin at first subject first  visit in the 
Extension Period and result in an anticipated total study duration of 
up to approximately [ADDRESS_1177721] a ny Extension Period visits that occur within 6 weeks 
before the study end date will be handled as completers. These subjects will attend the final study visit ( Extension Period Week 
88) in place of their next study visit or telephone contact [CONTACT_847050]-up telephone contact (Extension Period Week  90 ¬± 
3 days). Subjects who roll-over into the Extension Period prior to the Treatment Period [ADDRESS_1177722] meet all of the following inclusion criteria in 
order to be enrolled (randomized) into the study: 
‚Ä¢ Male or female.  
‚Ä¢ Aged 6 years or older at the time of providing written informed 
consent/assent (as appropriate).  
‚Ä¢ A diagnosis of HAE type I or II , as determined by [CONTACT_14504]: a clinical history consistent with HAE and C1 -INH 
functional activity levels  < 50%, concurrent with C4 antigen 
concentrations below normal limits . NOTE:  Additional details 
on the application of this criterion to ‚ÄúCSL830-Continuation/-
Interrupted/-Na√Øve‚Äù Subjects are presented in the protocol body.  
‚Ä¢ Have experienced HAE attacks (requiring acute treatment, 
medical attention or causing significant functional impairment) , 
as described below : 
o For ‚ÄúCSL830 Na√Øve‚Äù Subjects :  
ÔÉò ‚ÄúCSL830-Na√Øve‚Äù Subjects using intravenous C1- INH as 
routine (long- term) prophylaxis against HAE attacks must 
have experienced [ADDRESS_1177723] medical records.  
ÔÉò All other ‚ÄúCSL830- Na√Øve‚Äù Subjects (eg, treated using 
oral HAE prophylaxis against HAE attacks or on -demand 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 12 of 130 
([LOCATION_002])  Confidential  treatment) must have experienced [ADDRESS_1177724] medical records.   
o For ‚ÄúCSL830- Continuation‚Äù Subjects AND ‚ÄúCSL830-
Interrupted‚Äù Subjects : Subjects must have experienced 
[ADDRESS_1177725] medical records (ie, the HAE attack frequency required for eligibility to participate in study CSL830_3001). 
‚Ä¢ For subjects who have used oral medication for prophylaxis 
against HAE attacks (ie, androgens, tranexamic acid, 
progestins) during the [ADDRESS_1177726] udy visit : use 
of a stable  regimen of oral prophylactic medication (ie, dose 
and administration frequency) during the [ADDRESS_1177727] 
not be enrolled (randomized) into the study:  
‚Ä¢ Known incurable malignancies at the time of the first study 
visit. 
‚Ä¢ Any clinical condition that is likely to interfere with evaluation 
of CSL830 or satisfactory conduct of the stud y. 
‚Ä¢ A clinically significant history of poor response to C1- INH 
therapy for the management of HAE.  
‚Ä¢ A suspected or confirmed diagnosis of acquired HAE or HAE with normal C1 -INH (ie, HAE type III).  
‚Ä¢ Assessed by [CONTACT_847051] -demand 
treatment, when that on- demand treatment is administered 
independently or with assistance. 
Study Product Dose, 
Dosing Regimen and Administration   CSL830 is a C1 -INH concentrate, which is a volume -reduced 
formulation of the marketed product, Berinert, currently licensed for the acute treatment of HAE attacks. CSL830 is a lyophilized powder (1500 IU C1- INH per single -use vial) reconstituted with 
3 mL water for injection.  
During Treatment Periods 1 and 2 , subjects who do not increase 
their dose of CSL830 will administer CSL830 (40 IU/kg or 
60 IU/kg , per randomization) via a single SC injection, twice 
weekly. During Treatment Periods [ADDRESS_1177728] 500 IU, 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDODVWKLVFRUUHVSRQGVZLWKDSUDF WLFDOYROXPHRIP/RI&6/
'XULQJWKH([WHQVLRQ3HULRGWKH DFWXDOGRVHRI&6/WKDWLV
DVVLJQHGZLOOEHURXQGHGLHXS RUGRZQWRWKHQHDUHVW,8
IRUVXEMHFWVZHLJKLQJ¬ïNJVXEMHFWVZHLJKLQJNJZLOOFRQWLQXHWRXQGHUJRURXQGLQJDV GXULQJ7UHDWPHQW3HULRGVDQG 
LHURXQGHGXSWRWKHQHDUHVW,8
6XEMHFWVZKRDUHUDQGRPL]HGWRW UHDWPHQWZLWK,8NJ&6/
PD\XQGHUJRXSWRLQGHSHQGHQW,8NJGRVHLQFUHDVHVIRUD
PD[LPXPILQDOGRVHRI,8NJ 6XEMHFWVZKRDUHUDQGRPL]HGWR
WUHDWPHQWZLWK,8NJ&6/P D\XQGHUJRDVLQJOH,8NJ
GRVHLQFUHDVHIRUDPD[LPXPIL QDOGRVHRI,8NJ$OOGRVH
LQFUHDVHVZLOOEHPDGHLQHOLJ LEOHVXEMHFWVRQO\DQGDWWKH
GLVFUHWLRQRILQYHVWLJDWRU
,8NJ&6/LVHTXLYDOH QWWRDYROXPHRIP/NJ
,8NJ&6/LVHTXLYDOHQW WRDYROXPHRIP/NJ
,8NJ&6/LVHTXLYDOHQW WRDYROXPHRIP/NJ
'XULQJWKH([WHQVLRQ3HULRG HDFKVXEMHFWZLOOFRQWLQXHWREH
HOLJLEOHIRUGRVHHVFDODWLRQLQL QFUHPHQWVRI,8NJXSWRD 
PD[LPXPGRVHRI,8NJDFFRUG LQJWRWKHUXOHVRXWOLQHGIRU
7UHDWPHQW3HULRGVHHDERYH
(IILFDF\$VVHVVPHQWV 

 
 
 
 
 
 

 




6DIHW\$VVHVVPHQWV 7KHVDIHW\RI&6/IRUWKHO RQJWHUPSURSK\ODFWLFWUHDWPHQWR I
+$(ZLOOEHDVVHVVHGEDV HGRQWKHIROORZLQJ
x9LWDOVLJQV
x3K\VLFDOH[DPLQDWLRQ
x&OLQLFDOVFRUHVRIULVNDVV HVVPHQWIRU'97DQG3(CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx6ROLFLWHGORFDO$(VLQMH FWLRQVLWHUHDFWLRQV
x2WKHU$(VLQFOXGLQJ6$(V
x&OLQLFDOODERUDWRU\DVVHVVPHQWV
R+HPDWRORJ\ELRFKHPLVWU\D QGFRDJXODWLRQSURILOHV
R9LUDOVHURORJ\
R$QWL&,1+DQWLERGLHV
R8ULQDO\VLV
3KDUPDFRNLQHWLFV

3KDUPDFRG\QDPLFV 
2WKHU$VVHVVPHQWV 





6WDWLVWLFDO$QDO\VHV &RQWLQXRXVYDULDEOHVZLOOEHGH VFULEHGXVLQJPHDQZLWKWKH
UHOHYDQWFRQILGHQFHLQWHUYDOV &,JHRPHWULFPHDQDQGWKH
UHOHYDQW&,VWDQGDU GGHYLDWLRQUDQJHWKWKPHGLDQDQG
WKSHUFHQWLOHVJHRPHWULFFRHIILFLHQWRIYDULDWLRQH[SUHVVHGDVD 
SHUFHQWDJHDSSOLFDEOHWR3. DQG3'GDWDRQO\DQGFRXQWVRI
PLVVLQJDQGQRQPLVVLQJYDOXHV& DWHJRULFDOYDOXHVZLOOEH
GHVFULEHGXVLQJFRXQWVDQGSHUFHQWDJHV
6DIHW\$QDO\VHV
7UHDWPHQW3HULRGDQG 7UHDWPHQW3HULRG
6DIHW\DQDO\VHVZLOOEHSHUIRUP HGE\WUHDWPHQWJURXSLHE\
VXEMHFWVZKRDUHUDQGRPL]HGWR,8NJ&6/DQGE\VXEMHFWVZKRDUHUDQGRPL]HGWR,8NJ& 6/'DWDFROOHFWHGIURP
WKRVHVXEMHFWVZLOOEHLQFO XGHGLQWKH,8NJDQG,8NJ
&6/WUHDWPHQWJURXSVUHVS HFWLYHO\XQWLOWKHWLPHWKH\XQGH UJR
WKHILQDOVWXG\YLVLWRUXQGH UJRD&6/GRVHLQFUHDVHZKLFKH YHU
FRPHVILUVW
$VHFRQGDU\VDIHW\DQDO\VLVZ LOOEHSHUIRUPHGE\WUHDWPHQWJURX S
>LHE\VXEMHFWVZKRDUHUD QGRPL]HGWR,8NJ&6/DQGE\
VXEMHFWVZKRDUHUDQGRPL]HGWR ,8NJ&6/UHJDUGOHVVRI
DQ\GRVHLQFUHDVHV@'DWDFROO HFWHGIURPWKRVHVXEMHFWVZLOO EH
LQFOXGHGLQWKH,8NJDQG,8 NJ&6/WUHDWPHQWJURXSVCCI
CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2015  Page 15 of 130 
([LOCATION_002])  Confidential  respectively, until the time they undergo the final study visit . 
The analyses will be done both for Treatment P eriod 1 (only) and 
for Treatment Period 1 and 2 (together), unless otherwise noted. 
Furthermore, safety analyses will be summarized by [CONTACT_847052] 40 IU/kg CSL830 and who have 1 dose 
increase; by [CONTACT_847053] 40 IU/kg  CSL830 and 
who have 2 dose increases; by [CONTACT_847053] 
60 IU/kg  CSL830 and who have [ADDRESS_1177729] in Treatment Period 1 or 2. 
The person- time incidence rate of each primary endpoint safety 
event will be assessed  as primary safety analysis, as defined above 
and overall. Adverse events will be classified using the Medical Dictionary for 
Regulatory Activities (MedDRA).  Serious AEs,  temporally -related 
AEs,  increased ris k scores for DVT or  PE, thromboembolic events, 
inhibitory anti -C1-INH antibodies, or clinically significant 
abnormalities in laboratory assessments occurring during treatment 
will be summarized  for the safety analyses.  
Extension Period  
Data collected during the Extension Period will be summarized as follows:  
‚Ä¢ For the Extension Period only (separate from data collected during Treatment Period 1 and Treatment Period 2 using 
descriptive statistics. ) 
‚Ä¢ For Treatment Period 1, Treatment Period 2 and the Extension Period (combined) 
Only data collected from subjects who are in enrolled the 
Extension Period will be included in these analyses. 
Interim Analyses  Interim analyses will be conducted on an as-needed basis in order to support regulatory activities.  The results of interim analys es are 
not intended to be used to stop or adapt the study. Additional 
details will be provided in the statistical analysis plan ( SAP). 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO6FKHGXOHRI(YHQWVIRU¬≥&6/&RQWLQXDWLRQ¬¥6XEMHFWV$
 7UHDWPHQW3HULRG%& 7UHDWPHQW3HULRG& )ROORZXS'
:HHN 
6HH
)RRWQRWH''D\ 
:LQGRZGD\V ¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì
6WXG\FHQWHUYLVLW ;  ;  ;  ;;  ;  ;  ; ;
7HOHSKRQHFRQWDFW  ;  ;  ;   ;  ;  ;  
,QIRUPHG&RQVHQW$VVHQWDVDSSOLFDEOH( ;  
,QFOXVLRQH[FOXVLRQFULWHULD ;  
,QGLYLGXDODFXWHDFWLRQSODQ) ;  
(QUROOPHQWDQGUDQGRPL]DWLRQ ;  
'HPRJUDSKLFVDQGPHGLFDOKLVWRU\* ; 
3K\VLFDOH[DPLQDWLRQ ;+ ;    ;;  ;    ; 
,QGZHOOLQJFDWKHWHU\HVQR ;  ; 
9LWDOVLJQVLQFOXGLQJERG\ZHLJKW;+ ;  ;  ;;  ;  ;  ; 
+HLJKW ;   
$VVHVVULVNRI'97DQG3( ;+ ;  ;  ;;  ;  ;  ; 
   ;   ; 
 ;  ;    ;;  ;    ; 
&OLQLFDO/DERUDWRU\$VVHVVPHQWV, ;  ;    ;;  ;    ; 
'LVSHQVH&6/RWKHUVXSSOLHV ;  ;  ;  ;;  ;  ;   
&RQILUPDFFHVVWRRQGHPDQG+$(PHGLFDWLRQ ;  ;  ;  ;;  ;  ;  ; 
$VVHVVIRU&6/GRVHLQFUHDVH ./
7UDLQVXEMHFWREVHUYH&6/DGPLQ- ;  
&6/DFFRXQWDELOLW\ ;  ;  ;  ;;  ;  ;  ; 
3ULRUDQGFRQFRPLWDQWWKHUDS\
$GYHUVHHYHQWV
'LVSHQVHH'LDU\ ; 
5HYLHZH'LDU\UHFRUGDWWDFNVLQH&5)   ;  ;  ;;  ;  ;  ; ;CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2014  Page 17 of 130 
([LOCATION_002])  Confidential   Treatment Period 1 B, C Treatment Period 2 C Follow-up D 
Week 1 5 9 13 17 21 25 29 33 37 41 45 49 53 
See 
Footnote  D. Day 1 29 57 85 113 141 169 197 225 253 281 309 337 367 
Window (days)   ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± 2 ¬± [ADDRESS_1177730] eDiary                X M 
Schedule next visit / contact  X  X  X  X X  X  X  X  
[Abbrevi ations and footnotes are presented on the following page.]  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO$EEUHYLDWLRQVXVHGLQWKH6FKHGXOHRI(YHQWVIRU¬≥&6/&RQWLQ XDWLRQ¬¥6XEMHFWV
'97 GHHSYHLQWKURPERVLVH&5) HOHFWURQLFFDVHUHSRUWIRUP H'LDU\ HOHFWURQLFGLDU\ 
+$( KHUHGLWDU\DQJLRHGHPD 3( 
SXOPRQDU\HPEROLVP 

1RWHVWRWKH6FKHGXOHRI(YHQWVIRU¬≥&6/&RQWLQXDWLRQ¬¥6XEMH FWV
$¬≥&6/&RQWLQXDWLRQ¬¥6XEMHFWVDUHVXEMHFWVZKRFRPSOHWHSDUWLF LSDWLRQLQVWXG\&6/BDQGZKRFRQWLQXHGLUHFWO\RQWRSD UWLFLSDWHLQWKHFXUUHQW
VWXG\LH¬îZHHNEHWZHHQWKH(QGRI6WXG\9LVLWRI&6/B DQGWKHILUVWYLVLWRI&6/B7UHDWPHQW3HULRG
%¬≥&6/&RQWLQXDWLRQ¬¥6XEMHFWV
x0XVWPHHWWKHHOLJLELOLW\ FULWHULDSUHVHQWHGLQ 6HFWLRQDQG6HFWLRQLQRUGHUWRSDUWLFLSDWHLQ&6/B
x0D\XVHWKHUHVXOWVRIDVVHVVPHQWVFRQGXFWHGLQ&6/BLQ RUGHUWRVXSSRUWWKHDVVHVVPHQWRI&6/BHOLJLELOLW\DV GHVFULEHGLQ
6HFWLRQ
x6KRXOGVFKHGXOHWKHILQDOVWXG\YLVLWRI&6/BRQWKHVDP HGD\DVWKH'D\9LVLWRI&6/B7UHDWPHQW3HULRGZKH UHSRVVLEOH
&'XULQJ7UHDWPHQW3HULRGVDQGVXEMHFWVZLOODGPLQLVWHU&6/ WZLFHSHUZHHNHJ0RQGD\DQG7KXUVGD\RIHDFKZHHNLQGHSH QGHQWO\RUZLWK
DVVLVWDQFHWKHILQDODGPLQLVWUDWLRQRI&6/VKRXOGRFFXUSUL RUWRWKH:HHN9LVLWLQ7UHDWPHQW3HULRG
'6XEMHFWVZLOODWWHQGD)ROORZXS 9LVLWRFFXUULQJ GD\V¬ìGD \VDIWHUWKHILQDOYLVLWLQ7U HDWPHQW3HULRGRUDQ\YLVLWUH VXOWLQJLQVWXG\GLVFRQWLQXDWLRQ
XQOHVVLQIRUPHGFRQVHQWDVVHQWKDVEHHQZLWKGUDZQRULIWKH([W HQVLRQ3HULRGVWDUWVSULRUWR WKHVFKHGXOHG)ROORZXS9LVLW
(:ULWWHQLQIRUPHGFRQVHQWDVVHQW DVDSSURSULDWHPXVWEHSURYLG HGEHIRUHDQ\VWXG\VSHFLILFDVVHVVPHQWVRUSURFHGXUHVDUHSHUI RUPHG
)7KHLQYHVWLJDWRUVKRXOGFUHDWHXSGDWHWKHLQGLYLGXDODFXWHDFWL RQSODQDVDSSURSULDWHDQGUHYLHZZLWKWKHVXEMHFWRQ'D\R I7UHDWPHQW3HULRG
*'HPRJUDSKLFVDQGFOLQLFDOO\VLJ QLILFDQWPHGLFDOKLVWRU\ZLOOEH XSGDWHGDVQHHGHGWRSURYLGHDFRPSOHWH&6/BVXEMHFW UHFRUG
+,IWKHVHDVVHVVPHQWVZHUHFRQGXFWHGDWWKH&6/B(QGRI6 WXG\9LVLWWKHQWKH\GRQRWQHHGWREHUHSHDWHGRQ'D\RI7U HDWPHQW3HULRG
,7KHFOLQLFDOODERUDWRU\DVVHVVPHQ WVWREHFRQGXFWHGDUHSUHVHQW HGLQWKH6FKHGXOHRI(YHQWVIRU¬≥&6/,QWHUUXSWHG¬¥6XEMHFWVDQG¬≥&6/ 1DwYH¬¥
6XEMHFWV
-&6/LQMHFWLRQWHFKQLTXHDQGGRVLQJUHJLPHQDQGXVHRIH'LDU \ZLOOEHUHYLHZHGZLWKHDFKVXEMHFWWKHDGPLQLVWUDWLRQRI&6/ ZLOOEHREVHUYHG
.'XULQJWKHIL[HGGRVH7UHDWPHQW3HULRGVXEMHFWVZKRH[SHULHQ FHYHU\IUHTXHQW+$(DWWDFNVLH¬ïDWWDFNVDVGHILQHGSHU SURWRFROZLWKLQDZHHN
HYDOXDWLRQSHULRGDUHHOLJLEOHIRU&6/GRVHLQFUHDVHVLQLQ FUHPHQWVRI,8NJXSWRDPD[ LPXPGRVHRI,8NJ$OO&6 /GRVHLQFUHDVHVDUH
RSWLRQDODQGZLOOEHPDGHRQO\ LQVXEMHFWVZKRDUHHOLJLEOHD WWKHVROHGLVFUHWLRQRILQYHVWL JDWRU$QHYDOXDWLRQSHULRGIRU DQ\GRVHLQFUHDVHLVGHILQHGDV
EHJLQQLQJDIWHUDGRVHVWDEOHSHULRGLHZHHNVDIWHUWKHLQL WLDWLRQRUGRVHLQFUHDVHRI&6/6HH 6HFWLRQIRUDGGLWLRQDOGHWDLOVCCICCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2014  Page 19 of 130 
([LOCATION_002])  Confidential  L: Beginning with the Week 25 Visit and throughout Treatment Period 2 , subjects who experience ‚â• 3 HAE attacks (as determined per protocol) wi thin an 
8-week evaluation period are eligible for CSL830 dose increases in increments of 20 IU/kg  (up to a maximum dose of 80 IU/kg). All CSL830 dose increases 
are optional, and will be made only in subjects  who are eligible, at the sole discretion of investigator . An evaluation period for any dose increase is defined 
as beginning after a dose- stable period (ie,  2 weeks after the initiation or dose increase of CSL830) . See  Section 3.2 for additional details.  
M: The subject eDiary will not be collected from subject s at the  last visit of Treatment Period 2 (Follow -up Visit)  if they plan to participate in the E xtension 
Period .  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO6FKHGXOHRI/DERUDWRU\$VVHVVPHQWVIRU¬≥&6/&RQWLQXDWLRQ¬¥6X EMHFWV$
 7UHDWPHQW3HULRG 7UHDWPHQW3HULRG )ROORZXS%
:HHN 
6HH
)RRWQRWH%'D\
:LQGRZGD\V ¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì
6WXG\FHQWHUYLVLW ;  ;  ;  ;;;;; ;
7HOHSKRQHFRQWDFW  ;  ;  ;  ;;;
%ORRGVDPSOHV
x+HPDWRORJ\
x%LRFKHPLVWU\
x&RDJXODWLRQ;&; ;;; ; 

;'; ;;; ; 
%ORRGVDPSOHIRUDQWL&,1+DQWLERG\ ;& ; ; 
%ORRGVDPSOHIRUYLUDOVHURORJ\ ;& ; ; 
8ULQHVDPSOHIRUXULQDO\VLV ;&; ;;; ; 
8ULQHVDPSOHIRUSUHJQDQF\WHVW(;; ;  ; ; 
&,1+ &HVWHUDVHLQKLELWRU   
1RWHVWRWKH6FKHGXOHRI/DERUDWRU\$VVHVVPHQWVIRU¬≥&6/&RQ WLQXDWLRQ¬¥6XEMHFWV
$¬≥&6/&RQWLQXDWLRQ¬¥6XEMHFWVDUHVXEMHFWVZKRFRPSOHWHSDUWLF LSDWLRQLQVWXG\&6/BDQGZKRFRQWLQXHGLUHFWO\RQWRSD UWLFLSDWHLQWKHFXUUHQW
VWXG\LH¬îZHHNEHWZHHQWKH(QGRI6WXG\9LVLWRI&6/B DQGWKHILUVWYLVLWRI&6/B7UHDWPHQW3HULRG
%6XEMHFWVZLOODWWHQGD)ROORZXS 9LVLWRFFXUULQJGD\V¬ìG D\VDIWHUWKHILQDOYLVLWLQ7UHDWPHQW3HULRGRUDQ\YLVLWU HVXOWLQJLQVWXG\
GLVFRQWLQXDWLRQXQOHVVLQIRUPHGFRQVHQWDVVHQWKDVEHHQZLWKGU DZQRULIWKH([WHQVLRQ3HULRGVWDUWVSULRUWRWKHVFKHGXOHG)R OORZXS9LVLW
&,IWKHVHDVVHVVPHQWVDUHRUKDYHEHHQFRQGXFWHGDWWKH&6/B (QGRI6WXG\9LVLWWKHQWKH\GRQRWQHHGWREHUHSHDWHGKH UH
' 
CCI
CCI CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2014  Page 21 of 130 
([LOCATION_002])  Confidential  E: The urine test for beta -human chorionic gonadotropin will be performed at the study site. All females are to be tested to assess eligibility prior 
to randomization an d dosing.  A urine pregnancy test  will be conducted to assess eligibility ONLY if the CSL830_3001 End of Study Visit  and 
the first visit of  CSL830_3002 Treatment Period 1 (ie, Day 1) occur on different days .  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO6FKHGXOHRI(YHQWVIRU¬≥&6/,QWHUUXSWHG¬¥6XEMHFWV$DQG¬≥&6/1DwYH¬¥6XEMHFWV%
 6FUHHQLQJ& 7UHDWPHQW3HULRG' 7UHDWPHQW3HULRG' )ROORZXS(
:HHN WR 
6HH
)RRWQRWH('D\WR 
:LQGRZGD\V  ¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì
6WXG\FHQWHUYLVLW ;;;);  ;  ;;  ;  ;  ;;
7HOHSKRQHFRQWDFW    ;  ;; ;;; 
,QIRUPHG&RQVHQW$VVHQWDVDSSOLFDEOH*;        
,QFOXVLRQH[FOXVLRQFULWHULD ;;       
,QGLYLGXDODFXWHDFWLRQSODQ+ ;;       
0RQLWRU'RFXPHQW+$($WWDFNV, ;        
(QUROOPHQWDQGUDQGRPL]DWLRQ  ;       
'HPRJUDSKLFVDQGPHGLFDOKLVWRU\  ;        
3K\VLFDOH[DPLQDWLRQ ;    ;  ;;;; 
,QGZHOOLQJFDWKHWHU\HVQR ;        ; 
9LWDOVLJQVLQFOXGLQJERG\ZHLJKW-;    ;  ;;;;;; 
$VVHVVULVNRI'97DQG3( ;    ;  ;;;;;; 
   ; ; 
 ;   ;  ;;;; 
&OLQLFDO/DERUDWRU\$VVHVVPHQWV. ;;   ;  ;;;; 
'LVSHQVH&6/RWKHUVXSSOLHV ;  ;  ;;;;; 
&RQILUPDFFHVVWRRQGHPDQG+$(PHG ;;;  ;  ;;;;;; 
$VVHVVIRU&6/GRVHLQFUHDVH 01
7UDLQVXEMHFWREVHUYH&6/DGPLQ/ ;;      
&6/DFFRXQWDELOLW\  ;;  ;  ;;;;;; 
3ULRUDQGFRQFRPLWDQWWKHUDS\
$GYHUVHHYHQWV
'LVSHQVHH'LDU\  ; 
5HYLHZH'LDU\UHFRUGDWWDFNVLQH&5)   ;  ;  ;  ;;  ;  ;  ;;
&ROOHFWH'LDU\          ;2
6FKHGXOHQH[WYLVLWFRQWDFW ; ;;  ;  ;  ;;  ;  ;  ; 
>$EEUHYLDWLRQVDQGIRRWQRWHVDUHSUHVHQWHGRQWKHIROORZLQJSDJ H@CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO$EEUHYLDWLRQVXVHGLQWKH6FKHGXOHRI(YHQWVIRU¬≥&6/,QWHUU XSWHG¬¥6XEMHFWVDQG¬≥& 6/1DwYH¬¥6XEMHFWV
'97 GHHSYHLQWKURPERVLVH&5) HOHFWURQLFFDVHUHSRUWIRUP H'LDU\ HOHFWURQLFGLDU\ 
+$( KHUHGLWDU\DQJLRHGHPD PHG PHGLFDWLRQ3( SXOPRQD U\
HPEROLVP 

1RWHVWRWKH6FKHGXOHRI(YHQWVIRU¬≥&6/,QWHUUXSWHG¬¥6XEMHF WVDQG¬≥&6/1DwYH¬¥6XEMHFWV
$¬≥&6/,QWHUUXSWHG¬¥6XEMHFWVDUHVXEMHFWVZKRFRPSOHWHGSDUWLFL SDWLRQLQVWXG\&6/BEXWZKRGHOD\HGHQWU\LQWRWKHFXU UHQWVWXG\LH!ZHHNEHWZHHQWKH(QG
RI6WXG\9LVLWRI&6/BDQGWKHILUVWYLVLWRI&6/B 7UHDWPHQW3HULRG
%¬≥&6/1DwYH¬¥6XEMHFWVLQFOXGHWKHIROORZLQJ
x6XEMHFWVZKRGLGQRWSDUWLFLSDWHLQVWXG\&6/B
x6XEMHFWVZKRSDUWLFLSDWHGLQVWXG\&6/BEXWGLGQRWUHFH LYHEOLQGHGLQYHVWLJDWLRQDOSURGXFWDVSDUWRIWKDWVWXG\
&7KH6FUHHQLQJ9LVLWDQGWKH'D\9LVLWRI7UHDWPHQW3HULRGF DQRFFXURQWKHVDPHGD\,IDVXEMHFWIDLOV6FUHHQLQJDWDFRP ELQHG6FUHHQLQJ9LVLW 'D\9LVLWWKHQWKH
VXEMHFWZLOOEHWUHDWHGDVDVFUHHQIDLOXUH
''XULQJ7UHDWPHQW3HULRGVDQG VXEMHFWVZLOODGPLQLVWHU&6/ WZLFHSHUZHHNHJ0RQGD\DQG7KXUVGD\RI HDFKZHHNLQGHSHQGHQWO\RUZLWKDVVLVWDQFHWKHILQDO
DGPLQLVWUDWLRQRI&6/VKRXOGRFFXUSULRUWRWKH:HHN9LVL WLQ7UHDWPHQW3HULRG
(6XEMHFWVZLOODWWHQGD)ROORZXS9LVLWRFFXUULQJGD\V¬ìG D\VDIWHUWKHILQDOYLVLWLQ7U HDWPHQW3HULRGRUDQ\YLVLWU HVXOWLQJLQVWXG\GLVFRQWLQXDWLRQXQOHVVLQIRUPHG
FRQVHQWDVVHQWKDVEHHQZLWKGUDZQRULIWKH([WHQVLRQ3HULRGVW DUWVSULRUWRWKHVFKHGXOHG)ROORZXS9LVLW
)7KH'D\9LVLWPD\EHZDLYHGIRU¬≥&6/,QWHUUXSWHG¬¥6XEMHFWV RQO\LIWKHLQYHVWLJDWRUKDVFRQILUPHGWKDWWKHVXEMHFWFDQ DGHTXDWHO\WUHDWWKHPVHOYHVZLWK&6/
LHQRIXUWKHUWUDLQLQJLVQHFHVVDU\,QWKLVFDVHDOODFWLY LWLHVVFKHGXOHGIRUWKH'D\YLV LWPD\EHFRQGXFWHGDWWKH'D\ 9LVLW
*:ULWWHQLQIRUPHGFRQVHQWDVVHQWDVDSSURSULDWHPXVWEHSURYLG HGEHIRUHDQ\VWXG\VSHFLILFDVVHVVPHQWVRUSURFHGXUHVDUHSHUI RUPHG
+7KHLQYHVWLJDWRUVKRXOGFUHDWHXSGDWHWKHLQGLYLGXDODFXWHDFWL RQSODQDVDSSURSULDWHDQGUHYLHZZLWKWKHVXEMHFWRQ'D\R I7UHDWPHQW3HULRG
,%HJLQQLQJDIWHUWKH6FUHHQLQJ9LVLWXQWLO'D\RI7UHDWPHQW3H ULRG+$(DWWDFNVVKRXOGEHPRQLWRUHGDQGGRFXPHQWHGLQGHSHQG HQWO\RIWKHH'LDU\
-+HLJKWZLOOEHFROOHFWHGDWWKH6FUHHQLQJ9LVLWRQO\
.7KHFOLQLFDOODERUDWRU\DVVHVVPHQWVWREHFRQGXFWHGDUHSUHVHQW HGLQWKH6FKHGXOHRI(YHQWVIRU¬≥&6/,QWHUUXSWHG¬¥6XEMHFWVDQG¬≥&6/ 1DwYH¬¥6XEMHFWV 
/&6/LQMHFWLRQWHFKQLTXHDQGGRVLQJUHJLPHQDQGXVHRIH'LDU \ZLOOEHUHYLHZHGZLWKHDFKVXEMHFWWKHDGPLQLVWUDWLRQRI&6/ ZLOOEHREVHUYHG
0'XULQJWKHIL[HGGRVH7UHDWPHQW3HULRGVXEMHFWVZKRH[SHULHQ FHYHU\IUHTXHQW+$(DWWDFNVLH¬ïDWWDFNVDVGHILQHGSHU SURWRFROZLWKLQDZHHNHYDOXDWLRQSHULRG
DUHHOLJLEOHIRU&6/GRVHLQFUHDVHVLQLQFUHPHQWVRI,8N JXSWRDPD[LPXPGRVHRI,8NJ$OO&6/GRVHLQFUHDVHV DUHRSWLRQDODQGZLOOEHPDGHRQO\LQ
VXEMHFWVZKRDUHHOLJLEOHDWWKHVROHGLVFUHWLRQRILQYHVWLJDW RU$QHYDOXDWLRQSHULRGIRUDQ\GRVHLQFUHDVHLVGHILQHGDVEH JLQQLQJDIWHUDGRVHVWDEOHSHULRGLHZHHNVDIWHU
WKHLQLWLDWLRQRUGRVHLQFUHDVHRI&6/6HH 6HFWLRQIRUDGGLWLRQDOGHWDLOV
1%HJLQQLQJZLWKWKH:HHN9LVLWDQGWKURXJKRXW7UHDWPHQW3HULR GVXEMHFWVZKRH[SHULHQFH¬ï+$(DWWDFNVDVGHWHUPLQHGSHU SURWRFROZLWKLQDQZHHNHYDOXDWLRQ
SHULRGDUHHOLJLEOHIRU&6/GRVHLQFUHDVHVLQLQFUHPHQWVRI ,8NJXSWRDPD[LPXPGRVHRI,8NJ$OO&6/GRVHLQ FUHDVHVDUHRSWLRQDODQGZLOOEHPDGHRQO\
LQVXEMHFWVZKRDUHHOLJLEOHDWWKHVROHGLVFUHWLRQRILQYHVWL JDWRU$QHYDOXDWLRQSHULRGIRUDQ\GRVHLQFUHDVHLVGHILQHGDV EHJLQQLQJDIWHUDGRVHVWDEOHSHULRGLHZHHNV
DIWHUWKHLQLWLDWLRQRUGRVHLQFUHDVHRI&6/6HH 6HFWLRQIRUDGGLWLRQDOGHWDLOV CCICCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2014  Page 24 of 130 
([LOCATION_002])  Confidential  O: The subject eDiary will not be collected from subjects at the last visit of Treatment Period 2 (Follow -up Visit) if they plan to participate in the Extension Period.   
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO6FKHGXOHRI/DERUDWRU\$VVHVVPHQWVIRU¬≥&6/,QWHUUXSWHG¬¥6XE MHFWV$DQG¬≥&6/1DwYH¬¥6XEMHFWV%
 6FUHHQLQJ 7UHDWPHQW3HULRG 7UHDWPHQW3HULRG )ROORZXS&
:HHN WR 
6HH
)RRWQRWH&'D\WR 
:LQGRZGD\V ¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì
6WXG\FHQWHUYLVLW ;;;  ;  ;  ;;  ;  ;  ; ;
7HOHSKRQHFRQWDFW    ;  ;  ;  ;  ;  ;  
%ORRGVDPSOHV
x+HPDWRORJ\
x%LRFKHPLVWU\
x&RDJXODWLRQ;;;;;; 


;(;;;;;; 
%ORRGVDPSOHIRUDQWL&,1+DQWLERG\  ;;; 
%ORRGVDPSOHIRUYLUDOVHURORJ\  ;;; 
8ULQHVDPSOHIRUXULQDO\VLV  ;;;;;; 
8ULQHVDPSOHIRUSUHJQDQF\WHVW';;;  ;; 
&,1+ &HVWHUDVHLQKLELWRU   
1RWHVWRWKH6FKHGXOHRI/DERUDWRU\$VVHVVPHQWVIRU¬≥&6/,QW HUUXSWHG¬¥6XEMHFWVDQG¬≥& 6/1DwYH¬¥6XEMHFWV
$¬≥&6/,QWHUUXSWHG¬¥6XEMHFWVDUHVXEMHFWVZKRFRPSOHWHGSDUWLFL SDWLRQLQVWXG\&6/BEXWZKRGHOD\HGHQWU\LQWRWKHFXU UHQWVWXG\LH!ZHHNEHWZHHQWKH(QG
RI6WXG\9LVLWRI&6/BDQGWKHILUVWYLVLWRI&6/B 7UHDWPHQW3HULRG
%¬≥&6/1DwYH¬¥6XEMHFWVLQFOXGHWKHIROORZLQJ
x6XEMHFWVZKRGLGQRWSDUWLFLSDWHLQVWXG\&6/B
x6XEMHFWVZKRSDUWLFLSDWHGLQVWXG\&6/BEXWGLGQRWUHFH LYHEOLQGHGLQYHVWLJDWLRQDOSURGXFWDVSDUWRIWKDWVWXG\
&6XEMHFWVZLOODWWHQGD)ROORZXS9LVLWRFFXUULQJGD\V¬ìG D\VDIWHUWKHILQDOYLVLWLQ7U HDWPHQW3HULRGRUDQ\YLVLWU HVXOWLQJLQVWXG\GLVFRQWLQXDWLRQ
XQOHVVLQIRUPHGFRQVHQWDVVHQWKDVEHHQZLWKGUDZQRULIWKH([W HQVLRQ3HULRGVWDUWVSULRUWRWKHVFKHGXOHG)ROORZXS9LVLW
'7KHXULQHWHVWIRUEHWDKXPDQFKRULRQLFJRQDGRWURSLQZLOOEHSH UIRUPHGDWWKHVWXG\VLWH$OOIHPDOHVDUHWREHWHVWHGWRDVVH VVHOLJLELOLW\SULRUWR
UDQGRPL]DWLRQDQGGRVLQJCCI
CCI CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO( 
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO6FKHGXOHRI(YHQWVIRUWKH([WHQVLRQ3HULRG 
9LVLW&RQWDFW $%)ROORZ
XS&
([WHQVLRQ3HULRG:HHN  
([WHQVLRQ3HULRG'D\  
:LQGRZGD\V '¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì ¬ì
6WXG\FHQWHUYLVLW ;  ;  ;  ;  ;  ;  ;  ;; 
7HOHSKRQHFRQWDFW  ;  ;  ;  ;  ;  ;  ;   ;
([WHQVLRQ3HULRG,QIRUPHG&RQVHQW$VVHQW ;   
3K\VLFDOH[DPLQDWLRQ   ;; ; 
,QGZHOOLQJFDWKHWHU\HVQR ;(   ; 
9LWDOVLJQVLQFOXGLQJERG\ZHLJKW;( ;  ;  ;  ;  ;  ;  ;; 
$VVHVVULVNRI'97DQG3( ;( ;  ;  ;  ;  ;  ;  ;; 
  ;      ;   ; 
   ;      ;   ; 
%ORRGVDPSOHVIRU$/7$67DQGFRDJXODWLRQ         ;   ; 

 ;   ;    ;    ; 
%ORRGVDPSOHIRUDQWL&,1+DQWLERG\     ;    ;   ;   ; 
%ORRGVDPSOHIRUYLUDOVHURORJ\         ;   ; 
8ULQHVDPSOHIRUXULQDO\VLV                ; 
8ULQHVDPSOHIRUSUHJQDQF\WHVW;( ;    ;   ;   ; 
'LVSHQVH&6/RWKHUVXSSOLHV ;  ;  ;  ;  ;  ;  ;  ;  
&RQILUPDFFHVVWRRQGHPDQG+$(PHG ;( ;  ;  ;  ;  ;  ;  ;;) 
&6/DFFRXQWDELOLW\ ;( ;  ;  ;  ;  ;  ;  ;; 
6XEMHFWWUDLQLQJRQQHZGRVHURXQGLQJVFKHPH*;   
&6/DGPLQLVWUDWLRQ*
$VVHVVIRU&6/GRVHLQFUHDVH+ 
&RQFRPLWDQWWKHUDS\
$GYHUVHHYHQWVCCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO9LVLW&RQWDFW $%)ROORZ
XS&
([WHQVLRQ3HULRG:HHN  
([WHQVLRQ3HULRG'D\  
:LQGRZGD\V '¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì¬ì ¬ì
5HYLHZH'LDU\UHFRUGDWWDFNVLQH&5), ;( ;  ;  ;  ;  ;  ;  ;; 
&ROOHFWH'LDU\                ; 
6FKHGXOHQH[WYLVLWFRQWDFW ;  ;  ;  ;  ;  ;  ;  ;; 
           
             

$EEUHYLDWLRQVXVHGLQWKH6FKHGXO HRI(YHQWVIRUWKH([WHQVLRQ 3HULRG
&,1+ &HVWHUDVHLQKLELWRU'97 GHHSYHLQWKURPERVLVH&5 ) HOHFWURQLFFDVHUHSRUWIRUP H'LDU\ HOHFWURQLFGLDU\ 
+$( KHUHGLWDU\DQJLRHGHPD 
,8 LQWHUQDWLRQDOXQLWVPHG P HGLFDWLRQ 3( SXOPRQDU\HPE ROLVP 



>)RRWQRWHVDUHSUHVHQWHG RQWKHIROORZLQJSDJH@ 
C
CICCI
CCICCI
CCICCICCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1  10 JULY 2014  Page 29 of 130 
([LOCATION_002])  Confidential  Notes to the Schedule of Events for the Extension Period:  
A: This is the first visit of the Extension Period; the last visit of Treatment Period [ADDRESS_1177731] visit of the Extension Pe riod should  occur on the same day , 
when possible  (however, sub jects can elect to take a rest period of up to [ADDRESS_1177732] visit of the 
Extension Period).  
B:  This is the  last on-site visit of Extension Period.  
C: This is the Extension Period Follow -up Contact. Subjects will attend a Follow -up Visit occurring 14 days (¬± 3 days) after the final visit in the Extension 
Period or any visit resulting in study discontinuation, unless informed consent/assent has been withdrawn.  
D: Visit [ADDRESS_1177733] visit of Treatment Period 2.   
E:  To be repeated at Extension Period Visit 1only if the Final Visit of Treatment Period 2 and Extension Period Visit 1 are cond ucted on different days.  
F: The subject will be advised to re sume usual medical care upon completion of the study.  
G:  Starting with the Extension Period Visit [ADDRESS_1177734] ‚Äôs CSL830 by-weight dose will be rounded  to the nearest (ie, up or down)  [ADDRESS_1177735] weighing 
‚â• 40 kg ; subjects weighing < 40 kg will c ontinue to undergo rounding as during Treatment Periods 1 and 2 (ie, rounded up to the nearest 500 IU ).  
H:  Beginning with the Extension Period Visit 1  and throughout the Extension Period , subjects who experience ‚â• 3 HAE attacks (as determined per protocol) 
within an 8 week evaluation period are eligible for CSL830 dose increases in increments of 20 IU/kg (up to a maximum dose of 80 IU/kg). See Section 3.2 
for additional details.  
I: The subject diary will not be collected from subject s at the  last visit of Treatment Period 2 (Follow -up Visit)  if they plan to participate in the E xtension 
Period . For subjects who elect to take a rest period between Treatment Period 2 and the Extension Period, the diary will not be used after the already planned 
Treatment Period 2 follow -up period (approximately 2 weeks) ; however, information for the period during w hich no diary is in use will be  recorded (see 
Section [IP_ADDRESS].2  for additional details) . The subject diary will only be used at  the first visit of the Extension Period.  
J: The Quality of Life  Questionnaire for Patients with Recurrent Swelling Epi[INVESTIGATOR_1841] (AE Quality of Life ) will be self-administered and assessed by [CONTACT_847054] 6, 22, 46 and 70 of the Extension Period .  
K: The Hereditary Angioe dema Quality of Life Questionnaire (HAE Quality of Life ) will be self-administered and assessed by [CONTACT_160915] 26, 50 and 
74 of the Extension Period.  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO7DEOHRI&RQWHQWV
/LVWRI3HUVRQQHODQG2UJDQL]D WLRQV5HVSRQVLEOHIRU&RQGXFWRI WKH6WXG\  
6LJQDWXUHRQ%HKDOIRI6SRQVRU   
6LJQDWXUHRI,QYHVWLJDWRU    
3URWRFRO6\QRSVLV    
6FKHGXOHRI(YHQWVIRU¬≥&6/ &RQWLQXDWLRQ¬¥6XEMHFWV   
6FKHGXOHRI/DERUDWRU\$VVHVVPHQ WVIRU¬≥&6/&RQWLQXDWLRQ¬¥6X EMHFWV  
6FKHGXOHRI(YHQWVIRU¬≥&6/, QWHUUXSWHG¬¥6XEMHFWVDQG¬≥&6/ 1DwYH¬¥6XEMHFWV  
6FKHGXOHRI/DERUDWRU\$VVHVVPHQWV IRU¬≥&6/,QWHUUXSWHG¬¥6XE MHFWVDQG¬≥&6/
1DwYH¬¥6XEMHFWV   
6FKHGXOHRI(YHQWVIRU WKH([WHQVLRQ3HULRG   
/LVWRI7DEOHV    
/LVWRI$EEUHYLDWLRQV    
 ,QWURGXFWLRQ   
 %DFNJURXQG   
 %DFNJURXQG,QIRUPDWLRQRQ&6/   
  2YHUYLHZ   
  1RQFOLQLFDO(YDOXDWLRQ   
  3UHYLRXV&OLQLFDO([SHULHQFH   
 6WXG\2YHUYLHZ   
 3RWHQWLDO5LVNVDQG%HQHILWV   
 6WXG\2EMHFWLYHVDQG(QGSRLQWV   
 3ULPDU\2EMHFWLYHDQG(QGSRLQWV   
  3ULPDU\2EMHFWLYH   
  3ULPDU\(QGSRLQWV   
 6HFRQGDU\2EMHFWLYHVDQG(QGSRLQWV   
  6HFRQGDU\2EMHFWLYHV   
  6HFRQGDU\(QGSRLQWV   
   
     
     CCI
CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 31 of 130 
([LOCATION_002])  Confidential  [ADDRESS_1177736] ..................................................................................... 60  
5.2 Packaging, Labeling, Supply and Storage ........................................................ 60  
5.2.1  Packaging and Labeling  ............................................................................... 60  
5.2.2  Supply and Storage ....................................................................................... 61  
5.3 Accountability and Destruction ........................................................................ 61  
5.4 Other Intervention(s)  ........................................................................................ 61  
6 Allocation, Dosing and Administration  ................................................................ 61  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO $OORFDWLRQWR7UHDWPHQW   
  6XEMHFW$VVLJQPHQW   
  5DQGRPL]DWLRQ3URFHGXUHV   
  %OLQGLQJ3URFHGXUHV   
 'RVLQJDQG$GPLQLVWUDWLRQ   
  $GPLQLVWUDWLRQRIWKH,QY HVWLJDWLRQDO3URGXFW   
  6XEMHFW7UDLQLQJIRU6HOI$GPLQ LVWUDWLRQRIWKH, QYHVWLJDWLRQDO 3URGXFW  
 7UHDWPHQW&RPSOLDQFH   
 &RQWUDLQGLFDWLRQV3HUPLWWHG7KHUDS LHVDQG3URKLELWHG7KHUDSLHV   
 &RQWUDLQGLFDWLRQVDQG3UHFDX WLRQVWR)XUWKHU'RVLQJ   
 3HUPLWWHG7KHUDSLHV   
 3URKLELWHG7KHUDSLHV   
 'LHWDU\DQG/LIHVW\OH5HVWULFWLRQV   
 2YHUGRVH   
 6WXG\3URFHGXUHVDQG9LVLW6FKHGXOH   
 &OLQLFDO3URFHGXUHV   
  'HPRJUDSKLFVDQG6DIHW\$VVHVVPHQWV   
  5LVN$VVHVVPHQWVIRU'HHS9HLQ7 KURPERVLVDQG3XOPRQDU\(PEROLV P  
    
 5HWHQWLRQRI6DPSOHV   
 3ULRUDQG&RQFRPLWD QW7KHUDSLHV   
 9LVLW6FKHGXOH   
  ,QIRUPHG&RQVHQW$VVHQW   
  6FUHHQLQJ   
  7UHDWPHQW3HULRG   
  7UHDWPHQW3HULRG   
  6XEMHFW)ROORZXS   
  ([WHQVLRQ3HULRG   
  8QVFKHGXOHG9LVLWV   
  6XEMHFW$VVHVVPHQWV   
 $GYHUVH(YHQWV   
 'HILQLWLRQV   
  $GYHUVH(YHQW   
  $GYHUVH(YHQWRI6SHFLDO,QWHUHVW   CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO  6HULRXV$GYHUVH(YHQW   
 6HYHULW\RI$GYHUVH(YHQWV   
  8QVROLFLWHG$GYHUVH(YHQWV   
  6ROLFLWHG/RFDO$GYHUVH(YHQWV,QMHFWLRQ6LWH5HDFWLRQV   
 &DXVDOLW\RI$GYHUVH(YHQWV   
 2EVHUYDWLRQ3HULRGVIRU$GYHUVH(YHQWV   
 $GYHUVH(YHQW5HSRUWLQJ   
  $GYHUVH(YHQWV   
  $GYHUVH(YHQWVRI6SHFLDO,QWHUHVW   
 6HULRXV$GYHUVH(YHQW5HSRUWLQJ   
  5HTXLUHPHQWVIRU,PPHGLDWH5HSRU WLQJRI6HULRXV$GYHUVH(YHQWV   
 2WKHU6LJQLILFDQW(YHQW5HSRUWLQJ   
  2YHUGRVH   
  3UHJQDQF\DQG/DFWDWLRQ   
 ,5%,(&5HSRUWLQJ5HTXLUHPHQWV   
 )ROORZXSRI$GYHUVH(YHQWV   
 $VVHVVPHQWV   
  6XEMHFW&KDUDFWHULVWLFV   
     
     
  6DIHW\$VVHVVPHQWV   
    
     
     
     
    
  
   
  
   
 6WDWLVWLFV   
  6DPSOH6L]H(VWLPDWLRQ   
  'HVFULSWLRQRI$QDO\ VLV'DWDVHWV   
  6FUHHQLQJ3RSXODWLRQ   CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO  ,QWHQWWR7UHDW3RSXODWLRQ   
  6DIHW\3RSXODWLRQ   
  3HU3URWRFRO3RSXODWLRQ   
     
     
     
  6WDWLVWLFDO$QDO\VHVDQG0HWKRGV   
  6XEMHFW'LVSRVLWLRQDQG&KDUDFWHULVWLFV   
  (IILFDF\$QDO\VHV   
  6DIHW\$QDO\VHV   
    
     
  ,QWHULP$QDO\VLV   
  0LVVLQJ'DWD   
 4XDOLW\$VVXUDQFH   
 5HJXODWRU\DQG(WKLFV&RQVLGHUDWLRQV   
  5HJXODWRU\&RQVLGHUDWLRQV   
  ,QVWLWXWLRQDO5HYLHZ%RDUG,QGHSHQGHQW(WKLFV&RPPLWWHH   
  6XEMHFW,QIRUPDWLRQDQG,QIRUPHG&RQVHQW   
  6XEMHFW,GHQWLILFDWLRQDQG&RQILGHQWLDOLW\   
  ,QGHPQLW\DQG&RPSHQVDWLRQ   
 $GPLQLVWUDWLYH&RQVLGHUDWLRQV   
  &OLQLFDO7ULDO$JUHHPHQW   
  &OLQLFDO6WXG\5HJLVWUDWL RQDQG5HVXOWV'LVFORVXUH   
  ,PSOHPHQWDWLRQRIWKH3URWRFRO 3URWRFRO$PHQGPHQWV   
  3URWRFRO'HYLDWLRQV   
  'RFXPHQWDWLRQDQG5HFRUG.HHSLQJ   
  'DWD&ROOHFWLRQ   
  'DWD4XDOLW\$VVXUDQFH   
  5HFRUG5HWHQWLRQ   
  6WXG\DQG6LWH&ORVXUH   
  &OLQLFDO6WXG\5HSRUW   
  8VHRI'DWDDQG3XEOLFDWLRQV   
 5HIHUHQFHV   CCI
CCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO
/LVWRI7DEOHV
7DEOH  'HVFULSWLRQRI&6/   
7DEOH  &OLQLFDO3URFHGXUHV'HPRJUD SKLFVDQG6DIHW\(YDOXDWLRQ   
7DEOH  6FRULQJ6\VWHPIRUWKH5LVN$VVH VVPHQWRI'HHS9HLQ7KURPERVLV   
7DEOH  6FRULQJ6\VWHPIRUWKH5LVN$VVH VVPHQWRI3XOPRQDU\(PEROLVP   
7DEOH    
7DEOH  5HVXOWVIURP6WXG\&6/BW REHXVHGIRU6WXG\&6/B 
(OLJLELOLW\$VVHVVPHQWRI¬≥&6/&RQWLQXDWLRQ¬¥6XEMHFWV   
7DEOH  $VVHVVPHQWVIURP7UHDWPHQW3HU LRG:HHN9LVLWWR%H8VHG IRU9LVLW
RIWKH([WHQVLRQ3HULRG:KHQW KH([WHQVLRQ3HULRG6WDUWVRQWKH 6DPH'D\DV
7UHDWPHQW3HULRG   
7DEOH  $VVHVVPHQWVIURP7UHDWPHQW3HU LRG:HHN9LVLWWR%H5HSHD WHGIRU
9LVLWRIWKH([WHQVLRQ3HULRG :KHQWKH([WHQVLRQ3HULRG'RHV 1RW6WDUWRQ
WKH6DPH'D\DV7UHDWPHQW3HULRG   
7DEOH  &OLQLFDO&ULWHULDIRUWKH 'LDJQRVLVRI$QDSK\OD[LV   
7DEOH  6HYHULW\RI8QVROLFLWHG$GYHUVH(YHQWV   
7DEOH  ,QWHQVLW\RI6ROLFLWHG/RFDO$GYHUVH(YHQWV   

/LVWRI)LJXUHV
)LJXUH  6WXG\2YHUYLHZ   
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO/LVWRI$EEUHYLDWLRQV
$EEUHYLDWLRQ 'HILQLWLRQ
$&6 $EQRUPDOFOLQLFDOO\VLJQLILFDQW
$( $GYHUVHHYHQW
$(6, $GYHUVHHYHQWRIVSHFLDOLQWHUHVW
$/7 $ODQLQHDPLQRWUDQVIHUDVH
$377 $FWLYDWHGSDUWLDOWKURPERSODVWLQWLPH
$67 $VSDUWDWHDPLQRWUDQVIHUDVH
&,1+ &HVWHUDVHLQKLELWRU
&6/ &6/%HKULQJ*PE+
'97 'HHSYHLQWKURPERVLV
H&5) (OHFWURQLFFDVHUHSRUWIRUP
H'LDU\ (OHFWURQLFGLDU\
) 3URWKURPELQIUDJPHQWVDQG
)'$ )RRGDQG'UXJ$GPLQLVWUDWLRQ
*&3 *RRG&OLQLFDO3UDFWLFH
**7 *D[COMPANY_003]JOXWDP\OWUDQVIHUDVH

+$( +HUHGLWDU\$QJLRHGHPD
+,9 +XPDQLPPXQRGHILFLHQF\YLUXV
+%9 +HSDWLWLV%YLUXV
+&9 +HSDWLWLV&YLUXV
,&+ ,QWHUQDWLRQDO&RQIHUHQFHRQ+DUPRQLVDWLRQ
,&) ,QIRUPHGFRQVHQWIRUP
,(& ,QGHSHQGHQWHWKLFVFRPPLWWHH

,15 ,QWHUQDWLRQDOQRUPDOL]HGUDWLR
,5% ,QVWLWXWLRQDOUHYLHZERDUG
,57 ,QWHUDFWLYHUHVSRQVHWHFKQRORJ\
,77 ,QWHQWWR7UHDW
,8 ,QWHUQDWLRQDOXQLW
,9 ,QWUDYHQRXV
0HG'5$ 0HGLFDO'LFWLRQDU\IRU5HJXODWRU\$FWLYLWLHV

3( 3XOPRQDU\HPEROLVP
3() 3HDNH[SLUDWRU\IORZ

33 3HUSURWRFROCCI CCI
CCI CCI
C
CICCI
CCI CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO$EEUHYLDWLRQ 'HILQLWLRQ

6$( 6HULRXVDGYHUVHHYHQW
6$3 6WDWLVWLFDODQDO\VLVSODQ
6& 6XEFXWDQHRXV

686$5 6XVSHFWHGXQH[SHFWHG VHULRXVDGYHUVHUHDFWLRQ
7($( 7UHDWPHQWHPHUJHQWDGYHUVHHYHQW
7(( 7KURPERHPEROLFHYHQW

8 8QLW
9$6 9LVXDODQDORJVFDOH

CCI CCI
CCI CCI
CCI CCI
CCI CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 38 of 130 
([LOCATION_002])  Confidential  1 Introduction  
1.1 Background  
Hereditary angioedema (HAE) is a rare genetic disorder with 3 known types (I, II, and III) 
[Rosen et al 1965; Bork et al 2000]. Type I and II HAE are autosomal dominant inherited 
disorders, which are associated with a deficiency in C1- esterase inhibitor (C1 -INH) 
[Donaldson and Evans 1963]. In type I HAE (common form genotype), an impaired synthesis 
of a normal and functionally active C1- INH molecule occurs  [Rosen et al 1965]. This c auses  
a reduction in the availability of functionally active C1 -INH levels to between 6% and 25% 
of normal [ Rosen et al 1965]. In type II HAE (variant form genotype), normal levels of a 
functionally impaired C1-INH molecule are synthesized, but the normal form of C1 -INH is 
considerably reduced in the circulation. Type III HAE is even less frequent  and is not 
associated with C1 -INH deficiency [ Bork et al 2000]. The prevalence of type I and II HAE is 
estimated to be in th e order of 1:50,000 [ G√∂ring et al 1998, Kunschak et al 1998], with 
approximately 85% of subjects having type I HAE and approximately 15% of subjects 
having type II HAE [ Longhurst and Bork 2006].  
HAE is a debilitating disease and subjects with frequent attacks are severely affected in their quality of life. Clinically, type I and II HAE are  characterized by [CONTACT_847055] (SC) / submucos al swellings of the skin (ie, edema of the extremities, facial 
edema, and edema of the genitals), abdominal pain attacks, and, rarely, life -threatening 
attacks of laryngeal edema [ Bork 2008]. Attacks typi[INVESTIGATOR_192211] a course in which the 
edema increases for 24 to 36 hours and then slowly decreases during the following 48 to 72 hours [ Zuraw 2008].  
Treatment for type I and II HAE can be subdivided into the acute treatment of attacks and 
prophylaxis. T he treatment of choice in the event  of an HAE attack is the rapid replacement 
of the functionally missing plasma protein (ie, by [CONTACT_33980] [IV] administration of C1- INH 
concentrate or fresh frozen plasma) [ Bork 2008, Gompels et al 2005, Longhurst 2005]. 
Recently, compounds including a kallikrein inhibitor and a bradykinin receptor antagonist have been added to the spectrum of anti- HAE medications [ Cicardi et al 2010a , Cicardi et al 
2010b]. Attenuated androgens or antifibrinolytics are effective in some subjects as 
prophylactic therapy, but may have significant  side effects [ Banerji et al 2008 , G√∂ring et al 
1998]. Regular IV infusions of C1-INH can also be used for HAE prophylaxis [ Zuraw et al 
2010]. However, repeated IV administration may not be practical for all patients, and IV access can become progressively more difficult with time.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 39 of 130 
([LOCATION_002])  Confidential  A more convenient route of administration (eg, SC) may facilitate the use of C1- INH in HAE 
prophylaxis. The pharmacokinetics (PK) of subcutaneously administered C1-INH in pat ients 
with HAE have been investigated using a currently available formulation [ Martinez -Saguer et  
al 2013] . The study examined 1000 units (U) of C1-INH, in a volume of 20 mL, administered 
intravenously or subcutaneously; subcutaneously administered C1- INH had a bioavailability 
of approximately 40%, and was generally well tolerated [ Martinez -Saguer et al 2013].  
To further enhance the feasibility of SC administration of C1- INH, CSL830  has been 
developed as a human plasma- derived C1- INH concentrate that can be reconstituted in a low 
volume. CSL830 is being investigated for the prevention of HAE attacks. 
1.[ADDRESS_1177737] identical to that of 
Berinert. The major differ ence between these 2 products is the concentration of C1- INH after 
reconstitution; CSL830 contains [ADDRESS_1177738] been conducted in rabbits. In these 
2 nonclinical studies, administration of a single injection of CSL830 (3 mL; IV, SC, intra-
arterial, and intramuscular injection) revealed no findings of clinical significance and was 
locally well tolerated.  
1.2.3 Previous Clinical Experience  
Currently, clinical data are available from two studies that were conducted with CSL830: study CSL830_1001 and study CSL830_2001. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 40 of 130 
([LOCATION_002])  Confidential  Study CSL830_1001 was conducted in healthy subjects in order to compare the safety and 
PK of intravenously ad ministered CSL830 and Berinert (the currently marketed C1- INH 
concentrate). CSL830 had acceptable safety and local tolerability profiles. There were no adverse events ( AEs) causally related to CSL830 or Berinert, and there were no clinically 
significant ab normalities in laboratory parameters, viral safety assessments, vital signs, 
physical examinations, or electrocardiogram results. No anti -C1-INH antibodies were 
detected in any subject. There were no thromboembolic events (TEEs), and no surrogate markers s uggestive of pulmonary embolism (PE) or deep vein thrombosis (DVT) were 
identified. CSL830 and Berinert also had comparable PK profiles following single-dose, IV 
administration.  
Study CSL830_2001 was conducted in subjects with HAE (type I or II) in order to characterize the PK, pharmacodynamics (PD), and safety of SC administration. Functional 
levels of C1 -INH activity and levels of C1 -INH antigen and C4 antigen were achieved with 
each CSL830 dosing regimen that was tested. Subcutaneous administration of CSL830 of up to 6,000 IU was tolerated with local site events. Safety events were not related to either absolute CSL830 dose or dose per body weight. There was no evidence of a dose-response 
relationship between the administered dose of CSL830 and the intens ity of treatment -
emergent adverse events (TEAEs). Inhibitory auto - antibodies to C1-INH did not develop in 
any of the subjects in the study. Further, there were no TEEs. 
The efficacy and safety of SC CSL830 are currently being assessed  in a double-blind, 
randomized, placebo-controlled, crossover phase 3 study (study identifier CSL830_3001) 
that is enrolling at least 80 subjects with HAE . During participation in CSL830_3001 
subjects are randomly assigned to either a 40 IU/kg CSL830 or 60 IU/kg CSL830 treatment 
sequence. Each sequence consists of [ADDRESS_1177739] receives  
the assigned dose of CSL830 in 1 treatment period and placebo in the other treatment period. 
Subjects who participate in study CSL830_3001 will be eligible to participate in this long-term safety study if they meet all eligibility criteria (see Section 4.1).  
1.3 Study Overview  
This is a multicenter, randomized, open- label, parallel -arm, phase 3b study to investigate the 
clinical safety and efficacy of subcutaneously administered CSL830 in the prophylactic treatment of HAE.  Section 3 presents a detailed overview of the study design and other 
supporting information. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 41 of 130 
([LOCATION_002])  Confidential  1.4 Potential Risks and Benefits  
Potential for Virus T ransmission  
CSL830 contains human plasma-derived C1-INH and, therefore, has the potential for virus 
transmission to recipi[INVESTIGATOR_840]. However, CSL830 has a high margin of virus safety. T he risk of 
virus transmission is minimized by [CONTACT_847056] , and by 
[CONTACT_847057]-enveloped viruses using pasteurization, nanofiltration methods, and chromatography [ De Serres et al 2003 ].  
During study CSL830_2001 (see Section 1.2.3), no new viral infections were detected in 
subjects who received CSL830. No changes in serology results for HIV  (human 
immunodeficiency virus), hepatitis A virus, HBV (hepatitis B virus) , HCV  (hepatitis C virus) 
were observed from baseline to study exit. 
During this  12-month safety  study, evidence of potential viral transmission will be collected 
as part of the safety evaluations.  
Immunogenicity or Anaphylactic -type Reactions  
Immunologic or anaphylactic -type reactions have been rarely reported with the use of 
C1-INH. Antibodies against C 1-INH have been identified in patients with HAE, irrespective 
of whether they have received C 1-INH. However, the presence of antibodies against C 1-INH 
does not appear to inhibit the activity of C1 -INH [data on file at CSL; Farkas et al 2007 ].  
The immunogenicity of CSL830 was examined as a part of study CSL830_2001 (see 
Section  1.2.3). C1 -INH antibodies were detected for 7/18 subjects during that study; 
however, the presence of C1 -INH antibodies was not associated with inhibition of C1- INH 
activity. There was no apparent relationship between the dose of CSL830 administered and 
the presence of C1 -INH antibodies.  
The development of immune reactions to CSL830 will be monitored in this  study, and will 
include testing for and characterization of (eg, idiotypi[INVESTIGATOR_007]) anti -C1-INH an tibodies.  
Thromboembolic E vents  
Thromboembolic events have been occasionally reported following the use of C1- INH, 
especially in patients receiving off -label high doses of up to 500 U/kg IV in the setting of 
cardiac surgery and extracorporeal circulation. At the recommended IV doses, a causal 
relationship between TEEs and the use of C1-INH has not been established. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 42 of 130 
([LOCATION_002])  Confidential  During study CSL830_2001 (see Section 1.2.3) no TEEs were reported. Further, no subject 
treated with CSL830 was considered to be at risk for DVT , when assessed using a clinical 
model scoring system.   
TEEs  including DVT and PE will be monitored during this  study (see Section 8.1.2).  
Local Tolerance 
Because of the SC route of administration and the high protein concentration of CSL830, 
transient local reactions may occur at CSL830 injection sites.  
During study CSL830_2001, a small proportion of subjects administered CSL830 
experienced local administration site reactions. The reactions were mostly mild to moderate 
in intensity, most resolved within 3 days.  
Local reactions will be documented as part of the safety evaluation during this study.  
Efficacy 
Intravenous C1-INH has been demonstrated to be effective in the prevention of HAE attacks 
[Zuraw et al 2010]. However, the efficacy of SC C1 -INH for prop hylaxis of HAE attacks has 
not been established , but is under evaluation as a part of the pi[INVESTIGATOR_847042]830_3001 (see 
Section  1.2.3). As such, throughout the current study, eligible subjects will be permitted to 
use medication  for the treatment of breakthrough HAE attacks.  
Overview  
This clinical study may contribute to the development of a new therapy to effectively manage HAE. Given the low probability of potential risks and the study procedures that will closely 
monitor the safety of study subjects, the associated risk -benefit  assessment of the study is 
acceptable for s ubjects enrolled in the study. 
2 Study Objectives  and Endpoints  
2.1 Primary O bjective and Endpoint s 
2.1.1 Primary Objective  
The primary objective is  to assess the clinical safety of subcutaneously administered CSL830 
in the long- term prophylactic treatment of HAE . 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 43 of 130 
([LOCATION_002])  Confidential  2.1.2 Primary Endpoint s 
The primary endpoints are the person- time incidence rates of each of the following: 
‚Ä¢ Adverse events leading to premature study discontinuation. 
‚Ä¢ Thromboembolic events. 
‚Ä¢ Anaphylaxis.  
‚Ä¢ HAE attacks resulting in in -patient hospi[INVESTIGATOR_059]  (where hospi[INVESTIGATOR_847043]) . 
‚Ä¢ Solicited AEs (injection site reactions  at the CSL830 injection site ) graded as severe 
by [CONTACT_093].  
‚Ä¢ Related serious adverse events (SAEs) , other than events specifie d above . 
‚Ä¢ Anti-C1-INH antibodies (inhibitory or non-inhibitory). 
The person- time incidence rate s are the number of subjects experiencing each primary 
endpoint safety event during treatment with CSL830 , divided by [CONTACT_847048]‚Äôs 
time at risk.  
The primary endpoints will be assessed for Treatment Period 1, Treatment Period 2 and 
Treatment Period s 1 and 2 (together). The primary endpoints will also be assessed for the 
Extension Period (only) and for the treatment periods overall for subjects who are included in 
the Extension Period. 
2.2 Secondary O bjectives and Endpoints 
2.2.1 Secondary Objectives  
The secondary objectives are the following:  
1. To further characterize the clinical safety of sub cutaneously administered CSL830 in 
the long- term prophylactic treatment of HAE.  
2. To characterize the clinical efficacy of subcutaneously administered CSL830 in the 
long- term prophylactic treatment of HAE . 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 44 of 130 
([LOCATION_002])  Confidential  2.2.2 Secondary Endpoints  
1. The secondary safety endpoints are the following: 
a. The percentage of subjects experiencing the following events: SAEs, 
temporally -related AEs , increased risk scores for DVT  or PE, TEEs , inhibitory 
anti-C1-INH antibodies, or clinically significant abnormalities in laboratory 
assessments ( ie, lab abnormalities reported as AEs) . 
b. The percentage of administrations of CSL830 resulting in solicited local AEs (discomfort [eg, pain, burning], swelling, bruising, or itching at the CSL830  
injection site).  
c. The percentage of subjects who have at least  1 solicited local AE ( discomfort 
[eg, pain, burning], swelling, bruising, or itching  at the CSL830 injection site ). 
d. The percentage of subjects who become seropositive for HIV-1/-2, HBV , or 
H C V.  
The secondary safety endpoints will be assessed for Treatment  Period 1, Treatment Period 2 
and Treatment Period s 1 and 2 (together). The seconda ry safety  endpoints will also be 
assessed for the Extension Period (only) and for the treatment periods overall for subjects who are included in the Extension Period. 
2. Efficacy endpoints considered as secondary include the following:  
a. The percentage of subjects who experience a time -normalized HAE attack  
frequency  of < 1 HAE attack per 4-week period. 
b. The percentage of subjects who are responders. ‚ÄúR esponse‚Äù is defined as a 
‚â• 50% relative reduction in the time -normalized number of HAE attacks 
during treatment with CSL830, compared with the time -normalized number of 
attacks that is used to qualify the subject for participation in this study (see 
Section 4.1.2 [inclusion criterion 5]). 
The secondary efficacy  endpoints will be assessed for Treatment Period 1, and Treatment 
Period s 1 and 2 (together). The seconda ry efficacy  endpoints will also be assessed for the 
Extension Period (only) and for the treatment periods overall for subjects who are included in 
the Extension Period. 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO ([SORUDWRU\2EMHFWL YHVDQG(QGSRLQWV
 ([SORUDWRU\2EMHFWLYHV








 ([SORUDWRU\(QGSRLQWV




 
 
 
 


 
 
 
 


 
 
 CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO 





















C
CI
CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 47 of 130 
([LOCATION_002])  Confidential  3 Study Design 
3.1 Study Design and R ationale 
This is a multicenter, randomized, open- label, parallel -arm, phase 3b study designed to 
investigate the clinical safety and efficacy of subcutaneously administered CSL830 in the 
prophylactic treatment of HAE . An overview of the study is depi[INVESTIGATOR_6517] 1. 
Figure 1: Study Overview  
 
 
Footnotes to Figure 1 : 
a  ‚ÄúCSL830- Interrupted ‚Äù Subjects and ‚ÄúCSL830- Na√Øve ‚Äù Subjects  will participate in a Screening Visit in order to 
confirm their eligibility. ‚ÄúCSL830- Continuation‚Äù Subjects  will not be required to participate in a Screening 
Visit. Instead, data from study CSL830_3001 will be used to confirm their eligibility  (see Section [IP_ADDRESS] ). 
NOTE: The definitions for ‚ÄúCSL830- Continuation ‚Äù Subjects, ‚ÄúCSL830- Interrupted ‚Äù Subjects, and 
‚ÄúCSL830- Na√Øve ‚Äù Subjects are presented  in Section 4.1.1 . 
b  During the fixed -dose Treatment Period 1, subjects who experience very frequent HAE attacks  (ie, ‚â• 12 
attacks, as defined  per protocol , within a 4 -week evaluation period ) are eligible for  CSL830 dose increase s in 
increments of 20 IU/kg (up to a maximum dose of 80 IU/kg). All CSL830 dose increases are optional, and 
will be made only in subjects  who are eligible, at the sole discretion of investigator . An evaluation period for 
any dose increase is defined as beginning after a dose- stable period (ie,  2 weeks after the initiation or dose 
increase of CSL830) . See  Section 3.2 for additional details.  
c  Beginning with the Week 25 Visit and throughout Treatment Period 2 , subjects who experience ‚â• 3 HAE 
attacks (as determined per protocol) within an 8 -week evaluation  period are eligible for CSL830 dose 
increases in increments of 20 IU/kg  (up to a maximum dose of 80 IU/kg). All CSL830 dose increases are 
optional, and will be made only in subjects  who are eligible, at the sole discretion of investigator . An 
evaluation p eriod for any dose increase is defined as beginning after a dose -stable period (ie,  2 weeks after the 
initiation or dose increase of CSL830) . See  Section 3.2 for additional details.   
d  For subjects (from the [LOCATION_002]) enrolled in the Extension Period, their CSL830 dose  will be escalated in 
increments of 20 IU/kg (up to a maximum dose of 80 IU/kg) according to the rules outlined for Treatment 
Period 2  (see Section 3.2), but their CSL830 by -weight dose will be rounded to the nearest (ie, up or down) 
1000 IU based on their assigned dose  for subjects weighing ‚â• 40 kg ; subjects weighing < 40 kg will continue 
to undergo rounding as during Treatment Periods 1 and 2 (ie, rounded up to the nearest 500 IU ).   
e Subjects will undergo a 2- week (¬± 3 days) follow -up contact  [CONTACT_847058] /withdraw ing from the  Extension Period . 

CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 48 of 130 
([LOCATION_002])  Confidential  3.1.1 Screening Visit  
A Screening Visit will be conducted within the 4 weeks before  Treatment Period 1 in order to 
confirm the eligibility of the following subjects belonging to groups of subjects: 
‚Ä¢ ‚ÄúCSL830-Na√Øve‚Äù Subjects : subjects wh o did not participate in study CSL830_3001; 
subjects who participated in study CSL830_3001 but did not receive blinded 
investigational product as a part of that study. 
‚Ä¢ ‚ÄúCSL830- Interrupted ‚Äù Subjects : subjects who completed participation in study 
CSL830_3001, but who delayed entry into the current study (ie, > [ADDRESS_1177740] visit of CSL830_3002 Treatment 
Period  1). 
The first visit in Treatment Period 1 (ie, the Day 1 Visit) may occur on the same day as the 
Screening Visit. 
‚ÄúCSL830-Continuation‚Äù Subjects  will not have a Screening Visit. ‚ÄúCSL830 -Continuation‚Äù 
Subjects are subjects who complete participation in CSL830_3001 and who continue directly 
on to participate in the current study [ie,  ‚â§ [ADDRESS_1177741] visit of CSL830_3002 Treatment Period 1].  
The eligibility of ‚ÄúCSL830 -Continuation‚Äù Subjects will include evaluation based upon the 
assessments performed during study CSL830_3001 as described in Table 6 (see 
Section  [IP_ADDRESS]). For ‚ÄúCSL830-Continuation‚Äù Subjects, the End of Study Visit of 
CSL830_3001 and the first study visit of Treatment Period 1 of CSL830_3002 may occur on 
the same day.  
3.1.2 Treatment Period s 1 and 2 
Treatment Period 1 will begin with the Day 1 Visit and will end with the Week 25 Visit. 
Treatment Period 2 will begin either  during the Week 25 Visit (if CSL830 is administered at 
the study visit)  or immediately following the Week [ADDRESS_1177742] visit in Treatment Period 1 : 
‚Ä¢ 40 IU/kg CSL830 treatment group , OR   
‚Ä¢ 60 IU/kg CSL830 treatment group .  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 49 of 130 
([LOCATION_002])  Confidential  CSL830 will be administered as a single subcutaneous injection twice weekly  at home either 
independently (ie, self -administered by [CONTACT_423]) or with assistance (ie, with the help of a 
caretaker  such as a parent or guardian) during Treatment Period [ADDRESS_1177743]‚Äôs CSL830 dose if that subject is 
eligible  for dose increase. A subject‚Äôs eligibility  for a dose increase is  related to the frequency 
of their HAE attacks and the rules are different during the ‚Äú fixed dose‚Äù Treatment Period 1 
and the ‚Äúdose o ptimization‚Äù Treatment Period [ADDRESS_1177744] very frequent attacks; these increases are intended to provide an opportunity for such subjects to remain in the 
study. During Treatment Period 2, dose increases are intended to allow the inves tigator to 
optimize the dose for subjects whom the investigator considers may benefit from a higher prophylaxis dose. Dose increase rules are presented in Section 3.2. 
The last  visit of Treatment Period [ADDRESS_1177745] visit (Week 53 Visit, Day 367 ) 
of Treatment Period [ADDRESS_1177746] visit of the Extension Period (Extension Period 
Day 1) , unless there is a rest period of up to [ADDRESS_1177747] visit of the 
Extension Period will be a new (separate) visit . The Extension Period is intended to allow 
subjects from the [LOCATION_002] who complete Treatment Period 2 according to the protocol 
to continue to receive treatment with open -label CSL830. During the Extension Period 
(unlike during Treatment Periods [ADDRESS_1177748] 500 IU) for subjects weighing ‚â• [ADDRESS_1177749]‚Äôs dose will be rounded to the nearest 1000 IU (up or  down) based on his/her assigned by-weight dose ; 
subjects weighing < 40 kg will continue to undergo rounding as during Treatment Periods 1 and 2 (ie, rounded up to the nearest 500 IU). During the Extension Period, each subject  will 
continue to be eligible for dose escalation in increments of 20 IU/kg (up to a maximum dose of 80 IU/kg) according to the rules outlined for Treatment Period 2 (see Section 3.2). 
3.1.[ADDRESS_1177750]-treatment Follow -up  
Subjects will attend a Follow -up Visit occurring 14 days (¬± 3 days) after the final visit in 
Treatment Period 2 or any visit resulting in study discontinuation, unless informed consent/assent has been withdrawn or if the Extension Period starts prior to the scheduled 
Follow-up V isit.  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO (QUROOPHQW6WRSSLQJ5XOHV
7KHUHZLOOEHQRSUHVS HFLILHGHQUROOPHQWV WRSSLQJUXOHVIRUVD IHW\RUHIILFDF\UHDVRQV
 (QUROOPHQW5HVWDUWLQJ5XOHV
1RW$SSOLFDEOH
 6WXG\7HUPLQDWLRQ5XOHV
7KHUHZLOOEHQRSUHVSHFLILHGVWX G\WHUPLQDWLRQUXOHVIRUVDIH W\RUHIILFDF\UHDVRQV
 'RVHDQG'RVLQJ5HJLPHQ
7KHGRVHVRI&6/,8NJ DQG,8NJWREHDVVHVVHGLQW KHFXUUHQWVWXG\ZHUH
VHOHFWHGEDVHGRQWKHUHVXOWVRI WKH&6/BVWXG\%RG\ZH LJKWDGMXVWHGGRVHVFDQ
SURYLGHDPRUHDSSURSU LDWHH[SRVXUHWRVWXG\GUXJHVSHFLDOO\D WORZDQGKLJKERG\ZHLJKWV
$GRVLQJUHJLPHQRI,8NJWZLFHDZHHNLVH[SHFWHGWRDFKLHY HDPHDQVWHDG\VWDWHWURXJK
RIDSSUR[LPDWHO\ZKLFKLV DWDUJHWOHYHOWKDWPD\EH
DVVRFLDWHGZLWKFOLQLFDOHIILFDF\> 6SlWKHWDO @'RVLQJUHJLPHQVRI,8NJDQG
,8NJFDQDFKLHYHDPHDQVWHDG\VWDWHWURXJK RIDSSUR[LPDWHO\DQG UHVSHFWLYHO\ZLWKVXIILFLHQWVDIHW \H[SHULHQFHIURPWKH
SUHYLRXVVWXG\WRMXVWLI\LWVDVVHVVPHQWZLWKRXWERG\ZHLJKWUH VWULFWLRQV
'XULQJDOOWUHDWPHQWSHULRGVV XEMHFWVZKRGRQRWLQFUHDVHWKH GRVHRI&6/WRZKLFKWKH\
ZHUHDVVLJQHGZLOODGPLQLVWHU&6 /,8NJRU,8NJYLD DVLQJOH6&LQMHFWLRQ
WZLFHZHHNO\,8NJ&6/L VHTXLYDOHQWW RDYROXPHRI P/NJ,8NJ&6/
LVHTXLYDOHQWWRDYRO XPHRIP/NJ'XULQJ7UHDWPHQW3HULR GVDQGWKHDFWXDOGRVH
RI&6/WKDWLVDVVLJQHGZLOO EHURXQGHGXSWRWKHQHDUHVW ,8DVWKLVFRUUHVSRQGVZLWK
DSUDFWLFDOYROXPHRIP/RI&6/ 'XULQJWKH([WHQVLRQ3HUL RGWKHDFWXDOGRVHRI
&6/WKDWLVDVVLJQ HGZLOOEHURXQGHGLHXS RUGRZQWRWKHQHDUHVW,8IRUVXEMHFWV
ZHLJKLQJ¬ïNJVXEMHFWVZHLJK LQJNJZLOOFRQWLQXHWRXQ GHUJRURXQGLQJDVGXULQJ
7UHDWPHQW3HULRGVDQGLH URXQGHGXSWRWKHQHDUHVW,8 
7RSURPRWHFRPSOLDQFHWKHWZLFH ZHHNO\DGPLQLVWUDWLRQRI&6/ VKRXOGEHVFKHGXOHGRQ
IL[HGGD\VRIWKHZHHNHJ0RQGD\DQG7KXUVGD\7KHVXJJHVWHG LQWHUYDOEHWZHHQHDFK
DGPLQLVWUDWLRQRI&6/LV RUGD\V,QDGGLWLRQ&6/VK RXOGEHDGPLQLVWHUHGDW
DSSUR[LPDWHO\WKHVDPHWLPHRQ HDFKGD\$PLVVHGLQMHFWLRQVKR XOGEHDGPLQLVWHUHGDVVRRQ
DVSRVVLEOHXQOHVVZLWKLQKRXUV RIWKHQH[WVFKHGXOHGLQMHF WLRQLQWKLVVLWXDWLRQWKHCCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 51 of 130 
([LOCATION_002])  Confidential  missed injection should be omitted, and the administration of CSL830 should occur at the 
next sched uled day and time. 
If a subject requires the use of C1 -INH medication  for the treatment of breakthrough HAE 
attacks  within 24 hours before a scheduled injection of CSL830, the scheduled injection may 
be delayed by [CONTACT_8622] 24 hours. 
Additional information on the dosing regimen can be found in Section 6.2. 
CSL830 Dose Increase   
Some subjects may be eligible to increase the dose of CSL830 to whic h they were assigned at 
the beginning of Treatment Period 1.  During the fixed -dose Treatment Period 1, subjects who experience very frequent HAE 
attacks  (ie, ‚â• 12 attacks, as defined  per protocol, within a 4 -week evaluation period) are 
eligible for CSL830 dose increases in increments of 20 IU/kg  (up to a maximum dose of 80 
IU/kg). All CSL830 dose increases are optional, and will be made only in subjects who are 
eligible, at the sole discretion of investigator. D ose increases during Treatment Period [ADDRESS_1177751] very 
frequent HAE attacks to continue in the study during this  otherwise fixed -dose t reatment 
period.  
Beginning with the Week 25 Visit and throughout T reatment Period 2 , subjects who 
experience ‚â• 3 HAE attacks (as determined per protocol) within an 8-week evaluation period 
are eligible for CSL830 dose increases in increments of 20 IU/kg  (up to a maximum dose of 
80 IU/kg). All CSL830 dose increases are op tional, and will be made only in subjects who are 
eligible, at the sole discretion of investigator. D ose increases during Treatment Period [ADDRESS_1177752]/optimize the dose for subjects who may need a 
higher prophylactic dos e.  
During the Extension Period (unlike during Treatment Periods [ADDRESS_1177753] 500 IU) for subjects weighing 
‚â• [ADDRESS_1177754]‚Äôs dose will be rounded to the nearest 1000 IU (up or  down) based on 
his/her assigned by -weight dose ; subjects weighing < 40 kg will continue to undergo 
rounding as during Treatment Periods 1 and 2 (ie, rounded up to the nearest 500 IU). During the Extension Period, each subject will continue to be eligible for dose escalation in increments of 20 IU/kg (up to a maximum dose of 80 IU/kg) according to the rules outlined 
for Treatment Period 2 (see above ). 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 52 of 130 
([LOCATION_002])  Confidential  An evaluation period for any dose increase in Treatment Period 1 , Treatment Period 2 , or the 
Extension Period is defined as beginning after a dose- stable period (ie,  2 weeks after the 
initiation or dose increase of CSL830). 
All CSL830 dose increases are optional, and will be made only in subjects  who are eligible, 
at the sole discretion of investigator. CSL830 dose increases may be made in increments of 
20 IU/kg up to a maximum dose of 80 IU/kg.  Subjects who are randomized to treatment with 
40 IU/kg CSL830 and who are eligible for a dose increase may undergo up to 2 independent 
20 IU/kg dose increases (at the sole discretion of the investigator), up to a maximum dose of 
80 IU/kg. Subjects who are randomized to treatment with 60 IU/kg CSL830 and who are 
eligible for a dose increase may undergo a single 20 IU/kg dose increase (at the sole 
discretion of the investigator), up to a maximum dose of 80 IU/kg.   
Assessment of Subject Weight  
The weight of the subject is assessed at study visits. The baseline body weight for ‚ÄúCSL830-Na√Øve‚Äù and ‚ÄúCSL830 -Interrupted‚Äù Subjects will be recorded at Screening. The baseline body 
weight for ‚ÄúCSL830-Continuation‚Äù Subjects will be recorded at the CSL830_3001 End of Study Visit.   
The actual dose of CSL830 will be adjusted, if necessary. The actual dose administered wi ll 
be based on the weight at Day 1 of Treatment Period 1 and will only be adjusted if the patient has a body weight change of more than 10% compared to baseline. If a new body weight is used, this weight will become the new baseline weight and subsequent w eight measures will 
be compared to this. If there is a change of more than 10% compared to this new baseline weight the dose will be adjusted again. This will be repeated throughout the study. 
3.[ADDRESS_1177755] is expected to be up to 58 weeks . This 
estimation is based on: 
‚Ä¢ A Screening P eriod  lasting up to 4 weeks (‚â§  28 days), as needed . 
‚Ä¢ Two treatment period s totaling  52 weeks  (367 days ¬± 2 days) . 
‚Ä¢ A Follow-up Period  lasting  2 weeks  (14 days ¬± 3 days). 
The overall study duration (ie, from the first subject‚Äôs first Screening Visit to the last subject‚Äôs 
Follow- up Visit ) is planned to be 26 months, but will depend on recruitment. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 53 of 130 
([LOCATION_002])  Confidential  Extension Period  (Optional)  
The Ext ension Period (88 weeks) followed by [CONTACT_847059]-up (2 weeks) will 
begin at first subject  first visit in the Extension Period and  result  in an anticipated total study 
duration of up to approximately [ADDRESS_1177756] any 
Extension Period visits that occur within  6 weeks before the study end date will be handled as 
completers. These subjects will attend the final study visit ( Extension Period Week 88) in 
place of their next study visit or telephone c ontact and will receive follow -up telephone 
contact ( Extension Period Week 90 ¬± 3 days).  Subjects who roll-over into the Extension 
Period prior to the Treatment Period [ADDRESS_1177757] not participated in study CSL830_3001 will be enrolled so that the total 
number of subjects randomized is approximately 110.  
Assuming that up to 10% of subjects withdraw before the completion of the study, [ADDRESS_1177758] completed Treatment Period 1 and Treatment 
Period 2 according to the study protocol ar e eligible to enroll in the Extension Period. 
Approximately 50 of these subjects are anticipated to enroll in the Extension Period.  
3.6 Study Monitoring Procedures  
3.6.1 Steering Committee   
A Steering Committee has been established to provide scientific advice and safety monitoring for the study. 
Members of the Steering Committee will be  listed in the Investigator Study File.   
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 54 of 130 
([LOCATION_002])  Confidential  [ADDRESS_1177759] completed participat ion in CSL830_3001 will be offered treatme nt with 
CSL830 as a part of the study if they meet the eligibility criteria presented here. Additional subjects (ie, ‚ÄúCSL830- Na√Øve‚Äù Subjects  [see Section 4.1.1] ) will be eligible to participate in 
the current study in order to meet the planned  sample size.  
Subject eligibility will be reviewed and documented by [CONTACT_458780]‚Äôs study team before a subject  is enrolled  in the study. 
4.1.[ADDRESS_1177760] will be classified into 1 of the following categories: 
Treatment Period 1 and Treatment Period 2  
‚Ä¢ ‚ÄúCSL830- Na√Øve‚Äù Subjects : subjects who did not participate in study CSL830_3001; 
subjects who participate in study CSL830_3001 but did not receive blinded 
investigational product as a part of that study. 
NOTE : For ‚ÄúCSL830- Na√Øve‚Äù Subjects, the first study visit is the Screening Visit.  
‚Ä¢ ‚ÄúCSL830-Interrupted‚Äù Subjects : subjects who completed participation in study 
CSL830_3001, but who delay entry into the current study (ie, > [ADDRESS_1177761] visit of CSL830_3002 Treatment Period 1).  
NOTE : For ‚ÄúCSL830-Interrupted‚Äù Subjects, the first study visit is the Screening Visit.  
‚Ä¢ ‚ÄúCSL830-Continuation‚Äù Subjects : subjects who complete participation in study 
CSL830_3001 and who continue directly on to participate in the current study 
(ie, ‚â§ [ADDRESS_1177762] visit of 
CSL830_3002 Treatment Period 1).  
NOTE : For ‚ÄúCSL830-Continuation‚Äù Subjects, the first study visit is the first study visit in 
Treatment Period 1. For these subjects, the last study visit of CSL830_3001 and the first study visit of Treatment Period 1 from CSL830_3002 may occur on the same day. 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO([WHQVLRQ3HULRG
x¬≥([WHQVLRQ3HULRG¬¥6XEMHFWVVXEM HFWVIURPWKH8QLWHG6WDWHVZK RFRPSOHWHSD UWLFLSDWLRQ
LQ&6/B7UHDWPHQW3HUL RGDQGZKRFRQWLQXHRQWRSDUWLF LSDWHLQWKH([WHQVLRQ
3HULRG
127()RU¬≥([WHQVLRQ3HULRG¬¥6XEMHFWV WKHODVWVWXG\YLVLWRI&6/ B7UHDWPHQW
3HULRGDQGWKHILUVWVWXG\YLVLW RIWKH([WHQVLRQ3HULRGPD\ RFFXURQWKHVDPHGD\
 ,QFOXVLRQ&ULWHULD
6XEMHFWVPHHWLQJDOORIWKHIR OORZLQJLQFOXVLRQFULWHULDPD\EH HQUROOHGUDQGRPL]HGLQWRWKH
VWXG\
&DSDEOHRISURYLGLQJZ ULWWHQLQIRUPHGFRQVHQ WDVVHQWDVDSSURS ULDWHDQGZLOOLQJDQG
DEOHWRDGKHUHWRDOOSURWRFROU HTXLUHPHQWVDQGRUWKHVXEMHFW ¬∂VSDUHQWVRUOHJDOO\
DFFHSWDEOHUHSUHVHQWDWLYHV FDSDEOHRISURYLGLQJZULWWHQLQIRU PHGFRQVHQW
0DOHRUIHPDOH
$JHG\HDUVRUROGHUDWWKH WLPHRISURYLGLQJZULWWHQLQIRUPHG FRQVHQWDVVHQWDV
DSSURSULDWH
$GLDJQRVLVRI+$(W\SH,RU,,DVGHWHUPLQHGE\WKHIROORZL QJDFOLQLFDOKLVWRU\
FRQVLVWHQWZLWK+$( DQG

x)RU¬≥&6/1DwYH¬¥6XEMHFWV+LVWRULFDOO\GRFXPHQWHG 
WKDWDUHFRPSDWLEOHZLWK
SDUWLFLSDWLRQZLOOEHD FFHSWHGKRZHYHULIKLVWRULFDOGRFXPHQW DWLRQLVXQDYDLODEOH
WKHQWKHWHVWVPD\EHFRQGXFWHGD W6FUHHQLQJ%LRFKHPLFDOFRQIL UPDWLRQRI+$(
W\SH,RU,,GLDJQRVLVPXVW EHHVWDEOLVKHGIRUDVXEMHFWEHIR UHVWDUWLQJWKH
7UHDWPHQW3HULRG 
x)RU¬≥&6/,QWHUUXSWHG¬¥6XEMHFW V$1'¬≥&6/&RQWLQXDWLRQ¬¥6XE MHFWV7KH
GRFXPHQWDWLRQWKDWZDVXVHGW RFRQILUPHOLJLELOLW\LQ&6/B ZLOOEHXVHG
WRYHULI\WKHUHTXLUHGYDOXHIRU LQFOXVLRQLQWKHFXUUHQWVWXG\ &6/B
+DYHH[SHULHQFHG+$(DWWDFNVUH TXLULQJDFXWHWUHDWPHQWPHGLFD ODWWHQWLRQRU
FDXVLQJVLJQLILFDQWIXQFWLRQDOLPS DLUPHQWDVGHVFULEHGEHORZ
CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 56 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ For ‚ÄúCSL830- Na√Øve‚Äù Subjects :  
o ‚ÄúCSL830-Na√Øve‚Äù Subjects using intravenous C1-INH as routine (long- term) 
prophylaxis against HAE attacks must have experienced [ADDRESS_1177763] medical records.  
o All other ‚ÄúCSL830- Na√Øve‚Äù Subjects (eg, treated using oral HAE prophylaxis 
against HAE attacks or on -demand treatment) must have experienced [ADDRESS_1177764] medical records.  
‚Ä¢ For ‚ÄúCSL830-Continuation‚Äù Subjects  AND ‚ÄúCSL830-Interrupted‚Äù Subjects : 
Subjects must have experienced [ADDRESS_1177765] medical records (ie, the HAE attack frequency required for el igibility 
to participate in study CSL830_3001). 
6. For subjects who have used oral medication for prophylaxis against HAE attacks 
(ie, androgens, tranexamic acid, progestins) within  [ADDRESS_1177766] study visit: 
Use of a stable  regimen of oral prophyla ctic medication (ie, dose and administration 
frequency) during the [ADDRESS_1177767] 25 weeks. NOTE:  Subjects using oral medication for HAE prophylaxis are to maintain their 
stable, pre-study dose during Treatment Period 1, but may decrease their dose after entering Treatment Period [ADDRESS_1177768] igator as able to appropriately store CSL830, and  is capable of 
being trained to administer CSL830 ( independently or with assistance ) outside of the 
study center setting.   
9. Assessed by [CONTACT_847060], and is capable of using medication to treat breakthrough 
attacks (independently or with assistance) outside of the study center setting. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 57 of 130 
([LOCATION_002])  Confidential  4.1.[ADDRESS_1177769] not be enrolled (randomized) 
into the study: 
1. Subjects who were enrolled in CSL830_3001 but who were withdrawn before 
completion of that study for any reason . 
2. Known incurable malignancies at the time of the  first study  visit. 
3. Any clinical condition that is likely to interfere with evaluation of CSL830 or 
satisfactory conduct of the study.  
4. A clinically significant history of poor response to C1- INH therapy for the 
management of HAE.  
5. A suspected or confirmed diagnos is of acquired HAE or HAE with normal C1 -INH 
(ie, HAE t ype III). 
6. Assessed by [CONTACT_847061] -demand treatment, when that on- demand treatment is 
administered independently or with assistance. 
NOTE:  This must be documented by [CONTACT_847062]. 
7. Female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study, 
or not surgically sterile.   
8. Female subjects who  started taking or changed dose of any hormonal contraceptive 
regimen or hormone replacement therapy (ie, estrogen / progesterone containing 
products) during the [ADDRESS_1177770] study visit, or who intend to initiate 
these therapi[INVESTIGATOR_590051]. 
9. Intention to become pregnant during the course of the study. 
10. Pregnancy or nursing mother. 
11. Participated in an interventional clinical study (other than CSL830_3001) during the 
[ADDRESS_1177771] or at any time 
during the study. 
12. Alcohol, drug or medication abuse within 1 year before the study. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 58 of 130 
([LOCATION_002])  Confidential  13. Mental condition rendering the subject (or the subject‚Äôs legally acceptable 
representative[s]) unable to understand the nature, scope and possible consequences of the study. 
14. Known or suspected hypersensitivity to CSL830, or to any excipi[INVESTIGATOR_847044]830. 
15. Employee at the study site, or spouse / partner or relative of the investigator or sub-investigators.  
16. Any other issue that, in the opi[INVESTIGATOR_871], would render the subject 
unsuitable for participation in the study. 
4.[ADDRESS_1177772], or they may be withdrawn at any time at the discretion of the investigator or CSL for safety, behavioral or 
administrative reasons  (eg, due to an AE, protocol violation, loss to follow-up, subject 
noncompliance, and study termination).  
In accordance with International Conference on Harmonisation ( ICH) principles of Good 
Clinical Practice (GCP) the investigator always has the option to advise a subject to withdraw 
from the study if the s ubject's safety or well -being is compromised by [CONTACT_847063].  Concern for the interests of the subject must always prevail over 
the interests of the study.  
If a subject is withdrawn from the study or further participation is declined, they will 
continue to have access to medical care and will be treated as per routine medical practice.  
4.2.[ADDRESS_1177773]  visit in Treatment 
Period 2 (ie, the Week 53 Visit)  (see Section [IP_ADDRESS]) or the last visit in the Extension Period 
(Extension Period Week 88)(see Section [IP_ADDRESS]) . These subjects will then attend a Follow -
up Visit  occurring 14 days (¬± 3 days) after a visit resulting in study discontinuation, unless 
informed consent/assent has been withdrawn (see Section [IP_ADDRESS]). If the subject is withdrawn 
from the study after receiving CSL830, every effort will be made to ensure that the relevant 
safety assessments are completed.  The subject may also be asked by [CONTACT_847064].  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 59 of 130 
([LOCATION_002])  Confidential  If the subject withdraws from the study, and also withdraws consent /assent (as appropriate)  
for disclosure of future information, CSL  may retain and continue to use any data collected 
before such withdrawal of consent /assent (as appropriate) . 
In the event that a subject withdraws from the study, the investigator should record the reason 
and date of withdrawal in the e lectronic case report form (eCRF)  and in t he subject's medical 
records. 
Subjects who discontinue or withdraw from Treatment Periods 1 or 2 will not be eligible to 
participate in the Extension Period. 
4.2.3 Replacement Policy  
Subjects who discontinue participation in or are otherwise withdrawn from the study will not 
be replaced . Assuming that up to 10% of subjects withdraw before the completion of the 
study, 100 subjects are planned to  complete the study.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 60 of 130 
([LOCATION_002])  Confidential  [ADDRESS_1177774] 
5.1.1 CSL830 
Table 1:  Description of CSL830 
Substance number  CSL830 
Active substance  C1-esterase inhibitor  (C1-INH)  
Trade name  [CONTACT_847086]; 1500 IU C1- INH per 
single -use vial.  
Dose for Treatment 
Periods 1 and 2 40 IU/kg and/ or 60 IU/kg  and/or 80 IU/kg (rounded up to the 
nearest 500 IU) , as described in Section 3.2. 
Dose for Extension 
Period 40 IU/kg and/ or 60 IU/kg  and/or 80 IU/kg (rounded up or 
down to the nearest 1000 IU  for subjects weighing ‚â• 40 kg ; 
subjects weighing < 40 kg will continue to undergo rounding 
as during Treatment Periods 1 and 2 [ie, rounded up to the nearest 500 IU]), as described in Section 
3.2. 
Mode of administration  Subcutaneous injection  
Before use, each vial of CSL830 will be  reconstitu ted with 3 mL water for injection. Each 
vial of CSL830 requires a reconstitution time of 10 minutes. 40 IU/kg CSL830 is equivalent 
to a volume of 0.08 mL/kg; 60 IU/kg CSL830 is equivalent to a volume of 0.12 mL/kg ; 
80 IU/kg CSL830 is equivalent to a volume of 0.16 mL/kg. 
CSL830 will be manufactured by [CONTACT_847065].  
5.1.[ADDRESS_1177775]  
Not Applicable . 
5.2 Packaging, Labeling , Supply and Storage 
5.2.1 Packaging and Labeling  
CSL830 will be packaged and labeled according to current ICH Good Manufacturing 
Practice and GCP  guidelines, and national legal requirements. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 61 of 130 
([LOCATION_002])  Confidential  5.2.[ADDRESS_1177776] be accounted for throughout the study. At the end of the study, 
the original Drug Inventory Log, dated and signed by [CONTACT_163550] 
(eg, pharmacist) , must be retained at the study site as verification of final accountability of 
CSL830. 
Records for the delivery of CSL830 to the study site, the inventory at the study site, the use 
by [CONTACT_6992], and the destruction or r eturn of CSL830 to CSL  must be maintained by [CONTACT_1275] (or delegate).  The records will include dates, quantities, batch  numbers and 
unique code numbers assigned to CSL830 and unique code numbers assigned to the subjects. 
Information on the destruction of CSL830 is provided in the CSL830 Handling Instructions. 
5.4 Other Intervention(s)  
Not applicable.  
[ADDRESS_1177777] Assignment  
After providing written informed consent/assent (as appropriate), the subject will be issued with a study -level unique subject identification number. Each ‚ÄúCSL830-Continuation‚Äù and 
‚ÄúCSL830- Na√Øve‚Äù Subject will re-use the subject numbers they used in study CSL830_3001. 
The subject identification number will be used to identify the subject for the duration of the study. Subject identification numbers will not be reassigned or reused.  
Subjects who are enrolled in the Extension Period will continue to receive the CSL830 dose 
that they were originally administered  during Treatment Period 2.  This CSL830 dose may be 
escalated in increments of 20 IU/kg (up to a maximum dose of 80 IU/kg) according to the rules outlined for Treatment Period 2  (see Section 3.2).   
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 62 of 130 
([LOCATION_002])  Confidential  6.1.2 Randomization Procedures 
A stratified block randomization scheme will be used to ensure that subjects are randomized 
to a starting dose of CSL830 of either 40 IU/kg or 60 IU/kg in a balanced manner and  to 
ensure that ‚ÄúCSL830-Continuation‚Äù Subjects, ‚ÄúCSL830-Interrupted‚Äù Subjects, and ‚ÄúCSL830-
Na√Øve‚Äù Subjects are distributed evenly between the 2 CSL830 treatment groups. 
Eligible  subjects will be randomized to 1 of the 2 treatment groups ( CSL830  40 IU/kg or 
CSL830 60 IU/kg) by [CONTACT_847066] (IRT). The IRT will assign 
the appropriate s tudy treatment to each subject . CSL  will supply the investigator with a user 
guide for the IRT.  
6.1.[ADDRESS_1177778]  
The investigator (or delegate) will only dispense the investigational product (ie , CSL830) to 
subjects included in this  study following the procedures set out in this study protocol. 
CSL830 will be administered either independently (ie, self -administered by [CONTACT_423]) or 
with assistance (ie, with the help of a caretaker such as a par ent or guardian) at home via a 
single SC injection in the abdomen. The injection site should be changed for each new 
administration of CSL830 ; ideally, the site of injection should alternate between the right and 
left sides of the abdomen and should be at least 5 cm (2 inches) away from the previous injection site.  
The abdomen is the preferred injection location in this study. However, if the investigator 
believes that another SC injection site (eg, outer thigh, upper arm) is more clinically 
appropriate for an individual subject, this location can also be used. 
Additional information on the CSL830 dose and dosing regimen can be found in Section 3.2. 
6.2.[ADDRESS_1177779] been trained 
sufficiently to allow for home therapy to occur in Treatment Periods 1 and 2 and the 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 63 of 130 
([LOCATION_002])  Confidential  Extension Period. Mandatory formal training will be performed on Day 1 of Treatment 
Period 1 for all subjects. ‚ÄúCSL830-N a√Øve‚Äù S ubjects  and ‚ÄúCSL830- Interrupted ‚Äù Subjects will 
also have a second round of follow-up training on Day 4 of Treatment Period 1. During these training visits, subjects (or their caregivers, as appropriate) will administer CSL830 under the 
supervision of the investigator. Additional training (including at additional visits ) may be 
conducted for any subject by [CONTACT_3991], if required. Su bjects weighing ‚â• 40 kg 
who enroll in the Extension Period will receive training on the new dose rounding scheme (up or  down to the nearest 1000 IU) on Visit 1 of the Extension Period; subjects weighing 
< 40 kg will continue to undergo rounding as during Treatment Periods 1 and 2 (ie, rounded up to the nearest 500 IU). 
NOTE : The Day 4 Visit may be waived for ‚ÄúCSL830- Interrupted‚Äù Subjects (only) if the 
investigator has confirmed that the subject can adequately treat themselves with CSL830 (ie, 
no further training is necessary). In this case, all activities scheduled for the Day [ADDRESS_1177780] (ie, CSL830) will include the 
following: 
‚Ä¢ Correct storage.  
‚Ä¢ Correct recon stitution technique. 
‚Ä¢ Correct administration technique. 
‚Ä¢ Signs and symptoms of hypersensitivity reactions.  
‚Ä¢ Procedures in case of suspected hypersensitivity reactions.  
‚Ä¢ Correct completion of the eDiary (eg, recording of HAE symptoms, medication  for the 
treatm ent of breakthrough HAE attacks , AE reporting).  
Complete instructions for the handling, reconstitution, and administration of CSL830 will be 
detailed in the CSL830 Handling Instructions. These instructions will be provided to each 
study center prior to enr ollment of the first subject. Subjects will also be provided with 
written instructions for the preparation and administration of CSL830.
 
6.[ADDRESS_1177781] the dose and date of injection of CSL830 in the eDiary. In addition, subjects  will bring their used / partially used  vials of CSL830 to every study visit. Subjects 
will return all vials ( ie, used, partially used, and unused) of CSL830 to the site at last visit in 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 64 of 130 
([LOCATION_002])  Confidential  Treatment Period [ADDRESS_1177782] (ie, CSL830) for an individual subject: 
‚Ä¢ Anaphylaxis or severe and clinically significant allergic reaction causally related to 
CSL830. 
‚Ä¢ Any other CSL830-related SAE or CSL830- relate d important medical event that is 
considered by [CONTACT_1755] / or CSL to be serious and clinically significant, or that 
would suggest significant hazard to the subject following further administration of CSL830. 
‚Ä¢ Administration of a prohibited conco mitant therapy or a prohibited change in 
concomitant therapy (see Section 7.3). 
7.2 Permitted Therapie s 
The following therapi[INVESTIGATOR_847045], Treatment Period 1 , 
Treatment Period 2 , the Follow-up Period, and the Extension Period: 
‚Ä¢ Prescribed medication(s) required for the management of acute or chronic medical conditions, except those described in Section 7.3. 
‚Ä¢ Over the counter medications and dietary supplements.  
‚Ä¢ Medications (eg, IV C1-INH) for the pre -procedure prevention of acute HAE attacks, not 
to exceed 1 dose prior to each procedure.  
‚Ä¢ Medication s for the treatment of breakthrough HAE attacks, including the following: 
o Berinert (IV C1 -INH) . 
o Other plasma -derived or recombinant C1- INH, other than CSL830. 
o Firazyr ( Icatibant ). 
o Kalbitor (Ecallantide ). 
o Fresh frozen plasma. 
The following therapy is  PERMITTED during the Screening and Follow -up Periods (only): 
‚Ä¢ Intravenous C1-INH for routine prophylaxis against HAE attacks.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 65 of 130 
([LOCATION_002])  Confidential  The following therapi[INVESTIGATOR_847046] a stable  dose for [ADDRESS_1177783] study visit and used at the same dose during Treatment Period 1 *: 
‚Ä¢ Oral medications for HAE prophylaxis (eg, androgens, tranexamic acid, progestins) if 
used at a stable dose for [ADDRESS_1177784] study visit*.  NOTE : Subjects using oral medication for HAE prophylaxis may decrease their dose 
after entering Treatment Period 2  and the Extension Period. 
*  For ‚Äú CSL830 -Na√Øve ‚Äù Subjects AND ‚ÄúCSL830-Interrupted‚Äù Subjects : the first study visit is the Screening Visit; 
For ‚ÄúCSL830 -Continuation‚Äù Subjects: the first study visit is the first study visit in Treatment Period 1.  
7.3 Prohibited Therapie s 
Use of t he following therapy is NOT permitted during Treatment Period 1, Treatment Period 
2, and the Extension Period for subjects who are using CSL830: 
‚Ä¢ Intravenous C1-INH for routine prophylaxis against HAE attacks.  
NOTE : Use of IV C1-INH for the pre-procedure prevention of acute HAE attacks is 
permitted, not to exceed [ADDRESS_1177785] study visit*  and throughout the study: 
‚Ä¢ Hormonal contraceptive regimen or hormone replacement therapy (ie, estrogen  / progesterone containing product). 
*  For ‚ÄúCSL830 -Na√Øve ‚Äù Subjects AND ‚ÄúCSL830-Interrupted‚Äù Subjects : the first study visit is the Screening Visit; 
For ‚ÄúCSL830 -Continuation‚Äù Subjects: the first study visit is the first study visit in Treatment Period 1.  
7.[ADDRESS_1177786] that is considered excessive. In a previous study (CSL830_2001), doses up to 6000 IU (up to 120 IU/kg) were administered twice weekly for [ADDRESS_1177787] not been otherwise studied.  
The development of thrombosis has been reported after administering IV C1-INH doses up to 
500 U/kg body weight when used off label in newborns and young children with congenital heart anomalies during or after cardiac surgery under extracorporeal circulati on.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 66 of 130 
([LOCATION_002])  Confidential  There is no specific antidote for excessive dosing of CSL830; in these circumstances, 
appropriate supportive management should be instituted. 
8 Study Procedures and Visit Schedule 
8.1 Clinical Procedures  
8.1.1 Demographics and Safety Assessments 
The clinical procedures that will be conducted during this study related to the evaluation of 
population demographics and safety are provided in Table 2. Refer to the Laboratory Manual 
for details about the collection, storage, handling and transportation of biological specimens, 
and how the assessments should be performed.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 67 of 130 
([LOCATION_002])  Confidential  Table 2:  Clinical Procedures: Demographics and Safety Evaluation 
Assessment Description  
Demographics  Year of birth, age, sex, race and ethnicity . 
Medical history  Relevant medical history for the previous [ADDRESS_1177788] 3 month s. 
Contraception method (if relevant) . 
Current therapi[INVESTIGATOR_014] . 
Dipstick p regnancy test  Urine test for beta -human chorionic gonadotropin  (test conducted  at the study site ). 
Physical examination  As per the site‚Äôs standard procedure.  
Vital signs  Blood pressure (systolic and diastolic)  and respi[INVESTIGATOR_697].  
Pulse rate (per minute) will be measured from the radial pulse counted manually or 
with an automatic blood pressure monitor over ‚â•15 seconds.  
Body temperature.  
Body weight and height (height measurement at Screening only  or from 
CSL830_3001, as appropriate) ; body mass index will be determined from height 
and weight values . 
Urinalysis  
(Central laboratory)  Bilirubin . Blood . Erythrocytes . 
Glucose . Ketones . Leukocyte esterase . 
Nitrite . pH. Protein . 
Specific gravity . Urobilinogen .  
Hematology  
(Central laboratory)  Hemoglobin . Hematocrit .  
Blood cell counts: basophils, eosinophils, erythrocytes, leukocytes, lymphocytes, monocytes, neutrophils, platelets . 
Biochemistry  
(Central laboratory)  ALT . Chloride . GGT . 
Creatinine . Lactate dehydrogenase . Glucose . 
Protein . Total bilirubin . Potassium . 
Albumin . AST . Urea . 
Calcium . Sodium .  
Coagulation  
(Central laboratory)  INR. APTT . Fibrinogen . 
D-dimer . F1+2 .  
Viral serology  
(Central laboratory)  Blood samples to be tested for HIV- 1/-2, HBV, and HCV. 
Immunogenicity  
(Central laboratory)  Serum analyzed for the presence of binding antibodies specific to C1- INH.  
ALT = alanine aminotransferase; APTT = activated partial thromboplastin time ; AST = aspartate 
aminotransferase; F1+2 = prothrombin fragment 1+2; GGT  = Gamma glutamyl transferase; HAE = hereditary 
angioedema; HIV = human immunodeficiency virus; HBV = hepatitis B virus; HCV = hepatitis C virus; INR = 
international normalized ratio.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 68 of 130 
([LOCATION_002])  Confidential  8.1.2 Risk Assessment s for Deep Vein Thrombosis and Pulmonary 
Embolism  
The clinical model scoring system that will be used for the risk assessment of DVT  is 
described in Table 3. 
Table 3: Scoring System for the Risk Assessment of Deep Vein Thrombosis  
Clinical feature 1 Score 
Active cancer (treatment ongoing or within previous 6 months or palliative) . +1 
Paralysis, paresis, or recent plaster immobilization of the lower extremities . +1 
Recently bedridden for more than 3 days or major surgery, within 4 weeks . +1 
Localized tenderness along the distribution of the deep venous system . +1 
Entire leg swollen . +1 
Calf swelling by [CONTACT_726] 3 cm when compared with the asymptomatic leg (measured 10 cm 
below tibial tuberosity) . +1 
Pi[INVESTIGATOR_13034] (greater in the symptomatic leg) . +1 
Collateral superficial veins (non -varicose) . +[ADDRESS_1177789] has a risk score of ‚â• 1, a lower extremity ultrasound examination will be arranged 
by [CONTACT_847067] . If a DVT  is confirmed on ultrasound examination, the 
event will be classified as an AE of special interest ( AESI ) (see Secti on 9.1.2) and will be 
reported as an SAE . 
The clinical model scoring system that  will be used for the risk assessment of PE  is described 
in Table 4. 
Table 4: Scoring System for the Risk Assessment of Pulmonary Embolism 
Clinical feature 1 Score 
Previous pulmonary embolism or deep vein thrombosis . +1.5 
Heart rate >100 beats per minute. +1.5 
Immobilization or surgery in the previous 4 weeks . +1.5 
Clinical signs and symptoms of deep vein thrombosis (minimum of leg swelling and pain with 
palpation of the deep veins ). +3 
Alternative diagnosis less likely than pulmonary embolism . +3 
Hemoptysis . +1 
Malignancy (on treatment, treated within the last 6 months, or palliative) . +1 
1 From Wells et al 2000 . 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO,IDVXEMHFWKDVDULVNVFRUHRI ¬ïDFRPSXWHUL]HGWRPRJUDSKL FDQJLRJUDPRUDSSURSULDWH
LQYHVWLJDWLRQZLOOEHDUUDQJHGE\ WKHLQYHVWLJDWRUWRH[FOXGH3 (,I3(LVFRQILUPHGRQ
LQYHVWLJDWLRQWKHHYHQWZLOOEH FODVVLILHGDVDQ$(6,VHH 6HFWLRQ DQGZLOOEHUHSRUWHG
DVDQ6$(
 


 5HWHQWLRQRI6DPSOHV
,QIRUPHGFRQVHQWDVVHQWDVDSSURS ULDWHLQGHSHQGHQWWRWKDWI RUSDUWLFLSDWLQJLQWKHVWXG\
ZLOOEHUHTXHVWHGIURPVXEMHFWV WRDOORZVDPSOH VRIWKHLUEORRG WREHUHWDLQHGIRUXSWR
\HDUVDIWHUWKHHQGRIWKHVWXG\ IRUIXWXUHQRQJHQHWLFUHVH DUFKUHODWHGWR+$(
7KLVFRQVHQWDVVHQWZ LOOQRWEHYDOLGIRUIXW XUHUHVHDUFKWKDW LQYROYHVJHQHWLFDQDO\VLVRIWKH
UHWDLQHGVDPSOHVRUUHVHDU FKWKDWLVXQUHODWHGWR+$(
 3ULRUDQG&RQFRPLWDQW7KHUDSLHV
$OOGUXJVDQGRUSURFHGXUHVEHLQ JDGPLQLVWHUHGWRDVXEMHFWDW WKHWLPHRIVLJQLQJLQIRUPHG
FRQVHQWDVVHQWDVDSSURSULDWH DQGZKLFKFRQWLQXHWREHWDNHQ LQDGGLWLRQWRWKH
LQYHVWLJDWLRQDOSURGX FWLH&6/GXULQJWKHVWXG\DUHUHJD UGHGDVSULRUDQGRU
FRQFRPLWDQWWKHUDSLHVDQGPXVW EHGRFXPHQWHGDV VXFKLQWKHH& 5)
$GGLWLRQDOO\DOOPHGLFDWLRQVXV HGWRWUHDW+$(LH+$(SURSK\ OD[LVRURQGHPDQG
WUHDWPHQWIRU+$(ZLWKLQWKH PRQWKVEHIRUHHDFKVXEMHFW¬∂VIL UVWVWXG\YLVLWZLOODOVREH
FDSWXUHGLQWKHH&5)CCI
CCI
CCI CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 70 of 130 
([LOCATION_002])  Confidential  8.4 Visit Schedule  
The timing and frequency of all clinical procedures are described in the following tables:  
‚Ä¢ Schedule of Events for ‚ÄúCSL830-Continuation‚Äù Subjects . 
‚Ä¢ Schedule of Laboratory Assessments for ‚ÄúCSL830-Continuation‚Äù Subjects . 
‚Ä¢ Schedule of Events for ‚ÄúCSL830-Interrupted‚Äù Subjects and ‚ÄúCSL830- Na√Øve‚Äù Subjects . 
‚Ä¢ Schedule of Laboratory Assessments for ‚ÄúCSL830-Interrupted‚Äù Subjects and ‚ÄúCSL830-
Na√Øve‚Äù Subjects . 
‚Ä¢ Schedule of Events for the Extension Period.  
 
8.4.1 Informed Consent / Assent  
All subjects must provide written informed consent/assent (as appropriate) before any study-
specific assessments or procedures are performed. Written informed consent/assent is not required for assessments or procedures performed according to standard of care (eg, for diagnosis or treatment); results from such assessments may be used in the determination of 
study eligibility.  
Subjects who participate in the Extension Period are  to provide written informed 
consent/assent (as appropriate) before any study -specific assessments or procedures are 
performed during the Extension Period. 
8.4.2 Screening  
The eligibility of ‚ÄúCSL830 -Na√Øve‚Äù Subjects and ‚ÄúCSL830-Interrupted‚Äù Subjects  will be 
assessed at a Screening Visit conducted within the [ADDRESS_1177790] fails Screening at a combined Screening Visit / Day [ADDRESS_1177791] will be 
treated as a screen failure.  
‚ÄúCSL830-N a√Øve‚Äù Subjects include the following: 
‚Ä¢ Subjects who did not participate in CSL830_3001. 
‚Ä¢ Subjects who participated in CSL830_3001 but did not receive blinded investigational 
product as a part of that study. NOTE : For ‚ÄúCSL830- Na√Øve‚Äù Subjects, the first study visit is the Screening Visit.  
‚ÄúCSL830- Interrupted ‚Äù Subjects include the following: 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx6XEMHFWVZKRFRPSOHWHGSDU WLFLSDWLRQLQVWXG\&6/BEXW ZKRGHOD\HGHQWU\LQWR
WKHFXUUHQWVWXG\LH!Z HHNEHWZHHQWKH(QGRI6WXG\9LVLW RI&6/BDQGWKH
ILUVWYLVLWRI&6/B7UHDWPHQW3HULRG127()RU¬≥&6/,QWHUUXSWHG¬¥6XEM HFWVWKHILUVWVWXG\YLVLWLVW KH6FUHHQLQJ9LVLW 
,IDSRWHQWLDOVXEMHFWZDVQRWHQW HUHGLQWR7UHDWPHQW3HULRG RIWKHFXUUHQWVWXG\ZLWKLQWKH
ZHHNVIROORZLQJWKH6FUHHQLQJ 9LVLWWKHSRWHQWLDOVXEMHFWPD \DWWHQGDVHFRQG6FUHHQLQJ
9LVLWIRUDPD[LPXPRI6FUHHQLQJ9LVLWVSHUVXEMHFW,QWKH HYHQWWKDWDSRWHQWLDOVXEMHFW
LVVFUHHQHGWZLFHDOO6FUHHQLQ J3HULRGDVVHVVPHQWVLQFOXGLQJP HGLFDOKLVWRU\PXVWEH
UHSHDWHGDWWKHVHFRQG6FUHHQLQJ 9LVLWDQGWKHVHILQGLQJUHVX OWVZLOOVXSHUVHGHWKRVHIURP
WKHSUHYLRXV6FUHHQLQJ9LVLW 



7KHIROORZLQJSURFHGXUHVZLOO EHFRQGXFWHGDQGGRF XPHQWHGDWWK H6FUHHQLQJ9LVLW
x:ULWWHQLQIRUPHGFRQVHQWDVVHQWDVDSSURSULDWH
x5HYLHZRILQFOXVLRQDQG H[FOXVLRQFULWHULD
x'HYHORSDQLQGLYLGXDODFXWHDF WLRQSODQLQFOXGLQJDVVHVVPHQWR IVXEMHFW¬∂VDELOLW\WR
PDQDJH+$(DWWDFNVLQGHSHQGHQWO\RUZLWKDVVLVWDQFH
x'HPRJUDSKLFV
x&OLQLFDOO\VLJQLILFDQWKLVWRU \IURPWKHSUHYLRXVPRQWKV
x9LWDOVLJQVLQFOXGLQJZHLJKWDQGKHLJKW
x3K\VLFDOH[DPLQDWLRQ
x,QGZHOOLQJYHQRXVFDWKHWHULVSUHVHQW\HVQR
x$VVHVVULVNRI'97DQG3(
x 


 
 
 


CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO

x6WDUWPRQLWRULQJRI$(V
x5HFRUGSULRUFRQFRPLWDQWWKHUD SLHVLQFOXGLQJWKHUDS\UHODWLQ JWR+$(LQWKHSUHYLRXV
PRQWKV
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x%HJLQPRQLWRULQJGRFXPHQWLQJ+$(DWWDFNVLQYHVWLJDWRUVDQGV XEMHFWVVKRXOGPDLQWDLQ
JRRGFRPPXQLFDWLRQGXULQJWKH6FUHHQLQJ3HULRGWRDOORZFDSWXUH RIWKHDSSURSULDWH
LQIRUPDWLRQIURPWKH6FUHHQLQJ9LVLWWRWKHVWDUWRI7UHDWPHQW 3HULRG
x6FKHGXOHWKHQH[WVWXG\YLVLW
6XEMHFWVZKRFRPSOHWH DOORIWKHVHDVVHVVP HQWVDQGZKRIXOILOO WKHLQFOXVLRQH[FOXVLRQ
FULWHULDLHHOLJLEOHVXEMHFWV ZLOOEHHQWHUHGLQWR7UHDWPHQW 3HULRG,IWKHVXEMHFWLVQRW
HOLJLEOHIRUWKH7UHDWPHQW3 HULRGWKHSULPDU\UHDVRQIRUVFU HHQIDLOXUHPXVW EHHQWHUHGLQ
WKHH&5)
 7UHDWPHQW3HULRG
 :HHN'D\
7KHILUVWVWXG\YLVLWLQ7UHDWPHQW3HULRGZLOORFFXURQ:HHN 'D\7KHUHLVQRYLVLW
ZLQGRZIRUWKHYLVLW
¬≥&6/&RQWLQXDWLRQ¬¥6XEMHFWVV XEMHFWVZKRFRPSOHWHSDUWLFLSD WLRQLQ&6/BDQG
ZKRFRQWLQXHGLUHFWO\RQ WRSDUWLFLSDWHLQWKHFXUUHQWVWXG\>L H¬îZHHNEHWZHHQWKH(QGRI
6WXG\9LVLWRI&6/BDQGWKH ILUVWYLVLWRI&6/B7 UHDWPHQW3HULRG@ZLOO
QRWKDYHD6FUHHQLQJ9LVLW)RUW KHVHVXEMHFWVWKHODVWVWXG\ YLVLWRI&6/BDQGWKH
ILUVWVWXG\YLVLWRI7UHDWPH QW3HULRGIURP&6/BVKRXOG RFFXURQWKHVDPHGD\
ZKHUHSRVVLEOH
(OLJLELOLW\RI¬≥&6/&RQWLQXDWLRQ¬¥6XEMHFWVVHH 6HFWLRQ DQG6HFWLRQ ZLOOEH
DVVHVVHGXVLQJ&6/B GDWDDVGHVFULEHGLQ 7DEOHLIWKHUHTXLUHG&6/B
GDWDLVQRWDYDLODEOH RQWKH'D\9LVLWRIWKHFXUUHQWVWXG\ WKHQWKHFRUUHVSRQGLQJ
DVVHVVPHQWPXVW EHFRQGXFWHG
,IDVXEMHFWGLGQRWSDUWLFLSDWHL QD6FUHHQLQJ9LVLWLH¬≥&6/ &RQWLQXDWLRQ¬¥6XEMHFWV
WKHQZULWWHQLQIRUPHGFRQVHQWDVVH QWDVDSSURSULDWHPXVWEHR EWDLQHGEHIRUHDQ\VWXG\CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOVSHFLILFDVVHVVPHQWVRUSURFHGXUHV DUHSHUIRUPHG DWWKHILUVWY LVLWLQ7UHDWPHQW3HULRGWKH
'D\9LVLW
7DEOH 5HVXOWVIURP6WXG \&6/BWREHXVHGIRU6WXG\
&6/B(OLJLELOLW\$VVHVVPHQW RI¬≥&6/&RQWLQXDWLRQ¬¥
6XEMHFWV
$VVHVVPHQW 6RXUFH
'HPRJUDSKLFV &6/B6FUHHQLQJ9LVLW$
0HGLFDO+LVWRU\ &6/B6FUHHQLQJ9LVLW$
2QJRLQJ$GYHUVH(YHQWV &6/B(QGRI6WXG\9LVLW$
&RQFRPLWDQW0HGLFDWLRQ:LWKLQPRQWKVRIDQGLQFOXGLQJWKH
&6/B(QGRI6WXG\9LVLW$
3K\VLFDO([DPLQDWLRQ &6/B(QGRI6WXG\9LVLW
9LWDO6LJQVLQFOXGLQJ:HLJKW &6/B(QGRI6WXG\9LVLW


3UH&6/B+$($WWDFNV 5HVXOWVXVHGWRTXDOLI\IRU&6/B
8ULQH3UHJQDQF\7HVW &6/B(QGRI6WXG\9LVLW%
$7REHXSGDWHGDVQHHGHGLQR UGHUWRSURYLGHDFRPSOHWH&6/ BVXEMHFWUHFRUG
%7KHUHVXOWVRIWKHXULQHSUHJQDQF\WHVWFRQGXFWHGDWWKHHQGRI VWXG\YLVLWFDQRQO\EHXVHGWRVDWLVI\WKH
DSSOLFDEOHHOLJLELOLW\FULWHULRQ LIWKH&6/B(QGRI6WXG \9LVLWDQGWKHILUVWYLVLWRI&6/B
7UHDWPHQW3HULRGLH'D\R FFXURQWKHVDPHGD\2WKHUZLVH DQHZSUHJQDQF\WHVWPXVWEHSHUIRUPHGDWWKH
ILUVWVWXG\YLVLWLQ&/6B7UHDWPHQW3HULRGLQRUGHUWR FRQILUPHOLJLELOLW\
6XEMHFWVZKRIXOILOOWKHLQFOXVL RQH[FOXVLRQFULWHULDLHHOLJ LEOHVXEMHFWVZLOOEHHQWHUHG
UDQGRPL]HGLQWR7UHDWPHQW3HU LRG,IWKHVXEMHFWLVQRWHOL JLEOHIRUWKH7UHDWPHQW3HULRG
WKHSULPDU\UHDVRQIRUVFUHHQI DLOXUHPXVWEHHQWHUHGLQWKH H&5)
7KHIROORZLQJDVVHVVPHQWVZLOOEH FRQGXFWHGE\WKHLQYHVWLJDWRU RUGHOHJDWHIRUDOOVWXG\
VXEMHFWVXQOHVVRWKHUZLVHQRWHG
x5HYLHZRILQFOXVLRQH[FOXVLRQF ULWHULDLQRUGHUWRFRQILUPHO LJLELOLW\WRSDUWLFLSDWHLQWKH
FXUUHQWVWXG\
x8SGDWHGHPRJUDSKLFVDQGPHG LFDOKLVWRU\DVQHHGHG
x(QUROOVXEMHFWLQWRWKHVWXG\DQGUDQGRPL]HVXEMHFWWRDVWXG\ WUHDWPHQWDUPYLD
LQWHUDFWLYHUHVSRQVHWHFKQRORJ\
x'LVSHQVHH'LDU\WRVXEMHFW
x 
CCICCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx2EWDLQEORRGVDPSOHVIRUWKHIROOR ZLQJ>DSSOLFDEOHWRDOO¬≥&6/ 1DwYH¬¥DQG¬≥&6/
,QWHUUXSWHG¬¥6XEMHFWV$1'¬≥&6/ &RQWLQXDWLRQ¬¥6XEMHFWVZKRGL GQRWFRPSOHWHWKH
DVVHVVPHQWVDWWKH&6/B(QGRI6WXG\9LVLWRQO\@
R+HPDWRORJ\
R%LRFKHPLVWU\
R&RDJXODWLRQ
R9LUDOVHURORJ\
R$VVHVVPHQWRIDQWLERGL HVDJDLQVW&,1+
x$VVHVVULVNRI'97DQG3(>DSSOL FDEOHWR¬≥&6/&RQWLQXDWLRQ¬¥ 6XEMHFWVZKRGLGQRW
FRPSOHWHWKHDVVHVVP HQWVDWWKH&6/B(QGRI6WXG\9LVLW RQO\@
x



 
 
 
x2EWDLQDXULQHVDPSOHIRUXULQDO \VLV>DSSOLFDEOHWRDOO¬≥&6/ 1DwYH¬¥DQG¬≥&6/
,QWHUUXSWHG¬¥6XEMHFWV$1'¬≥&6/ &RQWLQXDWLRQ¬¥6XEMHFWVZKRGL GQRWFRPSOHWHWKH
DVVHVVPHQWVDWWKH&6/B(QGRI6WXG\9LVLWRQO\@
x)RUIHPDOHVXEMHFWVREWDLQDXULQ HVDPSOHIRUGLSVWLFNSUHJQDQ F\WHVWLQJWRDVVHVV
HOLJLELOLW\SULRUWRUDQGRPL]D WLRQDQGGRVLQJ>DSSOLFDEOHWRDO O¬≥&6/1DwYH¬¥6XEMHFWV
DQG¬≥&6/,QWHUUXSWHG¬¥6XEMHFW VDOVRDSSOLFDEOHWRDOO¬≥&6/ &RQWLQXDWLRQ¬¥
VXEMHFWVLIWKHLU&6/B(QGRI 6WXG\9LVLWDQGWKHLUILUV WYLVLWRI&6/B
7UHDWPHQW3HULRGLH:HHN'D\ RFFXURQGLIIHUHQWGD\V@ 
x6XEMHFWKHLJKW>DSSOLFDEOHWR¬≥ &6/&RQWLQXDWLRQ¬¥6XEMHFWVR QO\@
x,QGZHOOLQJYHQRXVFDWKHWHULVSUHVHQW\HVQR>DSSOLFDEOHWR¬≥ &6/&RQWLQXDWLRQ¬¥
6XEMHFWVRQO\@
x'LVSHQVH&6/DQGRWKHUVWXG\V XSSOLHV>DSSOLFDEOHWR¬≥&6/ &RQWLQXDWLRQ¬¥
6XEMHFWVRQO\@
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPVXEMHFWLVFDSDEOHRIXVLQ JPHGLFDWLRQIRU WKHWUHDWPHQ WRIEUHDNWKURXJK+$(
DWWDFNVLQGHSHQGHQWO\RUZLWKDVVLVWDQFH
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGSULRUFRQFRPLWDQWWKHUDSLHVCCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 75 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ Review the individual acute action plan with subject.  
‚Ä¢ Train subject: 
o Instruct on use of the eDiary. 
o Instruct on the CSL830 injection technique. 
o Instruct on the CSL830 dosing regimen. 
o Supervise (observe) subject‚Äôs first administration of CSL830. 
o Provide written instructions on the handling, reconstitution, and self- administration of 
CSL830; the suggested interval between each administration of CSL830 is 3 or 4 
days.  
‚Ä¢ Schedule the next telephone contact [CONTACT_847068]. 
[IP_ADDRESS] Week 1, Day 4 
‚ÄúCSL830- Na√Øve‚Äù Subjects and ‚ÄúCSL830- Interrupted ‚Äù Subjects will attend a study visit on 
Day 4 (+  1 day).   
The Day 4 Visit may be waived for ‚ÄúCSL830-Interrupted‚Äù Subjects (only) if the investigator 
has confirmed that the subject can adequately treat himself/herself with CSL830 (ie, no 
further training is necessary). In this case, all activities scheduled for the Day 4 V isit may be 
conducted at the Day 1 Visit. 
‚ÄúCSL830-Continuation‚Äù Subjects are not required to attend a study visit on Day 4. 
The following procedures will be performed by t he investigator or delegate: 
‚Ä¢ Review subject eDiary; record information on HAE attacks in eCRF.  
‚Ä¢ Confirm  access to on-demand medication  for the treatment of breakthrough HAE attacks. 
‚Ä¢ Record AEs . 
‚Ä¢ Record concomitant therapi[INVESTIGATOR_014].  
‚Ä¢ Train subject: 
o Instruct on use of the eDiary.  
o Instruct on the CSL830 injection technique. 
o Instruct on the CSL830 dosing regimen. 
o Supervise subject‚Äôs second administration of CSL830. 
‚Ä¢ Dispense CSL830/study supplies to subject. 
‚Ä¢ Perform CSL830 accountability.  
‚Ä¢ Schedule the next telephone cont act and the next study visit. 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO :HHN
6XEMHFWVZLOOEHFRQWDFWHGE\ WHOHSKRQHRQ'D\¬ìGD\VWR UHFRUG$(VD QGFRQFRPLWDQW
WKHUDSLHV
 :HHN
6XEMHFWVZLOODWWHQGDVWXG\ YLVLWRQ'D\¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x3K\VLFDOH[DPLQDWLRQ
x$VVHVVULVNRI'97DQG3(
x 

x2EWDLQEORRGVDPSOHVIRUWKHIROORZLQJ
R+HPDWRORJ\
R%LRFKHPLVWU\
R&RDJXODWLRQ
x 
 
 
 
x2EWDLQDXULQHVDPSOHIRUXULQDO\VLV
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJ
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x$VVHVVVXEMHFWIRU&6/GRVH FRQWLQXDWLRQRU&6/GRVHLQFU HDVH
R'XULQJWKHIL[HGGRVH7UHDWPH QW3HULRGVXEMHFWVZKRH[SHULHQ FHYHU\IUHTXHQW
+$(DWWDFNVLH¬ïDWWDFNVDV GHILQHGSHUSURWRFROZLWKLQ DZHHNHYDOXDWLRQ
SHULRGDUHHOLJLEOHIRU&6/ GRVHLQFUHDVHVLQLQFUHPHQWVRI ,8NJXSWRD
PD[LPXPGRVHRI,8NJ$OO&6/GRVHLQFUHDVHVDUHRSWLRQ DODQGZLOOEH
PDGHRQO\LQVXEMHFWVZKRDUHHOL JLEOHDWWKHVROHGLVFUHWLRQ RILQYHVWLJDWRU$Q
HYDOXDWLRQSHULRGIRUDQ\GRVHLQFU HDVHLVGHILQHGDVEHJLQQLQJ DIWHUDGRVHVWDEOH
SHULRGLHZHHNVDIWHUWKH LQLWLDWLRQRUGRVHLQ FUHDVHRI&6 /$GRVHLQFUHDVHLQ
7UHDWPHQW3HULRGLVLQWHQGHGDV UHVFXHSURSK\OD[LVWRSURYLG HWKHRSSRUWXQLW\IRU
VXEMHFWVZKRKDYHYHU\IUHTXHQW +$(DWWDFNVWRFRQWLQXHLQWKH VWXG\GXULQJWKH
RWKHUZLVHIL[HGGRVH7UHDWPHQW3HULRGCCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 77 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ Perform CSL830 accountability.  
‚Ä¢ Confirm  access to on-demand medication  for the treatment of breakthrough HAE attacks. 
‚Ä¢ Record AEs.  
‚Ä¢ Record concomitant therapi[INVESTIGATOR_014].  
‚Ä¢ If considered necessary, reinstruct subject on injection technique, dosing regimen, and use 
of eDiary.  
‚Ä¢ Dispense CSL830/study supplies to subject.  
‚Ä¢ Schedule the next telephone contact [CONTACT_847068]. 
[IP_ADDRESS] Week 13 
Subjects will be contact[CONTACT_304159] 85 (¬± 2 days) to record AEs and concomitant therapi[INVESTIGATOR_014] . 
[IP_ADDRESS] Week 17 
Subjects will attend a study visit on Day 113  (¬± 2 days). 
The following procedures will be performed by [CONTACT_163550]: 
‚Ä¢ Vital signs , including weight.  
‚Ä¢ Assess risk of DVT and PE.  
‚Ä¢ Review subject eDiary; record information on HAE attacks in eCRF.  
‚Ä¢ Assess subject for CSL830 dose continuation or CSL830 dose increase. 
o During the fixed -dose Treatment Period 1, subjects who experience very frequent 
HAE attacks  (ie, ‚â• 12 attacks, as defined per protocol, within a 4 -week evaluation 
period) are eligible for CSL830 dose increases in increments of 20 IU/kg  (up to a 
maximum dose of 80 IU/kg). A ll CSL830 dose increases are optional, and will be 
made only in subjects who are eligible, at the sole discretion of investigator. An 
evaluation period for any dose increase is defined as beginning after a dose- stable 
period (ie, 2 weeks after the initiation or dose increase of CSL830). A dose increase in 
Treatment Period [ADDRESS_1177792] very frequent HAE attacks to continue in the study during the 
otherwise fixed -dose Treatment Period 1. 
‚Ä¢ Perform CSL830 accountability.  
‚Ä¢ Confirm  access to on-demand medication  for the treatment of breakthrough HAE attacks. 
‚Ä¢ Record AEs.  
‚Ä¢ Record concomitant therapi[INVESTIGATOR_014].  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx,IFRQVLGHUHGQHFHVVDU\UHLQV WUXFWVXEMHFWRQLQMHFWLRQWHFKQL TXHGRVLQJUHJLPHQDQGXVH
RIH'LDU\
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
 :HHN
6XEMHFWVZLOOEHFRQWDFWHGE\ WHOHSKRQHRQ'D\¬ìGD\VW RUHFRUG$(VDQG
FRQFRPLWDQWWKHUDSLHV
 :HHN
6XEMHFWVZLOODWWHQGDVWXG\ YLVLWRQ'D\¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x3K\VLFDOH[DPLQDWLRQ
x$VVHVVULVNRI'97DQG3(
x 

x 
x 

x2EWDLQEORRGVDPSOHVIRUWKHIROORZLQJ
R+HPDWRORJ\
R%LRFKHPLVWU\
R&RDJXODWLRQ
R9LUDOVHURORJ\
R$VVHVVPHQWRIDQWLERGL HVDJDLQVW&,1+
x 
 
 
 
x2EWDLQDXULQHVDPSOHIRUXULQDO\VLV
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJ
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x$VVHVVVXEMHFWIRU&6/GRVH FRQWLQXDWLRQRU&6/GRVHLQFU HDVHCCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOR%HJLQQLQJZLWKWKH:HHN9LVLW DQGWKURXJKRXW7UHDWPHQW3HULR GVXEMHFWVZKR
H[SHULHQFH¬ï+$(DWWDFNVDVGH WHUPLQHGSHUSURWRFROZLWKLQ DQZHHNHYDOXDWLRQ
SHULRGDUHHOLJLEOHIRU&6/GRVH LQFUHDVHVLQLQFUHPHQWVRI ,8NJXSWRD
PD[LPXPGRVHRI,8NJ$OO&6/GRVHLQFUHDVHVDUHRSWLRQ DODQGZLOOEH
PDGHRQO\LQVXEMHFWVZKRDUHHOL JLEOHDWWKHVROHGLVFUHWLRQ RILQYHVWLJDWRU$Q
HYDOXDWLRQSHULRGIRUDQ\GRVHLQFU HDVHLVGHILQHGDVEHJLQQLQJ DIWHUDGRVHVWDEOH
SHULRGLHZHHNVDIWHUWKH LQLWLDWLRQRUGRVHLQ FUHDVHRI&6 /$GRVHLQFUHDVHLQ
7UHDWPHQW3HULRGLVLQWHQGHGWRD OORZLQYHVWLJDWRUVWRDGMXVW RSWLPL]HWKHGRVHIRU
VXEMHFWVZKRPD\QHHGDKLJKHUSURSK\ODFWLFGRVH
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x,IFRQVLGHUHGQHFHVVDU\UHLQV WUXFWVXEMHFWRQLQMHFWLRQWHFKQL TXHGRVLQJUHJLPHQDQGXVH
RIH'LDU\
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
 7UHDWPHQW3HULRG
 :HHN
$OOVXEMHFWVZLOODWWHQGDVWX G\YLVLWRQ'D\¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x3K\VLFDOH[DPLQDWLRQ
x$VVHVVULVNRI'97DQG3(
x 

x2EWDLQEORRGVDPSOHVIRUWKHIROORZLQJ
R+HPDWRORJ\
R%LRFKHPLVWU\
R&RDJXODWLRQ
x 
 
 CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO 
x2EWDLQDXULQHVDPSOHIRUXULQDO\VLV
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x$VVHVVVXEMHFWIRU&6/GRVH FRQWLQXDWLRQRU&6/GRVHLQFU HDVH
R'XULQJ7UHDWPHQW3HULRGVXEMHFW VZKRH[SHULHQFH¬ï+$(DWWD FNVDVGHWHUPLQHG
SHUSURWRFROZLWKLQDQZHHNH YDOXDWLRQSHULRGDUHHOLJLEOHI RU&6/GRVH
LQFUHDVHVLQLQFUHPHQWVRI, 8NJXSWRDPD[LPXPGRVHRI ,8NJ$OO&6/
GRVHLQFUHDVHVDUHRSWLRQDOD QGZLOOEHPDGHRQO\LQVXEMHFWV ZKRDUHHOLJLEOHDWWKH
VROHGLVFUHWLRQRILQYH VWLJDWRU$QHYDOX DWLRQSHULRGIRUDQ\G RVHLQFUHDVHLVGHILQHG
DVEHJLQQLQJDIWHUDGRVHVWDEOHSHULRGLHZHHNVDIWHUWKH LQLWLDWLRQRUGRVHLQFUHDVH
RI&6/6HH 6HFWLRQ IRUDGGLWLRQDOGHWD LOV$GRVHLQFUHDVHLQ7UHDWPHQW
3HULRGLVLQWHQGHGWRDOORZLQYHV WLJDWRUVWRDGMXVWRSWLPL]H WKHGRVHIRUVXEMHFWV
ZKRPD\QHHGDKLJKHUSURSK\ODFWLFGRVH
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x,IFRQVLGHUHGQHFHVVDU\UHLQV WUXFWVXEMHFWRQLQMHFWLRQWHFKQL TXHGRVLQJUHJLPHQDQGXVH
RIH'LDU\
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
 :HHN
6XEMHFWVZLOOEHFRQWDFWHGE\ WHOHSKRQHRQ'D\¬ìGD\VW RUHFRUG$(VDQG
FRQFRPLWDQWWKHUDSLHV
 :HHN
6XEMHFWVZLOODWWHQGDVWXG\ YLVLWRQ'D\¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x3K\VLFDOH[DPLQDWLRQ
x$VVHVVULVNRI'97DQG3(
x 
C
CI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx2EWDLQEORRGVDPSOHVIRUWKHIROORZLQJ
R+HPDWRORJ\
R%LRFKHPLVWU\
R&RDJXODWLRQ
x 
 
 
 
x2EWDLQDXULQHVDPSOHIRUXULQDO\VLV
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJ
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x$VVHVVVXEMHFWIRU&6/GRVH FRQWLQXDWLRQRU&6/GRVHLQFU HDVH
R'XULQJ7UHDWPHQW3HULRGVXEMHFW VZKRH[SHULHQFH¬ï+$(DWWD FNVDVGHWHUPLQHG
SHUSURWRFROZLWKLQDQZHHNH YDOXDWLRQSHULRGDUHHOLJLEOHI RU&6/GRVH
LQFUHDVHVLQLQFUHPHQWVRI, 8NJXSWRDPD[LPXPGRVHRI ,8NJ$OO&6/
GRVHLQFUHDVHVDUHRSWLRQDOD QGZLOOEHPDGHRQO\LQVXEMHFWV ZKRDUHHOLJLEOHDWWKH
VROHGLVFUHWLRQRILQYH VWLJDWRU$QHYDOX DWLRQSHULRGIRUDQ\G RVHLQFUHDVHLVGHILQHG
DVEHJLQQLQJDIWHUDGRVHVWDEOHSHULRGLHZHHNVDIWHUWKH LQLWLDWLRQRUGRVHLQFUHDVH
RI&6/6HH 6HFWLRQ IRUDGGLWLRQDOGHWD LOV$GRVHLQFUHDVHLQ7UHDWPHQW
3HULRGLVLQWHQGHGWRDOORZLQYHV WLJDWRUVWRDGMXVWRSWLPL]H WKHGRVHIRUVXEMHFWV
ZKRPD\QHHGDKLJKHUSURSK\ODFWLFGRVH
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x,IFRQVLGHUHGQHFHVVDU\UHLQV WUXFWVXEMHFWRQLQMHFWLRQWHFKQL TXHGRVLQJUHJLPHQDQGXVH
RIH'LDU\
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
 :HHN
6XEMHFWVZLOOEHFRQWDFWHGE\ WHOHSKRQHRQ'D\¬ìGD\VW RUHFRUG$(VDQG
FRQFRPLWDQWWKHUDSLHVCCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 82 of 130 
([LOCATION_002])  Confidential  [IP_ADDRESS] Week 45 
Subjects will attend a study visit on  Day 309 (¬±  2 days).  
The following procedures will be performed by [CONTACT_163550]: 
‚Ä¢ Vital signs including weight.  
‚Ä¢ Assess risk of DVT and PE.  
‚Ä¢ Review subject eDiary; record information on HAE attacks in eCRF.  
‚Ä¢ Assess subject for CSL830 dose continuation or CSL830 dose increase. 
o During Treatment Period 2 , subjects who experience ‚â• 3 HAE attacks (as determined 
per protocol) within an 8-week evaluation period are eligible for CSL830 dose 
increases in increments of 20  IU/kg  (up to a maximum dose of 80 IU/kg). All CSL830 
dose increases are optional, and will be made only in subjects who are eligible, at the 
sole discretion of investigator. An evaluation period for any dose increase is defined 
as beginning after a dose- stable period (ie,  2 weeks aft er the initiation or dose increase 
of CSL830) . See Section 3.[ADDRESS_1177793]/optimize the dose for subjects 
who may need a higher prophylactic dose. 
‚Ä¢ Perform CSL830 accountability.  
‚Ä¢ Confirm  access to on-demand medication  for the treatment of breakthrough HAE attacks. 
‚Ä¢ Record AEs.  
‚Ä¢ Record concomitant therapi[INVESTIGATOR_014].  
‚Ä¢ If considered necessary, reinstruct subject on injection technique, dosing regimen, and use of eDiary.  
‚Ä¢ Dispense CSL830/study supplies to subject.  
‚Ä¢ Schedule the next telephone contact [CONTACT_847068]. 
[IP_ADDRESS] Week 49 
Subjects will be contact[CONTACT_304159] 337 (¬±  2 days) to record AEs and 
concomitant therapi[INVESTIGATOR_014].  
[IP_ADDRESS] Week 53 
Subjects will attend a study visit on Day 367 (¬±  2 days).  See also Section [IP_ADDRESS] for the 
Week [ADDRESS_1177794] visit of the Extension 
Period . 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO$OOVXEMHFWVLQFOXGLQJ¬≥&6/ B1DLYH¬¥VXEMHFWVZLOODWWHQGW KH:HHN9LVLWLVWRRFFXU
QRHDUOLHUWKDQGD\VDIWHUUDQGRPL]DWLRQ
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x3K\VLFDOH[DPLQDWLRQ
x$VVHVVULVNRI'97DQG3(
x 

x 
x 

x2EWDLQEORRGVDPSOHVIRUWKHIROORZLQJ
R+HPDWRORJ\
R%LRFKHPLVWU\
R&RDJXODWLRQ
R9LUDOVHURORJ\
R$VVHVVPHQWRIDQWLERGL HVDJDLQVW&,1+
x 
 
 
 
x2EWDLQDXULQHVDPSOHIRUXULQDO\VLV
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJ
x,QGZHOOLQJYHQRXVFDWKHWHULVSUHV HQW\HVQR>LIVWDWXVKDVF KDQJHGWKHQSURYLGHD
UHDVRQIRUWKHFKDQJHZKHUHDYD LODEOHDQGGDWHRIFKDQJHZKH UHDYDLODEOHDQGFURVV
FKHFNZLWK$(VUHFRUGHGLQWKHH &5)IRUFRQVLVWHQF\ZKHUHDSSO LFDEOH@
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x6FKHGXOHWKHQH[WVWXG\YLVLWCCI
CCI
CCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 84 of 130 
([LOCATION_002])  Confidential  8.4.[ADDRESS_1177795] Follow-up  
[IP_ADDRESS] Follow-up Visit  
Subjects will attend a  Follow- up Visit occurring 14 days (¬± 3 days) after the final visit in 
Treatment Period 2 or any visit resulting in study discontinuation, unless informed 
consent/assent has been withdrawn or if the Extension Period starts prior to the scheduled 
Follow- up Visit.  See Section 8.4.6 for information on how subjects may continue onto the 
Extension Period from T reatment Period 2.  
The following procedures will be performed by [CONTACT_163550]: 
‚Ä¢ Review subject eDiary; record information on HAE attacks in eCRF.  
‚Ä¢ Collect eDiary from subject  (only if subject is not going to participate in the Extension 
Perio d). 
‚Ä¢ Record AEs.  
‚Ä¢ Record concomitant therapi[INVESTIGATOR_014].  
8.4.6 Extension Period  
[IP_ADDRESS]  Extension Period Week [ADDRESS_1177796] 
starts the Extension Period on the same day as the final visit for T reatment Period 2.  Please 
see the specific instructions as noted below. 
[IP_ADDRESS].1 Extension Period Starts on the Same Day as Treatment Period 2  
Completion  (Week 53 of Treatment Period 2)  
The following procedures will be performed by [CONTACT_847069] 2  in addition 
to the procedures performed on the final visit of Treatment Period 2. The Extension Period 
Visit 1 procedures will not be repeated if they were already performed for the final visit of 
Treatment Period 2  (see Section [IP_ADDRESS]). 
‚Ä¢ Ensure that the subject complete d an informed consent form ( ICF) if he/she did not 
already consent to participate in the Extension Period. 
‚Ä¢ Schedule the next study visit. 
‚Ä¢ Instruct the subject on dosing volume. Note: Determine volume to be administered 
based on new algorithm for subjects weighing ‚â• 40 kg (subjects weighing < 40 kg 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 85 of 130 
([LOCATION_002])  Confidential  will c ontinue to undergo rounding as during Treatment Periods 1 and 2 [ie, rounded 
up to the nearest 500 IU]) :  1. Determine weight -based dose. Round (up or  down to 
the nearest 1000 IU), 2. Determine the volume to be administered, and 3. Instruct the 
subject on the volume to be administered twice weekly.  
‚Ä¢ Dispense CSL830 and other supplies to subjects. 
 Table 7 shows the assessments from Treatment Period 2 (Week 53 Visit) that will be used for 
Visit 1 of the Extension Period when the Extension Period starts on the Same Day and Treatment Period 2 . 
Table 7:  Assessment s from Treatment Period 2 (Week 53 Visit)  to Be Used 
for Visit 1 of the Extension Period When the Extension Period 
Starts on the Same Day as Treatment Period 2  
Assessment s from Treatment Period 2 (Week 53 Visit)  
Study Center Visit  
Physical Examination  
Indwelling Catheter (yes/no)  
Vital Signs, including Body Weight  
Assess Risk of DVT and PE  
Urine Pregnancy Test A 
Confirm Access to On -demand HAE Medication  
CSL830 Accountability  
Concomitant Medication  
Adverse Events  
Abbreviations: DVT = deep vein thrombosis; HAE = hereditary angioedema; PE = pulmonary embolism.  
A The results of the urine pregnancy test can only be used to satisfy the applicable eligibility criterion if the 
Treatment Period [ADDRESS_1177797] visit of  the Extension Period (ie, Day 367) occur on 
exactly the same day. Otherwise, a new pregnancy test must be performed at the first study visit in the 
Extension Period in order to confirm eligibility. 
 
[IP_ADDRESS].2 Extension Period Does Not Start on the Same Day as Treatment 
Period 2 Completion  
It is strongly preferred that subjects initiate the Extension  Period on the same day they 
complete Treatment Period 2; however, a period of up to [ADDRESS_1177798] visit of the Extension Period.   
The procedures outlined above in Section [IP_ADDRESS].1 will be conducted with the following 
exceptions for subjects who do not start the Extension Period on the same day that  they 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 86 of 130 
([LOCATION_002])  Confidential  complete Treatment Period  2.  For subjects who have an interrupted course/elect to take a rest 
period (of up to 30 days) of CSL830 treatment between Treatment Period 2: 
1. The Treatment Period 2 End-of-Study Follow- up Visit will remain an on -site visit and 
will occur 14 days (¬± 3 days) after the last visit (Week 53) in Treatment Period [ADDRESS_1177799]‚Äôs Extension Period starts after the scheduled Follow- up Visit . (No T reatment 
Period [ADDRESS_1177800]‚Äôs Extension Period starts prior to 
the scheduled Follow -up V isit), and  
2. The diary will not be used after the already planned Treatment Period 2 follow-up 
period (approximately 2 weeks); however, the following information will be 
reviewed, documented in the medical record, and recorded at the Extension Period 
Visit 1 for the period during which no diary is in use: 
‚Ä¢ Any additional information on relevant medical history,  
‚Ä¢ Any HAE attacks,  
‚Ä¢ Any medication taken, and  
‚Ä¢ Any adverse events  
Table 8 shows the assessments from Treatment Period 2 (Week 53 Visit) that will be repeated  
for Visit 1 of the Extension Period when the Extension Period does not start on the Same Day and Treatment Period 2. 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO7DEOH $VVHVVPHQWVIURP7UH DWPHQW3HULRG:HHN9LVLWW R%H5HSHDWHGIRU
  9LVLWRIWKH([WHQVLRQ3HULR G:KHQWKH([WHQ VLRQ3HULRG'RH V1RW6WDUW
  RQWKH6DPH'D\DV7UHDWPHQW3HULRG
$VVHVVPHQWVIURP7UHDWPHQW3HULRG:HHN9LVLW
6WXG\&HQWHU9LVLW
3K\VLFDO([DPLQDWLRQ
,QGZHOOLQJ&DWKHWHU\HVQR
9LWDO6LJQVLQFOXGLQJ%RG\:HLJKW
$VVHVV5LVNRI'97DQG3(
8ULQH3UHJQDQF\7HVW$
&RQILUP$FFHVVWR2Q GHPDQG+$(0HGLFDWLRQ
&6/$FFRXQWDELOLW\
&RQFRPLWDQW0HGLFDWLRQ
$GYHUVH(YHQWV 
$EEUHYLDWLRQV'97 GHHSYHLQ WKURPERVLV+$( KHUHGLWDU\DQJ LRHGHPD3( SXOPRQDU\HPEROLVP
$7KHUHVXOWVRIWKHXULQHSUHJQDQF\WHVWFDQRQO\EHXVHGWRVDW LVI\WKHDSSOLFDEOHHOLJLELOLW\FULWHULRQLIWKH
7UHDWPHQW3HULRG(QGRI6WXG\9LVLWDQGWKHILUVWYLVLWRIWK H([WHQVLRQ3HULRGLH'D\RFFXURQ
H[DFWO\WKHVDPHGD\2WKHUZLVHDQHZSUHJQDQF\WHVWPXVWEHS HUIRUPHGDWWKHILUVWVWXG\YLVLWLQWKH
([WHQVLRQ3HULRGLQRUGHUWRFRQILUPHOLJLELOLW\

 ([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOEHFRQWDFWHGE\WH OHSKRQHDWWKH([WHQVLRQ3HULRG :HHN9LVLW¬ìGD\VWR
UHFRUG$(VDQGFRQFRPLWDQWWKHU DSLHVDQGVHOIDGPLQLVWHUWKH$( 4R/TXHVWLRQQDLUH
 ([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x$VVHVVULVNRI'97DQG3(
x 
x 

x 

x 
 
 CCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO 
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
 ([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOEHFRQWDFWHGE\WH OHSKRQHDWWKH([WHQVLRQ3HULRG :HHN9LVLW¬ìGD\VWR
UHFRUG$(VDQGFRQFRPLWDQWWKHUDSLHV
 ([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOVHOIDGPLQLVWHUWK H$(4R/TXHVWLRQQDLUHDW([WHQ VLRQ3HULRG:HHN¬ì
GD\V
 ([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x3K\VLFDOH[DPLQDWLRQ
x$VVHVVULVNRI'97DQG3(
x2EWDLQEORRGVDPSOHIRUDVVHVVPHQW RIDQWLERGLHVDJDLQVW&,1+ 
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJ
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLWC
CI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO ([WHQVLRQ3HULRG:HHN


 ([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOEHFRQWDFWHGE\WH OHSKRQHDWWKH([WHQVLRQ3HULRG :HHN9LVLW¬ìGD\VWR
UHFRUG$(VDQGFRQFRPLWDQWWKHUDSLHV
 ([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x$VVHVVULVNRI'97DQG3(
x 
 
 
 
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOEHFRQWDFWHGE\WH OHSKRQHDWWKH([WHQVLRQ3HULRG :HHN9LVLW¬ìGD\VWR
UHFRUG$(VDQGFRQFRPLWDQWWKHUDSLHV
([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOVHOIDGPLQLVWHUWK H$(4R/TXHVWLRQQDLUHDW([WHQ VLRQ3HULRG:HHN¬ì
GD\V
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x3K\VLFDOH[DPLQDWLRQ
x$VVHVVULVNRI'97DQG3(
x 
x 

x 

x2EWDLQEORRGVDPSOHVIRUWKHIROORZLQJ
R$/7$67
R&RDJXODWLRQ
R$VVHVVPHQWRIDQWLERGL HVDJDLQVW&,1+
R9LUDOVHURORJ\
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJ
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x3HUIRUP&6/DFFRXQWDELOLW\
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x5HFRUG$(V
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
([WHQVLRQ3HULRG:HHN


([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOEHFRQWDFWHGE\WH OHSKRQHDWWKH([WHQVLRQ3HULRG :HHN9LVLW¬ìGD\VWR
UHFRUG$(VDQGFRQFRPLWDQWWKHUDSLHVCCICCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x$VVHVVULVNRI'97DQG3(
x 
 
 
 
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOEHFRQWDFWHGE\WH OHSKRQHDWWKH([WHQVLRQ3HULRG :HHN9LVLW¬ìGD\VWR
UHFRUG$(VDQGFRQFRPLWDQWWKHUDSLHV
([WHQVLRQ3HULRG:HHN


([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x$VVHVVULVNRI'97DQG3(
x2EWDLQEORRGVDPSOHIRUDVVHVVPHQW RIDQWLERGLHVDJDLQVW&,1+ 
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJCCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
([WHQVLRQ3HULRG:HHN


([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOOEHFRQWDFWHGE\WH OHSKRQHDWWKH([WHQVLRQ3HULRG :HHN9LVLW¬ìGD\VWR
UHFRUG$(VDQGFRQFRPLWDQWWKHUDSLHV
([WHQVLRQ3HULRG:HHN
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x9LWDOVLJQVLQFOXGLQJZHLJKW
x$VVHVVULVNRI'97DQG3(
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
x3HUIRUP&6/DFFRXQWDELOLW\
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x'LVSHQVH&6/VWXG\VXSSOLHVWRVXEMHFW
x6FKHGXOHWKHQH[WW HOHSKRQHFRQWDFWDQGWKHQH[WVWXG\YLVLW
([WHQVLRQ3HULRG:HHN)LQDO9LVLW
6XEMHFWVZLOODWWHQGDVWXG\YLV LWDW([WHQVLRQ3HULRG:HHN ¬ìGD\V
7KHIROORZLQJSURFHGXUHVZLOOEHSHUIRUPHGE\WKHLQYHVWLJDWRU RUGHOHJDWH
x3K\VLFDOH[DPLQDWLRQ
x9LWDOVLJQVLQFOXGLQJZHLJKW
x$VVHVVULVNRI'97DQG3(CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx 
x 

x 

x2EWDLQEORRGVDPSOHVIRUWKHIROORZLQJ
R$/7$67
R&RDJXODWLRQ
R9LUDOVHURORJ\
R$VVHVVPHQWRIDQWLERGL HVDJDLQVW&,1+
x 
 
 
 
x2EWDLQDXULQHVDPSOHIRUXULQDO\VLV
x,QGZHOOLQJYHQRXVFDWKHWHULVSUHV HQW\HVQR>LIVWDWXVKDVF KDQJHGWKHQSURYLGHD
UHDVRQIRUWKHFKDQJHZKHUHDYD LODEOHDQGGDWHRIFKDQJHZKH UHDYDLODEOHDQGFURVV
FKHFNZLWK$(VUHFRUGHGLQWKHH &5)IRUFRQVLVWHQF\ZKHUHDSSO LFDEOH@
x)RUIHPDOHVXEMHFWVREWDLQXULQH VDPSOHIRUGLSV WLFNSUHJQDQF\ WHVWLQJ
x5HYLHZVXEMHFWH'LDU\UHFRUGL QIRUPDWLRQRQ+$(DWWDFNVLQH&5 )
x3HUIRUP&6/DFFRXQWDELOLW\
x&RQILUPDFFHVVWRRQGHPDQGPHGL FDWLRQIRUWKHW UHDWPHQWRIEUH DNWKURXJK+$(DWWDFNV
7KHVXEMHFWZLOOEHDGYLVHGWRU HVXPHXVXDOPHGLFDOFDUHXSRQF RPSOHWLRQRIWKHVWXG\
x5HFRUG$(V
x5HFRUGFRQFRPLWDQWWKHUDSLHV
x6FKHGXOHWKHQH[W WHOHSKRQHFRQWDFW
x&ROOHFWH'LDU\
([WHQVLRQ3HULRG:HHN)ROORZ8S
6XEMHFWVZLOOEHFRQWDFWHGE\ WHOHSKRQHGD\V¬ìGD\VDIWH UWKHILQDOYLVLW([WHQVLRQ
3HULRG:HHNRIWKH([WHQVL RQ3HULRGRUDQ\YLVLWUHVXOWLQJ LQVWXG\GLVFRQWLQXDWLRQ
XQOHVVLQIRUPHGFRQVHQWDVVHQW KDVEHHQZLWKGUDZQWRUHFRUG$(V DQGFRQFRPLWDQWWKHUDSLHVCCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO 8QVFKHGXOHG9LVLWV
8QVFKHGXOHGYLVLWVFDQEHDUUDQJ HGDWDQ\WLPHSRLQWGXULQJWKH VWXG\HJWRUHLQVWUXFW
VXEMHFWRQFRUUHFWLQMHFWLRQW HFKQLTXHGRVLQJUHJLPHQRUXVH RIH'LDU\WRUHSHDWDVWXG\
SURFHGXUHWRSLFNXSQHZVWXG\PH GLFDWLRQDWWKHGLVFUHWLRQ RIWKHLQYHVWLJDWRURUXSRQ
UHTXHVWRIWKHVXEMHFW
 6XEMHFW$VVHVVPHQWV
'XULQJ7UHDWPHQW3HULRGVD QGDQGWKH([WHQVLRQ3HULRGVXEM HFWVZLOOUHSRUWWKH
IROORZLQJLQIRUPDWLRQLQWKHH'LDU\
x'HWDLOVRIWKHDGPLQLVWUDWLRQRI &6/LHGRVHGDWHVWDUW WLPHRILQMHFWLRQORFDWLRQRI
LQMHFWLRQDQGQHHGOHW\SHXVHG
x/RFDOUHDFWLRQVDWWKHVLWHRI& 6/DGPLQLVWUDWLRQGLVFRPI[INVESTIGATOR_66160] W>HJSDLQEXUQLQJ@
VZHOOLQJEUXLVLQJLWFKLQJ\HVQR
x3URGURPDOV\PSWRPVH[SHULHQFHGIDWLJXHUDVKPXVFOHDFKHVQD XVHDWLQJOLQJ\HVQR
x+$(V\PSWRPVH[SHULHQFHG\HVQR
x'D\DQGWLPHRI+$(V\PSWRPRQVHW
x/RFDWLRQRI+$(V\PSWRPVIURPPR VWVHYHUHWROHDVWVHYHUHID FHOLSVWRQJXHLQVLGH
PRXWKWKURDWYRLFHER[DEGRPLQ DOJHQLWRXULQ DU\H[WUHPLWLHV >ULJKWDUPOHIWDUPULJKW
OHJOHIWOHJ@
x/RFDWLRQRISULPDU\+$(V\PSWRP IDFHOLSVWRQJXHLQVLGHPRXWK WKURDWYRLFHER[
DEGRPLQDOJHQLWRXULQDU\H[WUHPLWLHV>ULJKWDUPOHIWDUPULJ KWOHJOHIWOHJ@
x6HYHULW\RI+$(V\PSWRPV PLOGPRGHUDWHRUVHYHUH
x0HGLFDWLRQIRUWKHWUHDWPHQWRIEU HDNWKURXJK+$(DWWDFNVLVQHH GHG\HVQR
x,IPHGLFDWLRQIRUWKHWUHDWPHQW RIEUHDNWKURXJK+$(DWWDFNVLV QHHGHG
R0HGLFDWLRQXVHG%HULQHUW.DOELWR U)LUD]\U&,1+RWKHUWKDQ %HULQHUWIUHVKIUR]HQ
SODVPDRWKHU
R'RVHDGPLQLVWHUHG
R'D\DQGWLPHVWDUWHG
R$GPLQLVWUDWLRQRIPHGLFDWLRQE\D KHDOWKFDUHSURIHVVLRQDO\HV QR
x2WKHU$(V\HVQR
x2WKHUFRQFRPLWDQWPHG LFDWLRQ\HVQR


CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO





$GYHUVH(YHQWV
 'HILQLWLRQV
 $GYHUVH(YHQW
$VSHUWKH,&+JXLGHOLQHVDQ$( LVDQ\XQWRZDUGPHGLFDORFFXUU HQFHLQDVXEMHFWRUFOLQLFDO
LQYHVWLJDWLRQVXEMHFWDGPLQLV WHUHGDSKDUPDFHXWLFDOSURGXFWDQG ZKLFKGRHVQRWQHFHVVDULO\
KDYHDFDXVDOUHODWLRQVKLSZLWKW KLVWUHDWPHQW$Q$(FDQWKHU HIRUHEHDQ\XQIDYRUDEOHDQG
XQLQWHQGHGVLJQLQFOXGLQJDQD EQRUPDOFOLQLFDOO\VLJQLILFDQW ODERUDWRU\ILQGLQJV\PSWRP
RUGLVHDVHWHPSRUDOO\DVVRFLDWH GZLWKWKHXVHRIDPHGLFLQDOL QYHVWLJDWLRQDOSURGXFW
ZKHWKHURUQRWFRQVLGHUHGUHODWH GWRWKHPHGLFLQDOLQYHVWLJDWL RQDOSURGXFW
7KHSHULRGRIREVHUYDWLRQIRU$(VH [WHQGVIURPWKHWLPHWKHVXE MHFWJLYHVLQIRUPHG
FRQVHQWDVVHQWDVDSSURSULDWHXQWLOWKH)ROORZXS9LVLWVHH 6HFWLRQ DQG6HFWLRQ 
$GYHUVHHYHQWVPD\LQFOXGH
x([DFHUEDWLRQLHDQLQFUHDVHLQW KHIUHTXHQF\RUVHYHULW\RI DSUHH[LVWLQJFRQGLWLRQ
,OOQHVVSUHVHQWEHIRUHVWXG\H QWU\VKRXOGEHUHFRUGHGLQWKHPH GLFDOKLVWRU\VHFWLRQRIWKH
H&5)DQGRQO\EHUHSRUWHGDVDQ$( LIWKHUHLVDQLQFUHDVHLQW KHIUHTXHQF\RUVHYHULW\RI
WKHFRQGLWLRQGXULQJWKHVWXG\
x$FOLQLFDOHYHQWRFFXUULQJDIW HUFRQVHQWDVVHQW DVDSSURSULDWH EXWEHIRUHWKH
LQYHVWLJDWLRQDOSURGX FWDGPLQLVWUDWLRQ
x,QWHUFXUUHQWLOOQHVVHVZLWKDQRQV HWDIWHUDGPLQ LVWUDWLRQRIWK HLQYHVWLJDWLRQDOSURGXFW
$GYHUVHHYHQWVGRQRWLQFOXGH
x(YHQWVLGHQWLILHGDW6FUHHQLQJ WKDWPHHWH[FOXVLRQFULWHULD
x0HGLFDORUVXUJLFDOSURFHGXUHV WKHFRQGLWLRQWKDWOHDGVWRWKH SURFHGXUHLVWKH$(
x6LWXDWLRQVZKHUHDQXQWRZDUGPHG LFDORFFXUUHQFHKDVQRWWDNHQS ODFH)RUH[DPSOH
R3ODQQHGKRVSLWDOL]DWL RQVGXHWRSUHH[LVWLQJFRQGLWLRQVZKLFK KDYHQRWZRUVHQHGCCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 96 of 130 
([LOCATION_002])  Confidential  NOTE : A pre -planned surgery must have been pre-planned prior to the subject‚Äôs 
participation in the study (ie, at the time of signing informed consent/assent [as 
appropriate]). This information must be presented in the subject‚Äô s source 
documentation.  
o Hospi[INVESTIGATOR_254786] (eg, cosmetic surgery). 
o Hospi[INVESTIGATOR_5315] a diagnostic procedure where the hospi[INVESTIGATOR_254787] 24 hours in duration or for normal management procedures. 
‚Ä¢ Overdose of the investigational product or any concomitant therapy that does not result in any adverse signs or symptoms.  
‚Ä¢ HAE attacks; unless the attack meets the criteria of an SAE (see Section 9.1.3) or unless 
the attack significantly worsens following on- demand treatment (eg, with IV Berinert).  
For laboratory safety parameters, any instances of absolute values being outside the reference range or changes at any visit after study start that are considered by [CONTACT_458797]. In addition, at the investigator‚Äôs 
discretion, any changes or trends over time in laboratory parameters can be recorded in the eCRF as AEs if such changes or trends are considered to be clinically relevant, even if the absolute values are within the reference range.  
Laboratory findings do not need to be reported as AEs in the following cases: 
‚Ä¢ Laboratory parameters already beyond the reference range at Screening, unless a further 
increase/decrease can be considered an exacerbation of a pre -existing condition.  
‚Ä¢ Abnormal laboratory parameters caused by [CONTACT_285068] (eg, in vitro hemolysis) and flagged as such by [CONTACT_254845]. 
‚Ä¢ Abnormal parameters that are obviously biologically implausible (eg, values that are 
incompatible with life or outside the measuring range).  
‚Ä¢ An abnormal laboratory value that cannot be confirmed after repeat analysis, preferably in the same laboratory (ie, the previous result could be marked as not valid and should not 
necessarily be reported as an AE).  
9.1.[ADDRESS_1177801] therapy. Additional data may be requested for these events. The AESIs will be:  
‚Ä¢ Thrombotic or thromboembolic events. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 97 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ Anaphylaxis (defined as severe and clinically relevant systemic allergic reaction with 
sudden onset and rapid progression. Clinical criteria for the diagnosis of anaphylaxis are 
presented in  Table 9). 
Table 9: Clinical Criteria for the Diagnosis of Anaphylaxis 
Anaphylaxis is highly likely when any 1 of the following 3 criteria is fulfilled:  
1. Acute onset of an illness (minutes to several hours) with involvement of the skin, 
mucosal tissue, or both (eg, generalized hives, pruritus or flushing, swollen lips-tongue-
uvula) AND at least 1 of the following: 
a. Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze-bronchospasm, stridor, reduced peak 
expi[INVESTIGATOR_10229] [ PEF], hypoxemia) 
b. Reduced BP or associated symptoms of end-organ dysfunction (eg, hypotonia 
[collapse], syncope, incontinence) 
2. Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for 
that patient (minutes to several hours):  
a. Involvement of the skin- mucosal tissue (eg, generalized hives, itch -flush, swollen lips-
tongue-uvula) 
b. Respi[INVESTIGATOR_7798] (eg, dyspnea, wheeze-bronchospasm, stridor, reduced PEF, 
hypoxemia)  
c. Reduced BP or associated symptoms (eg, hypotonia [collapse], syncope, incont inence)  
d. Persistent gastrointestinal symptoms (eg, crampy abdominal pain, vomiting)  
3. Reduced BP after exposure to known allergen for that patient (minutes to several hours):  
a. Infants and children: low systolic BP (age specific) or greater than 30% decrease in 
systolic BP * 
b. Adults: systolic BP of less than 90 mm Hg or greater than 30% decrease from that 
person‚Äôs baseline 
PEF = peak expi[INVESTIGATOR_10229]; BP = blood pressure.  
*  Low systolic blood pressure for children is defined as less than 70 mm Hg from 1 month to 1 year, 
less than (70 mm Hg + [2 √ó age]) from 1 to 10 years, and less than 90 mm Hg from 11 to 17 years.  
Reference:  Sampson HA, Mu√±oz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et 
al. Second symposium on the definition and management of anaphylaxis: summary report‚Äî
Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol. 2006 Feb;117(2):391-7.  
9.1.3 Serious Adverse Event  
A serious adverse event ( SAE ) is defined as any untoward medical occurrence that at any 
dose: 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 98 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ Results in death: The event must be the cause of death for the SAE to meet this serious 
criterion.  
‚Ä¢ Is life-threatening:  The term ‚Äúlife -threatening‚Äù refers to an event in which the subject was 
at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it had been more severe.  
‚Ä¢ Requires in -patient h ospi[INVESTIGATOR_3850]: CSL  
considers ‚Äúhospi[INVESTIGATOR_1081]‚Äù for at least 24 hours as the defining criterion for an SAE. Hospi[INVESTIGATOR_847047] e management procedures (eg, chemotherapy) are not considered as 
defining criteria for SAEs.  
‚Ä¢ Results in persistent or significant disability or incapacity.  
‚Ä¢ Is a congenital anomaly or birth defect.  
‚Ä¢ Is medically significant:  A medically significant event is  defined as an event that does not 
necessarily meet any of the SAE criteria, but which is judged by a physician to potentially jeopardize the subject or require medical or surgical intervention to prevent 1 of the above outcomes listed as an SAE criterion. 
Adverse events that do not fall into the above categories are defined as non- serious AEs.  
9.2 Severity of Adverse Events  
9.2.1 Unsolicited Adverse Events  
The severity of each AE  (ie, non-serious and serious AEs) is to be assessed using the 
following criteria:  
Table 10: Severity of Unsolicited Adverse Events  
Severity Definition  [ADDRESS_1177802] . 
Severe  A type of AE that interrupts usual activities of daily living, or significantly affects clinical 
status, or may require intensive therapeutic intervention.  
1 CDISC SDTM Severity Intensity Scale for Adverse Event Terminology  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 99 of 130 
([LOCATION_002])  Confidential  9.2.2 Solicited Local Adverse Events (Injection Site Reactions)  
Solicited local AEs are injection site reactions at the CSL830 injection site  that are 
specifically asked for and recorded.  
Subjects will record the occurrence of local AEs (injection site reactions) in their eDiary by 
[CONTACT_16134]: ‚ÄúHave you experienced any local reactions at the injection 
site (eg, discomfort, swelling, bruising, or itching)? (yes/no)‚Äù. Subjects will be instructed to take notes (outside of the diary) to describe any local AEs they experience and to report that information to their investigator. Each investigator will use the information from the diary 
and the subject to identify and grade the intensity of each symptom. Each symptom will be 
entered as an independent AE.  
Solicited local AEs are defined an d graded as follows:  
Table 11: Intensity of Solicited Local Adverse Events  
Solicited Local 
Adverse Event  Intensity Grading  
Mild 
(Grade 1)  Moderate  
(Grade 2)  Severe 
(Grade 3)  
Discomfort at the 
injection site after 
the injection 
procedure (eg, pain, 
burning)  Present but does not 
interfere with activity  Repeated use of non -
narcotic pain reliever for 
over [ADDRESS_1177803] always be assessed by [CONTACT_093].  All 
AEs will be classified as either related or not related to CSL830. If a causality assessment is 
not provided for an AE (including an SAE ), that AE will be considered related to CSL830.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 100 of 130 
([LOCATION_002])  Confidential  The degree of certainty with which an AE is attributed to CSL830 or an alternative cause (eg, 
natural history of the underlying disease, concomitant therapy) will be determined by [CONTACT_1004]: 
‚Ä¢ Known pharmacology of CSL830. 
‚Ä¢ Clinically and  / or pathophysiologically plausible context. 
‚Ä¢ Reaction of a similar nature previously observed with similar products, or reported in the 
literature for similar products as being product related (eg, headache, faci al flushing, 
pallor). 
‚Ä¢ Plausibility supported by [CONTACT_254847] ( eg, the event being related by [CONTACT_847070]830, drug withdrawal or reproduced 
on re- challenge). 
9.4 Observation Period s for Adverse Events 
Treatment Period 1 and Treatment Period 2  
The observation period for AE (and SAE) reporting in an individual subject will start at the time of giving written informed consent/assent (as appropriate) for participation in this  study 
and finish with the final study visit.  
Extension Period  
The observation period for AE (and SAE) reporting in an individual subject will start at the 
time of giving written informed consent/assent (as appropriate) for participation in the 
Extension Period and finish with the follow-up visit contact .  
If the investigator becomes aware of an SAE that has started after the observation period has 
finished, and the event could in some way be associated with the investigational product, then 
this must also be reported to CSL Global Clinical Safety and Pharmacovigilance (see Section  9.6).  
9.5 Adverse Event Reporting 
9.5.1 Adverse Events  
At each clinical evaluation, the investigator (or delegate) will determine whether any AEs have occurred. AEs will be recorded in the AE page of the e CRF. I f known, the medical 
diagnosis of an AE should be recorded in preference to the listing of individual signs and 
symptoms.  The investigator must follow up on the course of an AE until resolution or 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 101 of 130 
([LOCATION_002])  Confidential  stabilization . If an  AE is ongoing after the final study visit , the AE  will continue to be 
followed up until resolution, stabilization, or for [ADDRESS_1177804]  should be considered medically significant and are 
therefore SAEs. The expedited reporting procedures for SAEs are described in detail in Section 9.6.1. 
9.6 Serious Adverse Event Reporting 
This study will comply with all applicable regulatory requirements and adhere to the full 
requirements of ICH Topic E2A (Clinical Safety Data Management: Definitions and Standards for Expedited Reporting). 
For SAEs occurring during the study, the investigator or delegate will enter all relevant 
information in the AE page of  the eCRF.  An electronic document containing the AE page and 
other applicable pages of the eCRF must be sent (via facsimile or email) to the sponsor 
together with a Notification of Serious Adverse Event at Investigator Site  cover page, 
which has been signed and dated by [CONTACT_737]. If an electronic document is not able to 
be generated (eg, internet access problem), a handwritten paper SAE report  must be 
completed, which must be signed and dated by [CONTACT_093]. In this case, the investigator 
should follow-up with a completed, signed, and dated electronic document. 
All SAEs that occur during the course of the study, whether or not causally related to 
CSL830, must be reported immediately (within 24 hours of the investigator becoming 
aware of the event) to CSL .  
Adverse events occurring in the period between the time the subject gave written informed consent /assent (as appropriate)  and the first exp osure to CSL830 that meet [ADDRESS_1177805] be reported to CSL  in the same manner as other SAEs and 
will be included in the clinical study database.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 102 of 130 
([LOCATION_002])  Confidential  Any SAE that occurs after the final  study visit that is considered to be causally related to 
CSL830 must be reported immediately (ie, within 24 hours of the investigator becoming 
aware of the event) to CSL . 
Contact [CONTACT_847071] s will be provided to study site before the 
study starts . 
9.6.1  Requirements for Immediate Reporting of  Serious Adverse 
Events 
The minimum reporting requirements for immediate reporting of SAEs include: 
‚Ä¢ Identifiable subject.  
‚Ä¢ Suspected medicinal product and / or procedure. 
‚Ä¢ Event term . 
‚Ä¢ Identifiable reporting source.  
In addition, the investigator must: 
‚Ä¢ Report all SAEs to the relevant institutional review board ( IRB) / independent ethics 
committee ( IEC) within the timeframe  specified by [CONTACT_1201] / IEC . 
‚Ä¢ Submit follow -up reports to CSL  Clinical Safety and Pharmacovigilance until the SAE 
has resolved, or, in the case of permanent impairment, until stabilized. 
‚Ä¢ Ensure that the causality assessment for all SAEs is entered in the eCRF.  
If the minimum requirements for reporting are fulfilled , the investigator should not wait to 
receive additional information to fully document the event before notifying CSL .  
When submitting SAE reports and any other related reports (eg, discharge summaries) to 
CSL, subjects should be identified only by [CONTACT_570762]. The 
investigator should not include the subject‚Äôs name, date of birth, or address.  
In cases of death, the investigator should supply CSL  and the IEC  / IRB (as applicable) with 
any additional inf ormation as it becomes available (eg, autopsy reports and detailed medical 
reports).  
The procedure to be followed if an ongoing AE becomes an SAE after the end of the observation period for AEs is described in Section 9.4. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 103 of 130 
([LOCATION_002])  Confidential  9.7 Other Significant Event Reporting 
9.7.1 Overdose  
Details (ie, volume, location of infusions, infusion rate) of overdose of CSL830 or any 
concomitant therapy must be recorded in the eCRF.  Any overdose of CSL830 that results in 
any adverse signs or symptoms, and considered by [CONTACT_847072], must be reported as an SAE (s ee Section 9.1.3).  
9.7.[ADDRESS_1177806] should be followed to term so as to assess any potential occurrence of congenital anomalies or birth defects. Any follow -up information, including premature termination and the status of the 
mother and child after delivery, should be reported by [CONTACT_847073] a 
Pregnancy Reporting / Outcome Form. 
If the partner of a male subject participating in this study becomes pregnant, the male subject 
should inform the investigator as soon as possible. The investigator will attempt to obtain 
written p ermission directly from the pregnant female that her gynecologist can be contact[CONTACT_847074]/or the sponsor. In this case, the investigator may contact [CONTACT_847075] C1 -INH and the pregna ncy 
will be followed to its outcome.  
9.8 IRB / IEC Reporting Requirements  
The time frame within which an IRB  / IEC must be notified of deaths and CSL830- related 
unexpected SAEs is stipulated by [CONTACT_9906]  / IEC. It is the investigator‚Äôs responsibility to 
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOFRPSO\ZLWKWKHUHTXLUHPHQWVIR U,5%,(&QRWLILFDWLRQ&6/ZL OOSURYLGHLQYHVWLJDWRUVZLWK
DOOGHWDLOVRIDOO6$(VUHSRUWH GWRUHJXODWRU\DXWKRULWLHV
 )ROORZXSRI$GYHUVH(YHQWV
(YHU\HIIRUWVKRXOGEHPDGHWRI ROORZXSVXEMHFWVZKRFRQWLQXH WRH[SHULHQFHDQ$(RUDQ
6$(RQFRPSOHWLRQRIWKHVWXG\ $VXEMHFWZLWKDQ6$(ZLOOEHI ROORZHGXQWLOWKH6$(KDV
UHVROYHGRUVWDELOL]HG$VXEM HFWZLWKDQRQVHULRXV$(ZLOOEH IROORZHGIRUDVORQJDVD
SHULRGRIGD\VDIWHUWKHILQDO DGPLQLVWUDWL RQRIWKHLQYHVWL JDWLRQDOSURGXFWLIWKH$(KDV
QRWUHVROYHGEHIRUHWKDWWLPH $OOIROORZXSLQIRUPDWLRQDQGD WWHPSWHGIROORZXSFRQWDFWV
VKRXOGEHGRFXPHQWHGLQWKHVXEMHFW ¬∂VPHGLFDOUHFRUGV)RU6$(V GHWDLOVRIWKHVXEMHFW¬∂V
SURJUHVVVKRXOGDOVREH VXEPLWWHGWR&6/*OREDO&OLQLFDO6DIHW\ DQG3KDUPDFRYLJLODQFH
&RQWDFWGHWDLOVIRU&6/*OREDO& OLQLFDO6DIHW\DQG3KDUPDFRYLJL ODQFHZLOOEHSURYLGHGWR
HDFKVLWHDWWKHWLPHRIVWXG\VWDUW
$VVHVVPHQWV
6XEMHFW&KDUDFWHULVWLFV
6XEMHFWFKDUDFWHULVWLFVWREHHYDOXDWHGZLOOLQFOXGH
x'HPRJUDSKLFVHJVH[UDFHKHLJKWERG\ZHLJKW
x&OLQLFDOO\VLJQLILFD QWPHGLFDOKLVWRU\
x&RQILUPDWLRQRI+$(GLDJQRVLVDQGL GHQWLILFDWLRQRI+$(W\SHV HH6HFWLRQ 
x)UHTXHQF\RI+$(DWWDFNVLQW KHPRQWKSHULRGWKDWZDVXVHGWR TXDOLI\VXEMHFWVIRU
SDUWLFLSDWLRQLQWKHF XUUHQWVWXG\VHH 6HFWLRQ 
x)UHTXHQF\RI+$(DWWDFNVGXULQJWKH6FUHHQLQJ3HULRGIRU¬≥&6/ 1DwYH¬¥6XEMHFWV
DQG¬≥&6/,QWHUUXSWHG¬¥6XEM HFWVRQO\>LHVXEMHFWVZKRSDUWL FLSDWHLQWKH6FUHHQLQJ
3HULRG@
x3ULRUDQGRUFRQFRPLWDQWWKHUDS\LQFOXGLQJWKHUDS\UHODWHGWR +$(
 


 
 
 CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO 


 

 
 
 
 

 
 
 
 
 


 
 
 
 
 









C
CI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO




6DIHW\$VVHVVPHQWV
6DIHW\ZLOOEHD VVHVVHGXVLQJ 
x9LWDOVLJQV
x3K\VLFDOH[DPLQDWLRQ
x&OLQLFDOVFRUHVRIULVNDVV HVVPHQWIRU'97DQG3(
x6ROLFLWHGORFDO$(VLHL QMHFWLRQVLWHUHDFWLRQV
x2WKHU$(VLQFOXGLQJ6$(V
x&OLQLFDOODERUDWRU\DVVHVVPHQWV
R+HPDWRORJ\
R%LRFKHPLVWU\
R&RDJXODWLRQSURILOH
R9LUDOVHURORJ\
R$QWL&,1+DQWLERGLHV
R8ULQDO\VLV
&OLQLFDOODERUDWRU\WHVWVZ LOOEHSHUIRUPHGDWWLPHSRLQWVDVG HWDLOHGLQWKHVFKHGXOHRI
DVVHVVPHQWVWKH 6FKHGXOHRI/DERUDWRU\$VVHVVP HQWVIRU¬≥&6/&RQWLQXDWLRQ¬¥6 XEMHFWV
WKH6FKHGXOHRI/DERUDWRU\$VVHVVPHQ WVIRU¬≥&6/,QWHUUXSWHG¬¥6XE MHFWVDQG¬≥&6/
1DwYH¬¥6XEMHFWV DQGWKH6FKHGXOHRI(YHQWVIRUWKH([WHQVLRQ3HULRG 0RUHIUHTXHQW
HYDOXDWLRQVPD\EHSHUIRUPHGLI FOLQLFDOO\LQGLFDWHGDWWKHG LVFUHWLRQRIWKHLQYHVWLJDWRU7KH
ODERUDWRU\YDOXHVZLOOEHHQWHUH GLQWRWKHH&5)XVLQJWKHVDPH XQLWVDVSURYLGHGE\WKH
ODERUDWRU\9HULILFDWLRQRIWKH ODERUDWRU\YDOXHVLIDSSOLFDEO HZLOOEHUHFRUGHGLQWKHVRXUFH
GDWD
$OODEQRUPDOODERUDWRU\YDOXHVZ LOOUHTXLUHDFRPPHQWE\WKHLQ YHVWLJDWRURQWKHUHVSHFWLYH
H&5)RUWKHODERUDWRU\UHSRUW 7KHIROORZLQJFRGHVVKRXOGEHXV HG
x(UURU(5HJODERUDWRU\HUURULPSURSHUVDPSOHSUHSDUDWLRQ KHPRO\VLVGHOD\HGWUDQVLW
WRODERUDWRU\
x$EQRUPDOQRWFOLQLFDOO\VLJQLILFDQW$1&6CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDOx$EQRUPDOFOLQLFDOO\VLJQLILFDQW$&6
7HVWVUHVXOWLQJLQDEQRUPDOODERUDWRU\YDOXHVGXULQJWKHVWXG\ SHULRGWKDWKDYHEHHQ
FODVVLILHGE\WKHLQYHVWLJDWRU DV$&6VKRXOGEHUHSHDWHGDVVRR QDVSRVVLEOHDIWHUUHFHLYLQJ
WKHODERUDWRU\UHSRUWWRUXOHRXWODERUDWRU\HUURU
$Q\ODERUDWRU\YDOXHVWKDWGHYLDW HIURPWKHUHIHUHQFHUDQJHVDQ GDUHFRQVLGHUHGE\WKH
LQYHVWLJDWRUDVFOLQLFDOO\VLJQLILFDQWLHFODVVLILHGDVDQ$& 6YDOXHDWDQ\YLVLWDIWHUEDVHOLQH
DOVRPXVWEHGRFXPHQWHG LQWKHH&5)DVDQ$(
 
 




 


 
 







 
CCI
CCI
CCI
CCI
CCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO









 






 
 
 
 




 

 


 
 CCI
C
CI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO 


 

 






 







6WDWLVWLFV
6DPSOH6L]H(VWLPDWLRQ
VXEMHFWVDUHSODQQHGWRFRP SOHWH7UHDWPHQW3HULRGVDQG RIWKHVWXG\7KHVDPSOHVL]H
LVEDVHGRQJXLGHOLQHVLVVXHGE\WK H,QWHUQDWLRQDO&RQIHUHQFHR Q+DUPRQLVDWLRQ> ,&+@
DQGQRWRQRWKHUVWDWLVWLFDOFDOFX ODWLRQV7KLVDOORZVREVHUYDW LRQRI¬ïDGYHUVHHYHQWZLWKD
SUREDELOLW\RID WFRQILGHQFH
2QO\VXEMHFWVIURPWKH8QLWHG6WD WHVZKRFRPSOHWHG7UHDWPHQW3H ULRGDUHHOLJLEOHWR
SDUWLFLSDWHLQWKH([WHQVLRQ3 HULRG$SSUR[LPDWH O\RIWKHVH VXEMHFWVDUHH[SHFWHGWRHQUROO
LQWKH([WHQVLRQ3HULRGC
CI
CCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO'HVFULSWLRQRI$QDO\VLV'DWDVHWV
6FUHHQLQJ3RSXODWLRQ
7KH6FUHHQLQJ3RSXODWLRQZLOOFR PSULVHDOOVXEMHFWVZKRSURYLGH LQIRUPHGFRQVHQWDVVHQWDV
DSSURSULDWHVHH 6HFWLRQ 
,QWHQWWR7UHDW3RSXODWLRQ
7KH,QWHQWWR7UHDW,773RSXO DWLRQZLOOFRPSULVHDOOVXEMHFWV ZKRSURYLGHLQIRUPHG
FRQVHQWDVVHQWDVDSSURSULDWH DQGDUHUDQGRPL]HGUHJDUGOHVV RIZKHWKHURUQRWWKH\UHFHLYH
&6/
6DIHW\3RSXODWLRQ
7KH6DIHW\3RSXODWLRQZLOOFRPS ULVHDOOVXEMHFWVZKRSURYLGHL QIRUPHGFRQVHQWDVVHQWDV
DSSURSULDWHZKRDUHUDQGRPL] HGDQGZKRUHFHLYHGDWOHDVWG RVHRUDSDUWLDOGRVHRI
&6/
3HU3URWRFRO3RSXODWLRQ
7KH3HUSURWRFRO33 3RSXODWLRQZLOOFRPSULVHDOOVXEMHFWVLQ WKH,773RSXODWLRQH[FOXGLQJ
VXEMHFWVZKRKDYHDVLJQLILFDQW SURWRFROYLRODWLRQ)XUWKHUGHW DLOVZLOOEHGHILQHGLQWKH
VWDWLVWLFDODQDO\VLVSODQ
 



 



 


CCI
CCI
CCI
CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO6WDWLVWLFDO$QDO\VHVDQG0HWKRGV
6XEMHFWGLVSRVLWLRQDQG+$(DWWDFNV GXULQJWKH6FUHHQLQJ3HULRG ZLOOEHVX[COMPANY_003]UL]HGXVLQJ
WKH6FUHHQLQJ3RSXODWLRQ'HPRJU DSKLFDQGVXEMHFWFKDUDFWHULVWL FVZLOOEHVX[COMPANY_003]UL]HGXVLQJ
WKH,77DQG6DIHW\3RSXODWLRQV$ GYHUVHHYHQWVWKDWRFFXUGXULQ JWKH6FUHHQLQJZLOOEHOLVWHG
XVLQJWKH6FUHHQLQJ3RSXODWL RQDQGZLOODOVREHV X[COMPANY_003]UL]HGIRU VXEMHFWVLQWKH6DIHW\
3RSXODWLRQ$OORWKHUVDIHW\GDW DZLOOEHVX[COMPANY_003]UL]HGXVLQJWKH 6DIHW\3RSXODWLRQ7KH
HIILFDF\HQGSRLQWVFRQVLGHUHGD VVHFRQGDU\ZLOOEHVX[COMPANY_003]UL]HGX VLQJWKH,77DQG33
3RSXODWLRQV 



&RQWLQXRXVYDULDEOHVZLOOEHGHVF ULEHGXVLQJPHDQZLWKWKHUHOH YDQWFRQILGHQFH
LQWHUYDOV&,JHRPHWULFPHDQD QGWKHUHOHYDQW&,VWDQGDU GGHYLDWLRQUDQJHWKWK
PHGLDQDQGWKSHUFHQWLOHVJHR PHWULFFRHIILFLHQWRIYD ULDWLRQH[SUHVVHGDVD SHUFHQWDJH
 DQGFRXQWVRIPLVVLQJDQGQRQPLVVLQJYDOXHV&DWHJRULFDOYDOXHVZLOOEHGHVFUL EHGXVLQJFRXQWVDQGSHUFHQWDJ HV
$FRPSOHWHGHVFULSWLRQRIWKHVW DWLVWLFDODQDO\VHVDQGPHWKRGV ZLOOEHDYDLODEOHLQVWDWLVWLFDO
DQDO\VLVSODQVIRUWKHRULJL QDOSURWRFRODQGIRUWKH([WHQ VLRQ3HULRGDPHQGPHQWZKLFK
ZLOOEHILQDOL]H GEHIRUHWKHGDWDEDVHLVORFNHG
6XEMHFW'LVSRVLWLRQDQ G&KDUDFWHULVWLFV
6XEMHFW'LVSRVLWLRQ
7UHDWPHQW3HULRGDQG 7UHDWPHQW3HULRG
$WDPLQLPXPWKHIROORZLQJZLOO EHSUHVHQWHGLQVX[COMPANY_003]U\WDEOHV IRUWKH6FUHHQLQJ
3RSXODWLRQE\WUHDWPHQWDQGRYHUDOO
x7KHQXPEHURIVXEMHFWVZKRSURYLGH FRQVHQWDVVHQWDVDSSURSULD WH
x7KHQXPEHURIVXEMHFWV ZKRXQGHUJR6FUHHQLQJ
x7KHQXPEHURIVXEMHFWVZKRFRQ WLQXHGLUHFWO\IURP&6/B LH¬≥&6/
&RQWLQXDWLRQ¬¥6XEMHFWV
x7KHQXPEHURIVXEMHFWV ZKRKDYHLQWHUUXSWH GWUHDWPHQWEHWZHHQ& 6/BDQG
&6/BLH¬≥&6/,QWHUUXSWHG¬¥6XEMHFWV
x7KHQXPEHURIVXEMHFWVZKRDUHU DQGRPL]HGWRWU HDWPHQWZLWK&6/ LHWKHQXPEHURI
VXEMHFWVZKRHQWHU7 UHDWPHQW3HULRGCCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 112 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ The number of subjects who are randomized to treatment with 40 IU/kg CSL830. 
‚Ä¢ The number of subjects who are randomized to treatment with 60 IU/kg CSL830. 
‚Ä¢ The number of subjects who undergo 1 CSL830 dose increase in Treatment Period 1 . 
‚Ä¢ The number of subjects who undergo 1 CSL830 dose increase in Treatment Period 2 . 
‚Ä¢ The number of subjects who under go 2 CSL830 dose increases in Treatment Period 1 . 
‚Ä¢ The number of subjects who undergo 2 CSL830 dose increases in Treatment Period 2.  
‚Ä¢ The number of subjects who administer the same CSL830 dose over Treatment Period 1 . 
‚Ä¢ The number of subjects who administer the same CSL830 dose over Treatment Period 2. 
‚Ä¢ The number of subjects who administer the same CSL830 dose over Treatment Periods 1 
and 2. 
‚Ä¢ The number of subjects who complete Treatment Period 2 .  
‚Ä¢ The number of subjects who discontinue participation in the stu dy (including the reason 
for discontinuation).  
Disposition data (including the reason for discontinuing use of CSL830 or withdrawing from the study) will be listed by [CONTACT_847076]. All Screen Failures will be listed.  
The number of subjects in each analysis population will be summarized ( by [CONTACT_847077] 40 IU/kg CSL830; by [CONTACT_847053] 60 IU/kg CSL830; and overall ). The number of subjects in each analysis population will also be summarized (by 
[CONTACT_847053] 40 IU/kg CSL830 and who have 1 dose increase; by [CONTACT_847078] 40 IU/kg CSL830 and who have 2 dose increases; by [CONTACT_847052] 60 IU/kg CSL830 and who have 1 dose increase; and overall) for both Treatment P eriod 1 (only) and for Treatment P eriod s 1 and 2 (together). A by -subject listing 
will be produced including the assignment of subjects to analysis  populations. 
Extension Period  
The above described summaries for subject disposition will be performed for subjects who 
continued into the Extension P eriod  by [CONTACT_11763], except for the number of 
subjects who provide consent/assent (as appropriate) and the number of subjects who 
complete Treatment Period 2.  In addition, the following will be presented by [CONTACT_11761]:  
‚Ä¢ The number of subjects who undergo no CSL830 dose increase in the extension 
Period  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 113 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ The number of subjects who undergo 1 CSL830 dose increase in the extension period 
‚Ä¢ The number of subjects who undergo 2 CSL830 dose increases in the extension 
period  
‚Ä¢ The number of subjects who undergo no CSL830 dose increase in Treatment Period 1, Treatment Period 2, and the E xtension P eriod  
[IP_ADDRESS] Subject Characteristics  
Subject characteristics will be presented in summary tables  for the ITT and Safety 
Populations.  
Treatment Period [ADDRESS_1177807] characteristics will be presented in summary tables  for all subjects in the ITT and 
Safety Populations. Demographic and baseline characteristics and medical history will be 
summarized (by [CONTACT_847053] 40 IU/kg CSL830; by [CONTACT_847077] 60 IU/kg CSL830; and overall). Demographic and baseline characteristics and 
medical history will also be summarized ( by [CONTACT_847053] 40 IU/kg 
CSL830 and who have 1 dose increase; by [CONTACT_847053] 40 IU/kg CSL830 
and who have 2 dose increases; by [CONTACT_847053] 60 IU/kg CSL830 and who have 1 dose increase; and overall) for both Treatment P eriod 1 (only) and for Treatment 
Period s 1 and 2 (together).  This will include age (years), sex, race, ethnicity, height, weight, 
and body mass index (BMI; calculated as kg/m ¬≤). Medical history will be presented  by 
[CONTACT_9313] (SOC) and preferred term  (PT) , and will be classified using the latest 
version of the Medical Dictionary for Regulatory Activities (MedDRA). Continuous data will 
be summarized by [CONTACT_847079]. A by -subject listing of demographic characteristics , baseline 
characteristics , and medical history will also be presented . 
Extension Period  
The above described summaries for demographic and baseline characteristics and medical 
history will be also performed for subjects who participated  in the Extension P eriod. The only 
difference is that data will also be summarized by [CONTACT_847080] e increase in the 
Extension Period. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 114 of 130 
([LOCATION_002])  Confidential  11.3.2 Efficacy Analyses 
[IP_ADDRESS] Primary Efficacy Analysis  
There is no primary efficacy analysis. The primary analysis for  study CSL830_3002 is 
safety -based and can be found in Section [IP_ADDRESS]. 
[IP_ADDRESS] Secondary Efficacy Analyses  
The ITT and PP Populations will be used as analysis populations for efficacy analyses . 
Treatment Period [ADDRESS_1177808] visit in Treatment period 2 , when 
‚Äúresponse‚Äù is defined as a ‚â•  50% relative reduction in the time -normalized number of HAE 
attacks during treatment with CSL830, compared with the time -normalized number of attacks 
used to qualify for participation in the current study will be assessed. The number and 
percent age of subjects will be summarized (by [CONTACT_847053] 40 IU/kg  
CSL830; and by [CONTACT_847053] 60 IU/kg CSL830). Subjects who undergo a 
dose increase will be flagged in the listing.  
The number and percentage of subjects who ex perience a time- normalized HAE attack  
frequency  of < [ADDRESS_1177809] visit in Treatment Period 2  (by [CONTACT_847077] 40 IU/kg CSL830 and by [CONTACT_847053] 60 IU/kg CSL830). 
Subjects who undergo a dose increase will be flagged in the listing. 
A within -subject analysis will give the  number and percentage of subjects who are responders 
or non- responders before a dose increase, after a first dose increase, and after a second dose 
increase (only applicable for subjects who are randomizes to the 40 IU/kg CSL830 treatment 
group) summarized by [CONTACT_847081] 40 IU/kg CSL830 and by [CONTACT_847081] 60 IU/kg CSL830 treatment group. Furthermore, a within- subject 
analysis will give the  number and percentage of subjects who experience or who do not 
experience a time -normalized HAE attack  frequency  of < [ADDRESS_1177810] dose increase, and after a second dose increase (only applicable for subjects who are randomizes to the 40IU/kg treatment group) summarized by 
[CONTACT_847082]:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 115 of 130 
([LOCATION_002])  Confidential  subjects who are randomized to the 40 IU/kg and by [CONTACT_847081] 60 
IU/kg treatment group.  
The secondary efficacy analyses will be done both for Treatment Period 1 (only) and for Treatment Periods 1 and 2 (together). 
A descriptive subgroup analysis will be done for subjects who use oral agents for the 
treatme nt of HAE and for subjects who do not. A d escriptive subgroup analysis will be done 
for subjects who previously used intravenously administered C1-INH for routine (long- term) 
prophylaxis. Additional subgroup analyses will be conducted for subjects who part icipate d in 
study CSL830_3001 and for subjects who did not AND for subjects who are aged < 18 years 
and ‚â• 18 years. Subjects who use oral agents for the treatment of HAE will be flagged in the listings.  
Extension Period  
For the subjects who are in the Extension Period, the above described analyses of the number and percentage of subjects who are responders and the number and percentage of subjects who experience a time-normalized number of HAE attacks of < 1 HAE attack per 4- week 
period will be summarize d for the Extension Period by [CONTACT_3148] (40 IU/kg CSL830; 60 
IU/kg CSL830) and for all treatment periods. 
11.3.3 Safety Analyses  
The Safety Population will be used for analyses of safety.  
Treatment Period 1 and Treatment Period 2  
All subjects in the Safety  Population will be included  in the safety  analyses.  The primary 
safety analysis will be performed by [CONTACT_1570] (ie, subjects who are randomized to 40 
IU/kg  CSL830 and by [CONTACT_847053] 60 IU/kg CSL830) . Data collected 
from those subjects will be included in the 40 IU/kg and 60 IU/kg CSL830 treatment groups, respectively, until the time they undergo the final study visit or they undergo a CSL830 dose increase, whichever comes first.  
A secondary safety analysis will be performed by [CONTACT_1570] [ie, subjects who are 
randomized to 40 IU/kg CSL830 and by [CONTACT_847053] 60 IU/kg CSL380, 
regardless of any  dose increase(s)] . Data collected from those subjects will be included in the 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 116 of 130 
([LOCATION_002])  Confidential  40IU/kg and 60IU/kg CSL830 treatment groups, respectively, until the time they undergo the 
final study visit. 
The analyses will be done both for Treatment P eriod 1 (only) and for Treatment Period 1 and 
2 (together) , unless otherwise noted. 
Furthermore, safety analyses will be summarized by [CONTACT_847053] 
40 IU/kg CSL830 and who have 1 dose increase; by [CONTACT_847053] 
40 IU/kg CSL830 and who have 2 dose increases; by [CONTACT_847053] 
60 IU/kg CSL830 and who have 1 dose increase.  
After the dose increase, data collected from  subjects who undergo a 20  IU/kg  dose increase 
from 40 IU/kg to 60 IU/kg or from 60  IU/kg to 80 IU/kg in Treatment Period 1 will be 
summarized separately for the 60 IU/kg and 80 IU/kg CSL830 doses. Furthermore, d ata 
collected from  subjects who undergo a 20 IU/kg  dose increase from 40 IU/kg to 60 IU/kg or 
from 60  IU/kg to 80 IU/kg in Treatment P eriod 2 will also be summarized separately for the 
60 IU/kg and 80  IU/kg CSL830 doses. 
After a second dose increase, data collected from  subjects who undergo a 20 IU/kg x 2  dose 
increase from 60 IU/kg to 80 IU/kg in Treatment P eriod 1will be summarized separately for 
the 80 IU/kg CSL830 dose. Furthermore, d ata collected from  subjects undergo a 20  IU/kg x 2  
dose increase from 60  IU/kg to 80 IU/ kg in Treatment P eriod 2 will also be summarized 
separately for the 80  IU/kg CSL830 dose. 
Subjects who undergo a CSL830 dose increase will be flagged in the listing  
A descriptive subgroup analysis will be done for subjects who use oral agents for the 
treatment of HAE and for subjects who do not. A d escriptive subgroup analysis will be done 
for subjects who previously used intravenously administered C1-INH for routine (long- term) 
prophylaxis. Additional subgroup analys es will be conducted for subjects w ho participated in 
study CSL830_3001 and for subjects who did not AND for subjects who are aged < 18 years 
and ‚â• 18 years. Subjects who use oral agents for the treatment of HAE will be flagged in the listings.  
Extension Period  
Data collected from subjects in  the Extension Period will be summarized  as follows:  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 117 of 130 
([LOCATION_002])  Confidential  ‚Ä¢ For the Extension Period only (separate from  data collected during Treatment 
Period 1 and Treatment Period 2) 
‚Ä¢ For Treatment Period 1, Treatment Period 2 and the E xtension P eriod  
(combined) 
Only data collected from subjects who are enrolled in the Extension Period will be  included 
in these analyses.  
[IP_ADDRESS] Primary Safety Analysis 
The person- time incidence rate of each primary endpoint safety event will be assessed as 
defined above in Section 11.3.[ADDRESS_1177811]‚Äôs time at risk  in the respective 
treatment . The  person -time incidence rate of each  primary endpoint safety event will be 
assessed for Treatment Period 1 and for the T reatment Periods 1 and 2 overall. For the 
subjects who are in the Extension Period, the person- time incidence rate of each primary 
endpoint safety event will also be assessed for the Extension Period and for the treatment 
periods overall. 
Adverse events will be classified using the Medical Dicti onary for Regulatory Activities 
(MedDRA).  
[IP_ADDRESS] Secondary Safety Analyse s 
Adverse event data will be presented in individual listings and summary tables.  The number and percentage of subjects experiencing SAEs, temporally -related AEs, 
increased risk scores for DVT or PE, thromboembolic events, inhibitory anti- C1-INH 
antibodies, or clinically significant abnormalities in laboratory assessments during treatme nt 
will be summarized as defined above in Section 11.3.3 and overall. The number and 
percentage of subjects who become seropositive for HIV-1, HIV-2, HBV , or HCV wi ll be 
summarized as defined above in Section 11.3.3 and overall. The number and percentage of 
subjects experiencing solicited local AEs, the number of solicited lo cal AEs, and the number 
of solicited local AEs per administration will be summarized as defined above in 
Section  11.3.3 and overall. The number and percentage of administrations of CSL830 
resulting in solicited local AEs will be summarized as defined above in Section 11.3.3 and 
overall. An overall summary of AEs will be given.  
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO7HPSRUDOO\UHODWHG$(VZLOOEH GHILQHGDV$(VZKLFKEHJDQZLWKL QKRXUVRI
DGPLQLVWUDWLRQRI&6/1RWHWK DWWHPSRUDOO\UHODWHG$(VDUH UHIHUHQFHGDV¬≥VXVSHFWHG
$'5V¬¥LQVWXG\&6/B7HPSRUDOO\UHODWHG$(VRFFXUULQJGX ULQJWUHDWPHQWZLOOEH
VX[COMPANY_003]UL]HGDVGHILQHGDERYHLQ 6HFWLRQ DQGRYHUDOOLQWKHFXUUHQWVWXG\
&6/B
6X[COMPANY_003]ULHVZLOOLQFOXGHWKHQXPEHU DQGSHUFHQWDJHRIVXEMHFWVW KHQXPEHURI$(VDQGWKH
QXPEHURI$(VSHUDGPLQLVWUDWL RQDQGSHUZHHNZKHUHDSSOLFDEOH DQGZLOODOVREH
VX[COMPANY_003]UL]HGDVGHILQHGDERYHLQ 6HFWLRQ DQGDWVWXG\YLVLWV6X[COMPANY_003]ULHVE\62&DQG
37ZLOODOVREHSUHVHQWHG
$GYHUVHHYHQWVZLOODOVREHGHVFUL EHGE\LQWHQVLW\UHODWLRQVKL SWR&6/GXUDWLRQDQG
VHULRXVQHVV
7KHVDIHW\DQDO\VHVZLOOEHF RQGXFWHGIRU7UHDWPHQW3HULRGR QO\7UHDWPHQW3HULRG
RQO\DQGIRU7UHDWPHQW3HU LRGDQGWRJHWKHU)RUWKHVX EMHFWVZKRDUHLQWKH([WHQVLRQ
3HULRGWKHVDIHW\DQDO\VHVZLOO EHFRQGXFWHGIRUWKH([WHQVLRQ 3HULRGDQGIRUW KHWUHDWPHQW
SHULRGVRYHUDOO
 













CCI
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO


























 
CCI
CCI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO 



 

























CCI
CCI
CCIC
CI
&6/%HKULQJ*PE+6WXG\1XPEHU &6/B
6WXG\3URGXFW &6/

&RXQWU\6SHFLILF$PHQGPHQW1R -8/< 3DJHRI
8QLWHG6WDWHV &RQILGHQWLDO






 














,QWHULP$QDO\VLV
,QWHULPDQDO\VHVZLOOEHFRQGXF WHGRQDQDVQHHGHGEDVLVLQRUG HUWRVXSSRUWUHJXODWRU\
DFWLYLWLHV7KHUHVXOWVRILQWHU LPDQDO\VHVDUHQRWLQWHQGHGWR EHXVHGWRVWRSRU DGDSWWKH
VWXG\$GGLWLRQDOGHWDLOVZ LOOEHSURYLGHGLQWKH6$3
0LVVLQJ'DWD
7KHSULPDU\VDIHW\HQGSRLQWVDUHWKHSHUVRQWLPHLQFLGHQFHUDWH RIHDFKSULPDU\HQGSRLQW
VDIHW\HYHQW2QO\LIDVXEMHFW VGURSVRXWGLUHFWO\DIWHUUDQGR PL]DWLRQWKLVZLOOOHDGWRPLVVLQJ
GDWD IRU D VXEMHFW EXW WKH SU LPDU\ VDIHW\ HQGSRLQWV DUH VWLOO FDOFXODEOH 7KHUHIRUH QR
LPSXWDWLRQLVSODQQHGCCI
CCI
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 122 of 130 
([LOCATION_002])  Confidential  [ADDRESS_1177812] to an audit by [CONTACT_254815] , an authorized representative(s) of CSL  and / or 
inspections by [CONTACT_254862] (eg, US Food and D rug Administration 
[FDA] ). Regulatory authorities may request access to all study documentation, including 
source documents for inspection and copying, in keepi[INVESTIGATOR_254797]. CSL  will 
immediately notify the investigator of an upcoming audit / inspection.  
In the event of an audit, all pertinent study- related documentation must be made available to 
the auditor(s). If an audit or inspection occurs, the investigator at each study site will permit 
the auditor / inspector direct access to all relevant documents and allocate their time as well 
as the time of relevant staff to discuss the findings and any relevant issues.  
[ADDRESS_1177813], 
evaluation and documentation of this study, as described in ICH Topic E6 (Guideline for GCP ). The study will also be carried out according to all applicable international and national 
regulatory requirements. 
13.[ADDRESS_1177814] / Independent Ethics Committee  
The investigator must submit the protocol and  informed consent forms (ICFs)  for review by 
[CONTACT_301645] (according to local guidelines) IRB / IEC. W ritten 
approval must be received from the IRB / IEC before commencement of the study. 
13.[ADDRESS_1177815] Information and Informed Consent  
Informed consent/assent must be implemented in this clinical study before protocol- specified 
procedures are carried out.  Information should be given in both oral and written form 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 123 of 130 
([LOCATION_002])  Confidential  whenever possible and deemed appropriate by [CONTACT_1201] / IEC.  Subjects, their relatives (or if 
necessary, legally acceptable representatives) must be given ample opportunity to inquire 
about details of the study. 
Should there be any amendments to the protocol that would directly affect the subject‚Äôs 
participation in the study (eg, a change in any procedure), the ICF must be amended to 
incorporate this modification . Subject s must be informed of the change and they must sign 
the amended ICF /assent form  indicating that they re -consent to participate in the study. 
13.[ADDRESS_1177816] (eg, name, address, phone number and identity in the study) so that regulatory 
agencies o r CSL may access this information should the need arise. These records should be 
retained in a confidential manner as long as legally mandated according to local requirements.  
Subject medical records pertaining to the study may be inspected / audited at an y time by 
[CONTACT_489243], a regulatory authority or the 
IRB / IEC. All records accessed will be strictly confidential.  Consent to participate in the 
study includes consent to these inspections / audits. 
13.5  Indemnity an d Compensation  
It is CSL policy that persons who participate in CSL ‚Äôs clinical studies should be no worse off 
for their having been involved in the study. These persons include the subjects / volunteers, 
the investigator, the hospi[INVESTIGATOR_254798] / IEC.  
CSL has taken out insurance to cover its obligations under both the Indemnity and the 
Compensation guidelines for injury to subjects involved in the study. Other details regarding  compensation and the obligations of the investigator / CSL  are 
provided in the Clinical Trial Agreement for the study ( see Section 14.1).  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 124 of 130 
([LOCATION_002])  Confidential  14 Administrative Considerations  
14.1 Clinical Trial Agreement  
This study will be conducted under a Clinical Trial Agreement between CSL  (‚ÄúSponsor‚Äù) and 
the institution(s) representing the investigational study site(s) (‚ÄúAuthority‚Äù).  Financial 
support to the investigational site(s) will be detailed in the Clinical Trial Agreement.  The 
Clinical Trial Agreement must be signed before the commencement of the study and will 
clearly delineate the responsi bilities and obligations of investigator and CSL , and will form 
the contractual basis under which the clinical study will be conducted.  
14.2 Clinical Study Registration and Results Disclosure  
CSL will provide the relevant study protocol information in public database(s) before or at 
commencement of the study.  CSL  may also provide study information for inclusion in 
national registries according to local regulatory requirements.  
Results of this study will be disclosed according to the relevant regulatory requirements.  All 
publications in peer- reviewed medical journals resulting from this study will be listed in the 
original study protocol registration record. 
14.3 Implementation  of the Protocol / Protocol Amendment(s)  
With the exception of medical emergencies, no chan ges or deviations in the conduct of the 
signed protocol will be permitted without documented approval of the CSL  Medical Monitor 
and the IRB / IEC. In the event of a medical emergency, the investigator at the study site will 
institute any medical procedure s deemed appropriate.  However, all such procedures must be 
promptly reported to the CSL Medi cal Monitor and the IRB / IEC. 
Modifications to the protocol that may affect subject safety or the way the study is to be conducted will be documented in a protocol amendment, which must be approved by [CONTACT_5040] / IEC.  
Adminis trative changes to the protocol, defined as minor corrections and / or clarifications 
that have no effect on the way the study is to be conducted, will not require IRB / IEC 
approval, but will be submitted to the  IRB / IEC for their information . 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 125 of 130 
([LOCATION_002])  Confidential  14.4 Protocol Deviations 
All instances where the requirements of the study protocol were not c omplied with will be 
tracked. Corresponding subjects may be withdrawn from the study at the discretion of the 
investi gator and  / or CSL. Study protocol deviations arise when subjects who have been 
entered in the study deviate from the IRB / IEC -approved study protocol.  
If a major protocol deviation (ie, a deviation that could have a significant effect on the 
subject‚Äôs s afety, rights, or welfare and / or on the integrity of the study data) occurs, the 
investigator must notify CSL and the appropriate IRB  / IEC as soon as possible or as per 
local requirements.  
14.[ADDRESS_1177817] Keepi[INVESTIGATOR_007]  
14.5.1 Data Collection  
The investigator (or delegate) will maintain individual records for each subject.  These 
records should include dates when a subject visited the study site, records of vital signs, medical history, or physical examinations, administration of CSL830 or concomitant therapy, 
any AEs experienced, and other notes as appropriate.  These records constitute source data.   
An eCRF will be provided by [CONTACT_254815]  (or delegate) for each subject enrolled  into the study.  The 
investigator is responsible for ensuring accurate and proper completion of the eCRF in a timely manner so that it always reflects the latest observations on the subjects enrolled in the study.  All entries on the eCRF must be backed up by [CONTACT_285084].   
All source data will be kept according to all applicable regulatory requirements.  Source data 
must be completed legibly for each subject enrolled into the study and signed by t he 
investigator (or delegate).  
The subjec t eDiary will be completed by [CONTACT_423].  At each clinic visit, the subject will 
present the completed diary to the investigator for review of entries and transfer of relevant information to the eCRF. 
14.5.[ADDRESS_1177818] records for completeness and accuracy.  CSL ‚Äôs study monitor will perform this 
function. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 126 of 130 
([LOCATION_002])  Confidential  Following completion of eCRF pages and entry of the data into a database, the data will be 
checked electronically for consistency and plausibility.  Queries will be generated for 
questionable data and clarification sought from the investigator. These data queries must be resolved in a timely manner by [CONTACT_093] (or delegate).  
14.5.[ADDRESS_1177819] Retention  
An investigator study file prepared by [CONTACT_254815]  (or delegate), containing all applicable documents 
for use at the study site, will be made available to the investigator before the start of the study.  All study documentation and materials maintained in the investigator study file  must 
be kept in conformance with applicable national laws and regulations.  
All study documentation and materials maintained in the investigator study file at the study site must be available for inspection by [CONTACT_254866]‚Äôs study monitor (or delegate) to determine 
that all required documentation is present and correct.  
The study may be audited or inspected by [CONTACT_847083] a competent 
regulatory authority. 
Following completion of the study, the investigator is responsible for archiving the 
investigator‚Äôs study file, the subject‚Äôs records and the source data according to applicable 
regulatory requirements.  
14.6 Study and Site Closure  
CSL reserves the right to prem aturely discontinue or suspend the study either at a particular 
site or at all study sites at any time and for any reason.  If such action is taken, the CSL  Study 
Monitor (or delegate) will discuss this with the investigator at each study site at that time and 
notify the investigators in writing.  If the study is suspended or terminated for safety reasons, 
all investigators and the relevant regulatory agencies will be immediately notified of the 
action  and the reason for it.  The investigator at each study site will advise the IRB / IEC 
overseeing the study at their site.  
14.7 Clinical Study Report  
A clinical study report will be written after the completion of the study.  CSL  or its agent will 
write the report in consultation with the investigator or, if applicable, a nominated  
coordinating investigator ( or delegate).  It is required by [CONTACT_847084] [INVESTIGATOR_44639].  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 127 of 130 
([LOCATION_002])  Confidential  Progress reports may be provided to the relevant regulatory bodies in accordance with their 
requirements.  
14.[ADDRESS_1177820] result of this study will be addressed specifically in the Clinical Trial Agreement  for the study.  
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 128 of 130 
([LOCATION_002])  Confidential  15 References  
Banerji A, Sloane DE, Sheffer AL. Hereditary angioedema: a current state -of-the- art review, 
V: attenuated androgens for the treatment of hereditary angioedema. Ann Allergy Asthma 
Immunol. 2008;100([ADDRESS_1177821] 2):S19-22. 
Bork K. Pasteurized C1 inhibitor concentrate in hereditary angioedema: pharmacology, 
safety, efficacy and future directions. Expert Rev Clin Immunol. 2008;4(1):13-20. 
Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor 
activity in women. Lancet. 2000;356(9225):213-7. 
Cicardi M, Banerji A, Bracho F, Malbran A, Rosenkranz B, Riedl M, et al. Icatibant, a new 
bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med. 2010a;363(6):532-41. 
Cicardi M, Levy RJ, McNeil DL, Li HH, S heffer AL, Campi[INVESTIGATOR_2394] M, et al. Ecallantide for the 
treatment of acute attacks in hereditary angioedema. N Engl J Med. 2010b;363(6):523-31. De Serres J, Groner A, Lindner J. Safety and efficacy of pasteurized C1 inhibitor concentrate 
(Berinert P) in hereditar y angioedema: a review. Transfus Apher Sci. 2003;29(3):247-54. 
Donaldson VH, Evans RR. A Biochemical Abnormality in Herediatry Angioneurotic Edema: 
Absence of Serum Inhibitor of C' 1-Esterase. Am J Med. 1963;35:37-44. 
Farkas H, Jakab L, Temesszentandrasi  G, Visy B, Harmat G, Fust G, et al. Hereditary 
angioedema: a decade of human C1 -inhibitor concentrate therapy. J Allergy Clin Immunol. 
2007;120(4):941-7. Gompels MM, Lock RJ, Abinun M, Bethune CA, Davies G, Grattan C, et al. C1 inhibitor 
deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379-94. 
G√∂ring HD, Bork K, Sp√§th PJ, et al. Untersuchungen zum heredit√§ren Angio√∂dem im 
deutschsprachigen Raum [Investigations of hereditary angioedema in German-speaking 
countries]. Hautarzt. 1998;49:114-22. 
International Conference on Harmonisation of Technical Requirements for Registration of 
Pharmaceutical for Human Use. The extent of population exposure to assess clinical safety 
for drugs intended for long- term treatment of non -life threatening conditions (E1). 
27 October 1994. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 129 of 130 
([LOCATION_002])  Confidential  Kunschak M, Engl W, Maritsch F, Rosen FS, Eder G, Zerlauth G, et al. A randomized, 
controlled trial to study the efficacy and safety of C1 inhibitor concentrate in treating hereditary angioedema. Transfusion. 1998;38(6):540-9. 
Longhurs t HJ. Emergency treatment of acute attacks in hereditary angioedema due to C1 
inhibitor deficiency: what is the evidence? Int J Clin Pract. 2005;59(5):594-9. Longhurst HJ, Bork K. Hereditary angioedema: causes, manifestations and treatment. Br J 
Hosp Med (Lond). 2006;67(12):654-7. 
Martinez -Saguer I, Cicardi M, Suffritti C, Rusicke E, Ayg√∂ren-P√ºrs√ºn E, Stoll H, Rossmanith 
T, Feussner A, Kalina U, Kreuz W. Pharmacokinetics of pdC1-INH after subcutaneous vs 
intravenous administration in subjects with mild or moderate HAE - the PASSION study . 
Transfusion. 2013 Nov [Epub ahead of print]. 
Rosen FS, Pensky J, Donaldson V , Charache P. Hereditary Angioneurotic Edema: Two 
Genetic Variants. Science. 1965;148:957-8. 
Sampson HA, Mu√±oz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, et al. 
Second symposium on the definition and management of anaphylaxis: summary report‚ÄîSecond National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis 
Network symposium. J Allergy Clin Immunol. 2006 Feb;117(2):391-7. 
Sp√§th PJ, W√ºthrich B, B√ºtler R. Quantification of C1- inhibitor functional activities by 
[CONTACT_847085] --evidence of a 
functionally critical level of C1 -inhibitor concentration. Complement. 1984;1(3):147-59. 
Wells PS, Anderson DR, Bormanis J, Guy F, Mitchell M, Gray L, et al. Value of assessment 
of pretest probability of deep- vein thrombosis in clinical management. Lancet 
1997;350:1795-8. 
Wells PS, Anderson DR, Rodger M, Ginsberg JS, Kearon C, Gent M, et al. Derivation of a 
simple clinical model to categorize patients probability of pulmonary embolism: Increasing the models utility with the simpliRED D -dimer. Thromb Haemost, 2000;83(3):416-20. 
Zuraw BL. Hereditary angiodema: a current state -of-the- art review, IV: short - and long- term 
treatment of hereditary angioedema: out with the old and in with the new? Ann Allergy Asthma Immunol. 2008;100([ADDRESS_1177822] 2):S13-8. 
CSL Behring GmbH   Study Number:  CSL830_3002  
Study Product:  CSL830  
 
Country -Specific Amendment No. 1   10 JULY 2015  Page 130 of 130 
([LOCATION_002])  Confidential  Zuraw BL, Busse PJ, White M, Jacobs J, Lumry W, Baker J, et al. Nanofiltered C1 inhibi tor 
concentrate for treatment of hereditary angioedema. N Engl J Med. 2010;363(6):513-22. 
Version: 1.0
Signature [CONTACT_3490] 1  of 1
--- Do Not Detach This Signature [CONTACT_3490] ---
glbdctmp Print Date: 03-Jul-2018 13:00:03 GMT-04:00Signature [CONTACT_254891]830_3002 - Protocol Amendment - 1 - NA Specific - 10Jul2015
Signed By [CONTACT_1782] (GMT)